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Chapter 1
GENERAL INTRODUCTION 
Healthy ageing and Intellectual disabilities Study (HA-ID study)
In 2008, a large cross-sectional epidemiological study on health and health-related 
factors in elderly with intellectual disabilities (ID) was started in a consortium of three 
Dutch health care provider services for adults with intellectual disabilities (Amarant, 
Ipse de Bruggen and Abrona), and two universities (Erasmus University Medical Center 
Rotterdam and Groningen University) (1). In this large study, in which 1050 elderly 
adults (50 years and older) with ID participated, three main themes were investigated: 
“Physical activity and fitness”, “Nutrition and nutritional state”, and “Depression and 
anxiety”. Besides these three main themes, research on cardiovascular risk factors, 
multimorbidity, polypharmacy, frailty, sleep-wake rhythm and a physical activity 
program was done as well. One of the main goals of the HA-ID study was to expand 
the knowledge on prevalence and risk factors on these health problems, and the 
relationships between them. In this way, a clinically relevant inside could be given 
into the care and support needs for elderly people with ID in the Netherlands. Since 
the start of the HA-ID study, an impressive number of international articles has been 
published, and the study has provided important results to further improve the care 
for elderly with an intellectual disability. Research outcomes of the “Depression and 
anxiety” theme (2), form the basis of my thesis. 
Depressive symptoms in adults with ID
In the population of adults with ID, the point prevalence of Major Depressive Disorder 
(MDD) is high (up to 8%) (3-6). In the large cohort study (n=1023) of Cooper et al. 
(2007), point prevalence rates of adults with affective disorder ranged from 3.6% to 
6.6%, depending on the different used diagnostic criteria (7). In the HA-ID study, it 
was shown that 16.8% (95% CI: 14.4–19.1) of the elderly participants had elevated 
depressive symptoms, and 7.6% (95% CI: 5.2–11.0) of the participants could be 
diagnosed with MDD (8). Besides elevated depressive symptoms, 16.3% (95% CI: 
14.0–18.6) of the participants had increased anxiety symptoms of whom 4.4% (95% 
CI: 2.6–7.0) could be diagnosed with an anxiety disorder (8). Furthermore, almost 
8% (95% CI: 6.1–9.5) of the participants had elevated depressive symptoms as well 
as elevated symptoms of anxiety (8). In the population of adults with ID, depressive 
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symptoms are positively associated with age (8, 9), chronic diseases (9) and increased 
anxiety symptoms (9). Depressive symptoms are also more prevalent in adults with 
moderate ID compared to other levels of ID (10). Adults with ID and depressive or 
anxiety symptoms experience significantly more life events compared to those 
without these symptoms (11). Furthermore, Hermans and colleagues (2012) found 
that almost all elderly with ID experienced two or more life events in the past year, and 
72% of this group experienced one or more negative life events in that same year (11). 
Difficulties in recognizing depressive symptoms in adults with ID
Depression has a negative impact on the quality of life (12-19) and therefore, it is 
essential to recognize depressive symptoms. Previous research showed that depressive 
symptoms are often not recognized in adults with ID, leading to an underestimation 
in clinical practice (8, 20, 21). The HA-ID study showed that only 37.5% of the MDD 
diagnoses during the study were previously reported by clinicians (8). This means that 
almost two-thirds of the participants with a MDD were not previously recognized. 
In clinical practice, depressive symptoms can be hard to recognize in adults with ID 
because depressive symptoms can be presented in a different way compared to those 
in the general population. The verbal and cognitive limitations in adults with ID make 
recognizing depressive symptoms challenging, because a part of the population of 
adults with ID cannot recognize and/or express their (changing) thoughts and feelings, 
or communicate about physical and mental complaints. Consequently, a large part of 
adults with ID and depressive symptoms must depend on their caregivers to notice 
their depressive symptoms and other physical and mental complaints. Consequently, 
diagnoses of MDD are missed, and these patients are not treated for their mental 
illness. Specific clinical characteristics of depression presented in adults with ID are 
signs of irritability, challenging behavior, withdrawal from social interactions and 
crying (20, 22, 23). In addition, these expressions of symptoms can vary between the 
different levels of impairment (24). These specific characteristics in adults with ID are 
not part of the diagnostic criteria for depression, such as defined in the fifth Diagnostic 
and Statistical Manual of Mental Disorders (DSM-5) (25). These specific characteristics 
can be found in the adapted criteria and accompanying notes of MDD as described 
in the Diagnostic Manual-Intellectual Disability 2 (DM-ID-2) (26). 
1
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Measuring depressive symptoms in adults with ID
Reliable and valid instruments for depressive symptoms are necessary to recognize 
depression and measure depressive symptoms in adults with ID. In clinical practice, 
the use of a questionnaire for depressive symptoms can help to identify those who 
need further diagnostic evaluation. Further, reliable and valid instruments can also be 
used to evaluate the effectiveness of treatment of depressive symptoms in individual 
patients, when used pre and post intervention. In the past few years, more attention 
has been paid to developing and studying instruments to screen for depressive 
symptoms in adults with ID (27-31), but there are still some gaps. In 2012, the Dutch 
translation of the Anxiety, Depression And Mood Scale (ADAMS) was studied as part 
of the HA-ID study (27). This instrument, specifically developed for the ID-population, 
was originally developed by Esbensen and colleagues in 2003 (30). The Dutch ADAMS 
is found to be a reliable and valid instrument to screen for depression and anxiety 
symptoms in elderly with ID, but was not investigated in adults with ID younger than 
50 years of age (27). 
(non-) Pharmacological treatment of depressive symptoms in adults with ID
Depressive symptoms are usually treated with antidepressants, mainly Selective 
Serotonin Reuptake Inhibitors (SSRI) and tricyclic antidepressants (TCA) (32, 33). In 
the HA-ID study, 10% of the participants used antidepressants (8). The indication for 
the prescription of these antidepressants was not described, so it is possible that 
these antidepressants were prescribed for other clinical symptoms such as anxiety. A 
retrospective study showed that half of adults with ID benefit from antidepressants, 
which were often used in combination with other psychotropic drugs (33). 
Antidepressants were used for a variety of diagnoses, but primarily for depression, 
generalized anxiety disorder or obsessive-compulsive disorder (33). A systematic 
literature review showed that the effect of antidepressants in adults with ID is low, 
but the amount of adverse events is high (34). In the included studies of this review, 
antidepressants were prescribed for various reasons: depressive symptoms, problem 
behavior, stereotype and repetitive behavior, compulsive behavior and self-injurious 
behavior. Given the high number of polypharmacy, side effects and interaction effects, 
pharmacological treatment is not always desirable (35-37). Besides, finding the most 
suitable antidepressant and dosage to treat depressive symptoms in adults with ID 
PaulineHamers_BNW.indd   10 12/03/2020   16:39:01
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can be difficult, because not all adults with ID can communicate about treatment and/
or adverse effects.
In clinical practice, (adapted) Cognitive Behavioral Therapy is sometimes used to treat 
depressive symptoms, predominantly in the sub-population of adults with ID with 
minor verbal and intellectual limitations. A meta-analysis on this kind of treatment 
showed moderate effect sizes in adults with mild or moderate ID and depressive 
symptoms, and overall more effect with individual therapy than with group-based 
therapy (38). A recent study on behavioral activation and self-help for depression in 
adults with mild ID showed that both interventions decreased depressive symptoms, 
but unfortunately, a control group was lacking (39). In general, there are limited non-
pharmacological treatment options known in clinical practice for adults with ID and 
depressive symptoms that are effective. Therefore, a systematic review of all non-
pharmacological interventions to treat depressive symptoms in adults with ID was 
needed. 
Light and Bright Light Therapy in the general population
In the general population, depression is associated with circadian rhythm disturbances 
(40-44). Particularly, the sleep-wake cycle and hormone cycles are frequently disturbed 
in adults with depressive symptoms (40-42, 45). These circadian rhythms are regulated 
by biological clocks in our body and our master biological clock, the suprachiasmatic 
nucleus (SCN), which is located in our brain (46, 47). Light (via retinal input) has a 
major impact on this master biological clock in the SCN, and therefore influences the 
circadian rhythms (44, 47). Although recent research in mice showed that the effect of 
light (via retinal input) on mood, can also take place independently of the SCN (48). It 
was shown that not the SCN, but the perihabenular nucleus in the brain region of the 
thalamus was involved in regulating mood via light (48).
The impact of light on (mental) health is not a novel concept. Already in previous 
centuries, the influence of light has been associated with influencing (mental) health 
and circadian rhythms (49). For example, ancient Egyptians, Chinese and Indians used 
light in the treatment of many diseases, including psychosis (50). In the 1980s, the 
use of bright light to treat depressive symptoms in seasonal depression was studied 
for the first time (51-53). Nowadays, Bright Light Therapy (BLT) is widely studied and 
1
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proven to be effective in the general population, both in patients with seasonal and 
non-seasonal depression (54-58). Although it is not yet clear to what amount of daily 
light people with (mental) health problems are generally exposed. It is possible, for 
example, that people with (mental) health problems are less exposed to light during 
the day because they spend more time indoors than people without (mental) health 
problems. Another question is if there is an association between natural light exposure 
during the day, mood and/or sleep problems. Therefore, this topic needed to be 
further investigated to fill this gap in knowledge. 
Light and Bright light therapy in adults with ID
Studies regarding the influence of natural light on (mental) health in adults with ID are 
lacking. Generalization of the results of light and BLT studies of the general population 
to the population of adults with ID is not possible. The reason lies in the working 
mechanism of BLT, which is located in the brain. Patients with ID have congenital brain 
malformations or brain damage which caused the ID, and as a result may respond 
differently to BLT. Other factors in lives of adults with ID may also contribute to a 
different response on BLT. For example, the amount of time spent outside in daylight. 
Adults with ID are often dependent on their caregiver to go outside, and therefore 
may be exposed to less natural daylight during the day than adults of the general 
population. Another factor are circadian sleep-wake disturbances in adults with 
ID. These sleep-wake disturbances occur frequently in this population, even more 
frequent than in the general population, and these sleep-wake disturbances are, like 
in the general population, associated with depression (59, 60). As BLT influences the 
release of the hormone melatonin in the brain, which has influence on the sleep-wake 
rhythm, BLT may therefore have a different effect in adults with ID.
In the population of adults with ID, the use of BLT was first described in 1998 by Cooke 
& Thomson (61), followed by two other papers containing case reports (62, 63). These 
case reports showed that depressive symptoms decreased after BLT, which lead to a 
pilot feasibility study of BLT in adults with ID and depressive symptoms by Hermans 
and colleagues (64). In this pilot study (n=14), feasibility of BLT in adults with (moderate, 
severe or profound) ID was good, and BLT decreased the level of depressive symptoms 
in six of nine participants who scored above the clinical cut-off point prior to BLT (64). 
These positive results, but also the lack of a control group and the small sample size 
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of the pilot study, made it essential to further investigate this non-pharmacological 
intervention to decrease depressive symptoms in adults with ID. Especially for those 
with a severe or profound ID, as there are little alternative treatments to decrease 
depressive symptoms in this group. A multicenter randomized controlled study was 
needed to expand the knowledge on the use of BLT to treat depressive symptoms in 
the population of adults with ID. 
Depression and stress
Besides associations with circadian rhythm disturbances, depressive symptoms are 
also associated with life events and stress. This applies for patients with and without 
ID (11, 65-68). In the field of endocrinology, scalp hair cortisol concentrations (HCC) 
are used as a biomarker to retrospectively examine stress in patients (69-73). This non-
invasive reliable and valid method can measure integrated long-term glucocorticoids 
(74-76). Studies in the general population have shown associations between depressive 
symptoms and HCC. These results are inconclusive, as both positive and negative 
associations were found (72). As far as we know, HCC had not previously been studied 
in adults with ID. In the general population, BLT appears to influence the level of 
cortisol (57, 77, 78), but this was also not yet investigated in the population of people 
with ID. Research into this type of biomarkers in the population of adults with ID is of 
great importance, because in this way, subjective complaints on stress that are difficult 
to identify in this population can be partially objectified. Therefore, research on this 
topic was needed to expand our knowledge about the use of hair glucocorticoids 
(cortisol and cortisone) as a biomarker to retrospectively examine stress in adults with 
ID.
STUDY AIMS AND OUTLINE OF THIS THESIS
For clinical practice, it is essential that there are valid and reliable questionnaires to 
detect depressive symptoms in adults with ID. These instruments will contribute to 
better recognition of depressive symptoms in this population. With better recognition, 
more adults with a depression will get proper treatment. If appropriate, these 
instruments can be used to monitor the effectiveness of antidepressant interventions 
as well. In the Netherlands, there was a lack of instruments for adults below 50 years of 
age. Therefore, the first aim of this thesis was to investigate the reliability and validity 
1
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of the Dutch Anxiety, Depression And Mood Scale (ADAMS) in adults aged <50 years 
with intellectual disabilities. The ADAMS can now be used in the whole Dutch adult 
ID population. This reliability and validity study of the ADAMS is described in Chapter 
2. The second aim of this thesis was to investigate the associations between light 
exposure during the day, mood and sleep in adults with (mental) health problems. 
This was studied with a systematic review and described in Chapter 3. Although 
depressive symptoms can be treated with antidepressants, this is not always the most 
desirable method. The third aim of this thesis was to expand the knowledge on non‐
pharmacological interventions for adults with intellectual disabilities and depressive 
symptoms. We investigated this with a systematic review, and the results are discussed 
in Chapter 4. In the next chapter, Chapter 5, the study protocol of our multicenter 
randomized controlled trial for bright light therapy in adults with intellectual disabilities 
and depressive symptoms is described. In this chapter, we also give an overview of 
the obstacles we faced during the preparation and execution of our study, and how 
we tried to manage these obstacles. As mentioned above, we aimed to improve the 
recognition of depressive symptoms in adults with ID. But when those symptoms 
are recognized, the number of possibilities to treat these depressive symptoms in 
the population of adults with ID is rather small, especially in those with severe ID. In 
Chapter 6, we present the results of our multicenter randomized controlled trial to 
treat depressive symptoms in adults with ID. With this study we want to expand the 
knowledge on a potential intervention to decrease depressive symptoms in adults 
with ID, including those with severe ID. In Chapter 7, we explored the use of hair 
glucocorticoids in adults with intellectual disabilities and depressive symptoms. In 
this study, we examined the associations between hair glucocorticoids and depressive 
symptoms, and co-morbid anxiety symptoms. Besides, we investigated the influence 
of light therapy on hair glucocorticoids. In the general discussion, Chapter 8, we reflect 
on the main findings of this thesis. Implications for clinical practice and directions for 
future research are discussed. 
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ABSTRACT 
Background: Reliable and valid screening instruments for depression and anxiety are 
needed for adults with intellectual disabilities (ID). 
Methods: Internal consistency (n=198), interrater reliability (n=41), test-retest reliability 
(n=37) and criterion validity (n=43) were studied. Internal consistency was also studied 
in a sample with epilepsy (n=98). 
Results: Internal consistencies of the Dutch ADAMS total scale and subscales were 
satisfactory to good (α: 0.76 to α: 0.92). Internal consistency in the subgroup with 
epilepsy was satisfactory to good (α: 0.74 to α: 0.88). Interrater reliability and test-retest 
reliability were fair to excellent for the total scale (ICC’s: 0.57-0.84) and subscales (ICC’s: 
0.43 – 0.86). The criterion validity of the Dutch ADAMS Depressive Mood subscale 
was good with a sensitivity of 88% (95% CI: 53%-98%) and a specificity of 80% (95% 
CI: 64%-90%). 
Conclusions: The Dutch ADAMS is a reliable and valid instrument and can be used in 
research and clinical practice in adults with ID. 
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INTRODUCTION
In the population of adults with intellectual disabilities (ID), the prevalence of 
depression ranges from 2.2% to 8.3% and the prevalence of anxiety disorders varies 
from 1.7% to 7.8%, depending on the study population and which (clinical) diagnostic 
criteria are used (Cooper, Smiley, Morrison, Williamson, & Allan, 2007; Deb, Thomas, & 
Bright, 2001; Hermans, Beekman, & Evenhuis, 2013; Elita Smiley, 2005; E. Smiley et al., 
2007). Depressive symptoms can be hard to recognize and are often missed in people 
with ID (Hermans et al., 2013). Limited cognitive and verbal abilities make diagnosing 
depression challenging. Therefore, accurate screening and diagnostic instruments, 
specifically developed for the ID population, are important to detect depressive 
symptoms and also to monitor the effectiveness of interventions. Unfortunately, the 
number of reliable and valid screening instruments to detect psychopathology, such 
as depression, in the adult ID population is limited (Hermans & Evenhuis, 2010; Matson, 
Belva, Hattier, & Matson, 2012).
Having epilepsy is associated with an even higher prevalence of depressive symptoms 
in adults with ID (van Ool et al., 2016). Moreover, Van Ool and colleagues suggest 
that more severe epilepsies are risk factors for behavioral problems and psychiatric 
disorders (van Ool et al., 2016). Depressive and anxiety symptoms may result from 
epilepsy due to seizure-related or psychosocial factors, such as increased dependence, 
experienced stigma, restrained activity, and poor seizure control (Peterson, Walker, 
& Shears, 2014; Reisinger & DiIorio, 2009), or may come from the same underlying 
neurobiological mechanism (Kanner et al., 2012). Depression in patients with epilepsy 
seems under-diagnosed (Kanner, 2006) and depressive symptoms may be partly hard 
to distinguish from epilepsy related symptoms, such as fatigue and concentration 
problems. Therefore, proper screening instruments for adults with ID and comorbid 
epilepsy are needed as well.
In 2003, Esbensen and colleagues published the Anxiety, Depression And Mood Scale 
(ADAMS) which is specifically developed for the ID population (Esbensen, Rojahn, 
Aman, & Ruedrich, 2003). Hermans and colleagues investigated the reliability and 
validity of the Dutch translation in adults with ID aged 50 years and older (Healthy 
Ageing and Intellectual Disabilities Study, HA-ID study) (Hermans, Jelluma, van der 
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Pas, & Evenhuis, 2012). The authors concluded that the feasibility, test-retest reliability 
and internal consistency of the Dutch translation of the ADAMS are fair to good, 
with exception of a poor interrater reliability of the Social Avoidance subscale in the 
borderline/mild ID subgroup. The clinical manual of the Dutch ADAMS was published 
in 2013 including new data and reordered subscales (Hermans & Evenhuis, 2013). 
Nowadays, this version of the Dutch ADAMS is used in many different care provider 
services of people with ID in the Netherlands. As the HA-ID study focused on people 
of 50 years and older, no conclusions can be drawn about the reliability and validity 
of the Dutch ADAMS within a younger adult population (18-49 years). Therefore, the 
aim of this study is to investigate the validity and reliability of the Dutch ADAMS in 
adults with ID in a sample of adults younger than 50 years of age. 
METHODS
Study population
Participants were recruited by behavioral scientists, psychologists and physicians 
of different care provider services for adults with ID in in the Netherlands. The only 
exclusion criterion of this study was age below 18 or above 49 years. The legal 
guardians of the participants gave informed consent to participate if the participant 
was not able to give informed consent. Adapted information letters were used for the 
people with ID who gave permission themselves. The questionnaires were completed 
by professional caregivers of the participants who knew the participants for at least 
3 months. The Medical Ethical Testing Committee of the Erasmus University Medical 
center concluded that the rules laid down in the Dutch Medical Research Involving 
Human Subjects Act (WMO) do not apply to the current study (MEC-2015-587 and 
MEC-2016-408). 
Instrument characteristics
ADAMS
The Anxiety, Depression And Mood Scale (ADAMS) is a by proxy instrument for adults 
with ID (Esbensen et al., 2003). This instrument consists of 28 items (4-point scale) and 
five subscales (‘Manic/Hyperactivity Behavior’, ‘Depressive Mood’, ‘Social Avoidance’, 
‘General Anxiety’ and ‘Obsessive/Compulsive behavior’). The minimum total score is 
0 and the maximum score is 84.
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 In 2012, the ADAMS was translated into Dutch and feasibility, reliability and validity 
of the Dutch version of the ADAMS was studied as part of the HA-ID study (Hermans 
et al., 2012). In total, 975 participants of 50 years and older were screened with the 
ADAMS. Internal consistency was tested in a sample of 127 participants and was good 
(Cronbach’s alpha 0.80-0.88 for the five different subscales). Test-retest reliability was 
tested in a sample of 93 participants and was good as well (ICC total ADAMS: 0.83, ICC 
subscales: 0.75-0.86). The test-retest reliability of the total score and subscales was also 
studied in different subgroups based on level of ID. Good test-retest reliability was 
found in all level of ID subgroups, with exception of a fair test-retest reliability in the 
severe/profound ID group (0.52, 95% CI: 0.11-0.78). Interrater reliability, measured in a 
sample of 83 participants, was fair to good for all subscales (ICC total ADAMS: 0.76, ICC 
subscales: 0.57-0.78). Interrater reliability was fair to good for all levels of ID subgroups 
except for the borderline/mild ID subgroup where a poor interrater reliability was 
found (0.38, 95% CI: 0.02-0.66). Criterion validity of the ADAMS Depressive Mood 
Subscale was tested in a sample of 288 participants by studying the sensitivity and 
specificity rates compared to the outcome of the PAS-ADD interview (Moss, 2011). 
Sensitivity and specificity ranged from sufficient to good (Hermans et al., 2012).
After the study of Hermans et al. was published in 2012, more data has been collected 
in clinical practice. In 2013, Hermans and colleagues published the manual of the 
Dutch ADAMS which included this new data (Hermans & Evenhuis, 2013). In response 
to an explorative factor analyses and to what extent a subscale is indicative of a 
depression or anxiety disorder, the ‘Depressive Mood’ subscale was extended with 
six items, the ‘Manic/Hyperactivity Behavior’ and ‘Obsessive/Compulsive behavior’ 
subscales have been removed and a subscale labeled ‘Other problems’ has been 
added. The anxiety subscale and social avoidance subscale are unchanged. The current 
‘Depressive Mood’ subscale covers the following topics: ‘Sleeps more’, ‘Depressed’, 
‘Sad’, ‘Worried’, ‘Attention’, ‘Fatigued’, ‘Lacks energy’, ‘Distracted’, ‘Facial expression’, 
‘Starting routine tasks’, ‘Listless’, ‘Trembles’ and ‘Tearfull’. The Anxiety subscale 
includes the original topics: ‘Nervous’, ‘Does not relax’, ‘Tense’, ‘Worried’, Anxious’, 
‘Panic attacks’ and ‘Trembles’. As the previous subscale, the ‘Social Avoidance’ subscale 
covers the same topics as the original subscale: ‘Communication’, ‘Withdraws’, ‘Shy’, 
‘Avoids others’, ‘Facial expression’, ‘Avoids eye contact’, ‘Avoids peers’. The fourth 
subscale of the Dutch ADAMS, ‘Other Problems’, consists of some items included in 
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the ‘Manic/Hyperactive Behavior’ and the ‘Compulsive Behavior’ subscales of the 
original ADAMS complemented by other items. The following topics are included in 
the ‘Other Problems’ subscale of the Dutch ADAMS: ‘Communication’, ‘Overactive’, 
‘Ritualistic behavior’, ‘Attention’, ‘Checker’, ‘Distracted’, ‘Rituals’, ‘Facial Expression’, 
‘Starting routine tasks’, ‘Panic attacks’, ‘Avoid eye contact’.
PAS-ADD
The Psychiatric Assessment Schedule for Adults with Developmental Disability (PAS-
ADD) is a semi-structured clinical interview which provides full diagnoses under 
both ICD-10 and DSM-IV (TR) for several disorders, including depression and anxiety 
disorders (Moss, 2011). The PAS-ADD can be used for the patient, as well as with an 
informant when the patient’s language or verbal level is poor (Moss, 2011). The test-
retest and interrater reliability analysis of the PAS-ADD show moderate to high kappa 
values (Gonzalez-Gordon, Salvador-Carulla, Romero, Gonzalez-Saiz, & Romero, 2002). 
The PAS-ADD has a good interrater reliability as well (mean Kappa of 0.65 for individual 
items) (Costello, Moss, Prosser, & Hatton, 1997). Criterion validity of the PAS-ADD was 
investigated with psychiatric diagnoses of experts. The validity of the PAS-ADD in 
relation to depressive symptoms was good (Moss et al., 1997) . 
Procedure
After informed consent, the main professional caregiver of the participant was asked 
to fill out the Dutch ADAMS (baseline, T1, n= 198). For the participants in sample A, a 
second professional caregiver of the participant was asked to fill out the Dutch ADAMS 
at baseline as well, independent of the main professional caregiver (interrater reliability 
sample). In sample A, the main professional caregiver was also asked to fill out the 
Dutch ADAMS four weeks after baseline (T2) (test-retest sample). Further, a random 
part (n= 43) of sample A was assessed with the PAS-ADD interview as well (only the 
Depression section). Personal characteristics (gender, age, level of ID) and type of 
care setting of the participants were retrieved from the personal files. The interrater 
reliability, test-retest reliability and criterion validity were not studied at the tertiary 
epilepsy center (sample B).
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Statistical analyses
For the reliability analyses, we calculated that the sample size must be at least 39 
participants (minimal 95% confidence interval (CI)) (Esbensen et al., 2003; Hermans et 
al., 2012; Walter, Eliasziw, & Donner, 1998). In order to be able to examine the reliability 
for subgroups based on the degree of ID (mild, moderate, severe/profound), we 
needed at least 117 participants. IBM SPSS Statistics version 22 was used to perform 
the statistical analyses with a significance level of α= 0.05. Differences on baseline in 
means of the total Dutch ADAMS score and four Dutch ADAMS subscales were studied 
in the whole sample with t-tests for gender and two age groups (18-34 and 35-49) 
and with One-way ANOVA for level of ID. Differences between sample A and sample 
B were studied with Pearson’s Chi-square tests for independence for gender, the two 
age groups and level of ID. The Yates Continuity Correction is used with 2 by 2 tables. 
Besides, we used a two-way between-groups ANOVA to explore the impact of two 
independent variables (level of ID and sample A/B) on the total Dutch ADAMS score.
Pearson’s Chi-square tests for independence were used to study if the three 
subsamples (the interrater reliability sample, test-retest reliability sample and criterion 
validity sample) are representative for sample A. The Yates Continuity Correction is 
used with 2 by 2 tables. The following characteristics of the participants were used to 
determine representativeness: gender, age and level of ID. Our hypothesis was that 
the participants in sample A and the interrater reliability, test-retest reliability and 
criterion validity are not significantly different.
Cronbach’s alpha was used to analyze internal consistency of the Dutch ADAMS (total 
scale and the subscales). Correlations below 0.40 are considered to be poor, between 
0.40 and 0.59 fair and between 0.60 and 0.74 are considered as good. Excellent 
correlations are those above 0.75 (Cicchetti & Sparrow, 1981). With item analysis we 
studied if one or more items decreased the internal consistency. Test-retest reliability 
was used to measure stability and reliability of the Dutch ADAMS over time. Intraclass 
Correlation Coefficients (ICCs) were used to examine if professional caregivers scores 
were correlated. The scores of the Dutch ADAMS can be influenced by an occurrence 
of a major event. If a major event occurred between T1 and T2, the scores of the 
participant were not included into the analyses. To measure the interrater reliability, 
the T1 scores of the main professional caregiver and the second professional caregiver 
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were examined. ICCs were used to measure the interrater reliability. Both test-retest 
reliability and interrater reliability were measured for the total test-retest and interrater 
reliability samples as well as for subgroups (mild ID, moderate ID and severe / profound 
ID). The criterion validity of the Dutch ADAMS Depressive mood subscale was studied 
with sensitivity and specificity rates. The PAS-ADD interview (Depression section) was 
used as the reference standard. 
RESULTS
Participants characteristics
The total study population consisted of 198 adults aged between 18 - 49 years with 
mild, moderate, severe or profound ID and were recruited from different care provider 
services in the Netherlands. The participants of sample A (n=100) lived in different 
care provider services for people with ID. The participants of sample B (n=98) lived in 
residential facilities of a tertiary epilepsy center. All the participants of sample B had 
epilepsy. Details of the participants characteristics can be found in Table 1. 
In the total sample (n=198), we did not find significant differences in mean total 
score and subscale scores for gender, age and level of ID. There were no significant 
differences in gender and age between sample A and sample B. There were significant 
differences in level of ID between sample A and sample B: less participants with mild 
ID and more participants with profound ID were included in sample B. The interaction 
effect between group (sample A/B) and level of ID was not significant (p = 0.10). A 
significant main effect was found for ‘group’ (p = 0.027), but the effect size was small 
(partial eta squared = 0.03). The main effect of level of ID was not significant (p = 0.632). 
Representativeness
Interrater reliability sample
No significant differences in gender (p = 0.566) and age (p = 0.416) between sample A 
and the interrater reliability sample were found. There were significant differences in 
level of ID (p = 0.000), because no adults with mild ID were included in the interrater 
reliability sample. 
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Table 1. Participants characteristics
Total 
sample
n= 198*
Sample A
n= 100
Sample B
n= 98
Interrater 
reliability
sample**
n= 41
Test-retest 
reliability
sample**
n= 37
Criterion 
validity 
sample**
n= 43
Gender
 Male/female 108/90 51/49 57/41 19/22 25/12 17/26
Age (%)
 18-34
 35-49
 97 (49.0)
101 (51.0)
50 (50.0)
50 (50.0)
47 (48.0)
51 (52.0)
18 (43.9)
23 (56.1)
18 (51.4)
19 (48.6)
19 (44.2)
24 (55.8)
Level of ID (%)
 Mild ID
 Moderate ID
 Severe ID
 Profound ID
 Unknown
44 (22.2)
46 (23.2)
57 (28.8)
41 (20.7)
10 (5.1)
28 (28.0)
21 (21.0)
30 (30.0)
11 (11.0)
10 (10.0)
16 (16.3)
25 (25.5)
27 (27.6)
30 (30.6)
0 (0.0)
 
0 (0.0)
11 (26.8)
18 (43.9)
11 (26.8)
 1 (2.4)
13 (35.1)
 8 (21.6)
13 (35.1)
 2 (5.4)
 1 (2.7)
 
9 (20.9)
11 (25.6)
12 (27.9)
11 (25.6)
 0 (0.0)
Residential setting (%)
 Central location
 Community-based
 Independent with
 support
 Unknown
129 (65.2)
 33 (16.7)
 12 (6.1) 
24 (12.1)
53 (53.0)
15 (15.0)
 8 ( 8.0) 
24 (24.0)
76 (77.6)
18 (18.3)
 4 (4.1) 
 
0 (0.0)
41 (100)
 0 (0.0)
 0 (0.0) 
 
0 (0.0)
25 (67.6)
 7 (18.9)
 5 (13.5) 
0 (0.0)
32 (74.4)
 8 (18.6)
 3 (7.0) 
0 (0.0)
Epilepsy (%)
Diagnoses of epilepsy
Epilepsy data not 
collected
 98 (49.5)
100 (50.5)
 0 (0.0)
100 (100.0)
98 (100.0)
 0 (0.0)
 0 (0.0)
41 (100.0)
 0 (0.0)
37 (100)
 0 (0.0)
43 (100)
* Total sample = sample A + sample B, ** Part of sample A. 
Test-retest reliability sample
There was a significant difference in gender (less women) (p = 0.020) and no significant 
differences in age (p= 1.000) and level of ID (p = 0.418) between sample A and the 
test-retest reliability sample. 
Criterion validity sample
There were no significant differences in gender (p = 0.073) and age (p = 0.419) between 
sample A and the criterion validity sample. Significant differences were found in level 
of ID between sample A and the criterion validity sample (p = 0.001) due to less adults 
with mild ID and more adults with profound ID in the criterion validity sample. 
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In the total sample (n=198), the alpha coefficient of the total Dutch ADAMS scale was 
0.91. The alpha coefficients of the four subscales ranged from 0.76 to 0.87. The internal 
consistency was also calculated for sample A. The alpha coefficient of the total Dutch 
ADAMS scale in sample A was 0.92. The alpha coefficients of the four subscales of 
sample A ranged from 0.77 to 0.90. The internal consistency was calculated for the 
subgroup with epilepsy as well (sample B). The alpha coefficient for the total Dutch 
ADAMS in this subgroup was 0.88 and the alpha coefficient for the four subscales 
ranged from 0.74 to 0.84. Details of the internal consistency results can be found in 
Table 2. For the interrater reliability, 41 second professional caregivers also completed 
the Dutch ADAMS at baseline. The interrater reliability of the total Dutch ADAMS was 
0.64 (ICC; 95% CI: 0.42 -0.79). The interrater reliability of the four subscales ranged from 
0.64 to 0.77. Interrater reliability was also measured for the different levels of ID. These, 
and the details of the overall interrater reliability, are presented in Table 2.
To measure the stability and reliability of the Dutch ADAMS over time (test-retest 
reliability), professional caregivers completed the Dutch ADAMS at T1 and T2. Sixteen 
participants who experienced major life events between T1 and T2 were not included 
into the test-retest analyses, resulting in a sample of 37 participants. The test-retest 
period (T1-T2) ranged from 27 to 72 days. The test-retest reliability of the whole Dutch 
ADAMS was 0.71 (ICC; 95% CI: 0.51-0.84). The test-retest reliability of the four subscales 
varied from 0.72 to 0.79. The details of the test-retest reliability of the Dutch ADAMS, 
as well as the results in the level of ID subgroups, can be found in Table 2. 
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Validity
The criterion validity was studied in a sample of 43 participants. A cut-off score of 
≥14 on the Depressive Mood subscale was used for the sensitivity and specificity 
analyses based on the manual of the Dutch ADAMS (Hermans & Evenhuis, 2013). When 
a participant was diagnosed with a major depressive disorder (MDD) according to the 
DSM criteria of the PAS-ADD clinical interview, this participant was marked as ‘positive’ 
on the PAS-ADD. When a participant did not reach the required number of symptoms 
on the PAS-ADD clinical interview to be diagnosed with a MDD, the participant was 
marked as ‘negative’ on the PAS-ADD. Of the 43 participants, 28 participants scored 
‘negative’ on the PAS-ADD clinical interview as well as on the ADAMS Depressive Mood 
subscale (true negatives). Seven out of the 43 participants scored ‘positive’ on the PAS-
ADD clinical interview (MDD diagnosed) and also positive on the ADAMS Depressive 
Mood subscale (true positives). Seven out of the 43 participants were not diagnosed 
with an MDD according to the PAS-ADD clinical interview, but scored above the cut-
off point of the ADAMS Depressive Mood subscale (false positives). One out of the 43 
participants had a MDD according to the PAS-ADD clinical interview, but did not have a 
score above the cut-off point of the ADAMS Depressive Mood subscale (false negative).
The sensitivity of the Dutch ADAMS Depressive Mood subscale is 88% (95% CI: 53%-
98%). The specificity of the Dutch ADAMS Depressive Mood subscale is 80% (95% CI: 
64%-90%). As the criterion validity sample is small, sensitivity and specificity rates of 
the Dutch ADAMS Depressive Mood subscale were not measured for the level of ID 
groups separately. 
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DISCUSSION
Depressive and anxiety symptoms can be difficult to recognize in adults with ID. 
Therefore, reliable and valid screening instruments are needed for this population. The 
results of our study show a good internal consistency of the Dutch ADAMS total scale 
and satisfactory to good internal consistency of the subscales, for adults younger than 
50 years of age. In the subgroup of participants with epilepsy (sample B), the internal 
consistency of the Dutch ADAMS total scale is good and the internal consistency of 
the subscales is satisfactory to good. Thus, including participants with epilepsy did 
not have consequences for the internal consistency of the Dutch ADAMS.
Furthermore, our results suggest a good interrater reliability of the total Dutch ADAMS 
scale and a good to excellent interrater reliability for the subscales. In the level of ID 
subgroups, the interrater reliability is fair to good for the total scale and fair to excellent 
for the subscales (Cicchetti & Sparrow, 1981). The stability over time of the Dutch 
ADAMS (measured with test-retest reliability) is good for the total scale and good 
to excellent for the subscales. In the level of ID subgroups, the test-retest reliability 
of the total scale is excellent for the severe/profound subgroup and fair to good for 
the mild and moderate subgroups. The test-retest reliability of the subscales in the 
ID subgroups ranges from fair tot excellent (Cicchetti & Sparrow, 1981). The criterion 
validity of the Dutch ADAMS Depressive Mood subscale, expressed with sensitivity 
and specificity rates, is good. In summary, our results show that the Dutch ADAMS 
is a reliable and valid screening instrument for detecting anxiety and depressive 
symptoms in adults aged between 18-49 years.
Previous research by Hermans and colleagues in an elderly sample showed a good 
internal consistency of all subscales of the Dutch ADAMS (Hermans et al., 2012). 
Moreover, they also found a good test-retest reliability for the total group and good 
test-retest reliability in the level of ID subgroups (except for the Social avoidance 
subscale in their severe/profound ID subgroup which had a fair test-retest reliability) 
(Hermans et al., 2012). Furthermore, they also mentioned a fair to good interrater 
reliability for the total scale and subscales. In their level of ID subgroups, the interrater 
reliability was fair to good, with exception of a poor interrater reliability in the 
borderline/mild ID subgroup (Hermans et al., 2012). Besides, their criterion validity 
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analyses of the Dutch ADAMS showed a sufficient to good sensitivity and specificity. 
Rojahn and colleagues mention in their study an excellent internal consistency of 
the total ADAMS, which is comparable to ours (Rojahn, Rowe, Kasdan, Moore, & van 
Ingen, 2011). The French version of the ADAMS was evaluated in 2004 (Methot, 2004). 
They found a satisfactory to excellent internal consistency and an excellent test-
retest reliability. The results in the studies of Hermans and colleagues (Hermans et 
al., 2012) and Rojahn and colleagues (Rojahn et al., 2011) are based on the ADAMS 
with five subscales and the study of Methot and colleagues (Methot, 2004) is based 
on an ADAMS with three subscales. As the Dutch ADAMS in the present study has 
four subscales, results of the previous studies are not completely comparable with 
the current study.
The first strength of the present study is the large sample used in the internal 
consistency analyses. A second strength of the current study is the significant amount 
of adults with intellectual disabilities and comorbid epilepsy who are included. Third, 
the mean age of the participants of the current study (34.8 years) is almost 30 years 
below the mean age of the previous study in 2012 by Hermans and colleagues (62.2 
years). As a result, the current study adds valuable information to the existing literature 
about the reliability and validity of the Dutch ADAMS.
 The small sample sizes of the subgroups used in the reliability and validity analyses is 
a limitation of this study. A second limitation of this study is that the three subsamples 
of this study (interrater reliability sample, test-retest reliability sample and criterion 
validity samples ) are not a complete representation of sample A. There was a difference 
between the interrater reliability sample and sample A because no adults with mild ID 
were included in the interrater reliability sample. In the test-retest reliability sample 
there was a underrepresentation of women and in the criterion validity sample, the 
overrepresentation of participants with profound ID and the underrepresentation of 
participants with mild ID caused significant differences. A third limitation is the rather 
large range of the test-retest period.
In conclusion, the Dutch ADAMS is a reliable and valid screening instrument which 
can be used to screen for depressive symptoms and anxiety symptoms in the adult 
population with ID in clinical practice and to monitor the effectiveness of interventions. 
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Routinely screening is recommended in order to prevent underdiagnosis, especially 
among those with epilepsy. In the future, larger subgroups based on level of ID are 
needed and more research can be done in analyzing the underlying factors in the 
Dutch ADAMS in the ID population aged between 18-49 years. 
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ABSTRACT 
Background Although high rates of depression symptoms are reported in adults with 
intellectual disabilities (ID), there is a lack of knowledge about non-pharmacologic 
treatment options for depression in this population. The first research question of this 
paper is: Which non-pharmacological interventions have been studied in adults with 
ID and depression? The second research question is: What were the results of these 
non-pharmacological interventions? 
Method Systematic review of the literature with an electronic search in six databases 
completed with hand searches. PRISMA guidelines have been followed. Selected 
studies met pre-defined inclusion criteria. 
Results Literature search resulted in 4267 papers of which 15 met the inclusion 
criteria. Five different types of non-pharmacological interventions have been studied: 
Cognitive Behavioral Therapy, behavioral therapy, exercise intervention, Social 
Problem-Solving Skills Program and Bright Light Therapy. 
Conclusion There are only a few studies of good quality evaluating non-
pharmacological interventions for adults with ID and depression. Some of these 
studies, especially studies on CBT, show good results in decreasing depressive 
symptoms. High-quality randomized controlled trials evaluating non-pharmacological 
interventions with follow-up are needed. 
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BACKGROUND 
Since the 1980’s there is awareness that psychiatric disorders can co-occur with intellectual 
disabilities (ID) (Sovner and Hurley, 1983, Cooper et al., 2007, Hermans et al., 2013, Marston 
et al., 1997, Hurley, 2008). Nowadays, we know that depression is a common psychiatric 
disorder in adults with ID. The prevalence range of depression in the ID population varies 
from 2.2% to 7.6% (Cooper et al., 2007, Deb et al., 2001, Hermans et al., 2013, Smiley, 2005). 
The prevalence is higher compared to the general population, despite the fact that 
depressive symptoms can be difficult to recognize in this population (Hurley, 2008, Marston 
et al., 1997, Hermans et al., 2013). Depression is mainly characterised by sadness and loss 
of interest or pleasure (American Psychiatric Association, 2013). Depression has a major 
impact on the quality of life (QoL) and leads to cognitive, social and physical problems (Bijl 
and Ravelli, 2000, Beekman et al., 2002, Sprangers et al., 2000, Hays et al., 1995, Alonso et 
al., 2004, Coryell et al., 1993, Judd et al., 2008, Rand and Malley, 2017, Kober, 2010, Horovitz 
et al., 2014). Horovitz and colleagues found a significantly higher QoL in a group of adults 
with ID without Axis I diagnosis compared to adults with ID in the anxiety/mood disorder 
diagnosis group (Horovitz et al., 2014). Furthermore, adults with ID with higher levels of 
anxiety/depression are more likely to report a poor QoL (Rand and Malley, 2017).
In the general population, antidepressants are frequently prescribed to treat depressive 
symptoms. Psychoactive medications, including antidepressants, are regularly 
prescribed in adults with ID, primarily to reduce challenging behavior (Lott et al., 2004, 
Matson and Mahan, 2010, Sheehan et al., 2015, Deb et al., 2009). There is some evidence 
that antidepressant medication can decrease depressive symptoms in adults with ID 
(Janowsky et al., 2005, Masi et al., 1997, Verhoeven et al., 2001). For example, in a group 
of 20 participants, Verhoeven and colleagues found Citalopram effective in decreasing 
depressive symptoms (Verhoeven et al., 2001). Many adults with ID use more than 
one medication and polypharmacy is common in adults with ID (Bowring et al., 2017, 
Häβler et al., 2015, Haider et al., 2014). Negative side effects (short term and long term) 
can appear when psychoactive medications are used in adults with ID (Matson and 
Mahan, 2010, Mahan et al., 2010, Häβler et al., 2015, Eady et al., 2015, Deb et al., 2009). 
For example, physical complaints, neurological damage, movement side effects and 
physiological problems are mentioned (Matson and Mahan, 2010, de Leon et al., 2009, 
Sheehan et al., 2017). Besides, adults with ID seem to be more amenable to develop side 
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effects compared to the general population when psychoactive medications are used 
(Arnold, 1993, Matson and Mahan, 2010, Sheehan et al., 2017). Moreover, it can take a 
while for a psychoactive medication to work in the right daily dosage and adults with ID 
may experience even more side effects when more than one psychotropic medication 
is used (Matson and Mahan, 2010). Therefore, there is a need for evidence based non-
pharmacological treatments for depression in adults with ID.
In the general population, a wide range of systematic reviews on non-pharmacological 
interventions for depression have been published over the last couple of years (Catalan-
Matamoros et al., 2016, Cox et al., 2012, Merry et al., 2011, Kvam et al., 2016, Lee et al., 2016, 
Stubbs et al., 2016). Unfortunately, the conclusions of these reviews (both positive and 
negative) cannot be generalized to the ID population because a large part of the non-
pharmacological interventions for depression of the general population are not suitable 
for adults with ID. Next to cognitive limitations, adults with ID frequently have verbal 
limitations. Psychological interventions, for example CBT, are too difficult for adults 
with a more severe ID and for those with verbal limitations. Furthermore, a large part 
of people with ID have physical limitations as well (Cooper et al., 2015). Consequently, 
exercise interventions can be too complicated to perform or physically impossible. 
A few systematic reviews concerning non-pharmacological interventions for depression for 
adults with ID have been published. Some studies are investigating interventions for a part of 
the ID population. For example, Osugo & Cooper (2016) focused on interventions for adults 
with mild ID and mental ill-health (Osugo and Cooper, 2016). They concluded that there was 
some evidence for Group CBT (although larger trials are needed), but that in general the 
evidence based interventions for people with mild ID and mental problems were limited. 
Koslowski and colleagues (2016) investigated in their systematic review and meta-analyses the 
effectiveness of interventions on mental health problems in adults with mild to moderate ID 
(Koslowski et al., 2016). They found no strong evidence for interventions aimed at improving 
mental health problems, including depression, and found a non-significant moderate effect 
size (d=0.49, 95% CI - 0.05 to 1.03; P=0.08) for depression interventions (psychotherapy only). 
The focus of other reviews in this research area are on specific treatments only. For instance, 
Vereenooghe & Langdon (2013) did a meta-analysis on psychological therapies for people 
with ID and mental health problems and found an overall moderate between-group effect 
size (g = 0.682, 95% CI [0.379, 0.985]). Furthermore, a subgroup meta-analysis indicated that 
individually psychological therapy (g = 0.778, 95% CI [0.110, 1.445]) was more effective than 
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group-based psychological therapy (g = 0.558, 95% CI [0.212, 0.903]) and psychological 
interventions for depression had a moderate effect size (g = 0.742, 95% CI [-0.116, 1.599]). 
Depression can occur in all levels of ID. Hence, an overview of evidence based non-
pharmacological interventions for depression for the whole ID population is needed, as the 
severe and profound ID population got no or little attention in previous reviews. Therefore, 
the aim of this review is to evaluate non-pharmacological treatments for adults with ID 
(all levels) and depression. Our first research question is: Which non-pharmacological 
interventions have been studied in adults with ID and depression? Our second research 
question is: What were the results of these non-pharmacological interventions? 
2. METHOD
We have used the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta- 
Analyses) checklist to perform this study (Moher et al., 2009). The study is registered in 
the PROSPERO database (PROSPERO 2016: CRD42016051524). 
2.1 Data sources
An electronic search in six databases, Embase, Medline, Web of Science, Cochrane, PsycINFO 
and Google scholar, has been performed on October 3rd 2016. The search strategy (for the 
databases mentioned above) are included in Appendix 1. The electronic search has been 
completed with hand searches in reference lists of recent systematic reviews (published 
between January 2012- October 3rd 2016) and in reference lists of included papers. 
2.2 Study selection
2.2.1 Inclusion criteria
Inclusion criteria have been clearly defined before the start of the study. All papers 
published in English before October 3rd 2016, mentioning non-pharmacological 
interventions for treating depression (of any type) or depressive symptoms in adults 
(aged ≥16 years) with ID (IQ ≤70) have been selected. Outcome measures on depressive 
symptoms must be mentioned in the paper to be included. Because the aim of this study 
is to find all non-pharmacological interventions for adults with ID and depression, no 
exclusion on type of study-design has been made. Therefore, all different kinds of study 
designs, from case study to RCT, were included. The choice to include all study designs 
4
PaulineHamers_BNW.indd   73 12/03/2020   16:39:04
74
Chapter 4
contributes to the presentation of the current state of evidence for the different types of 
non-pharmacological interventions and possible gaps of knowledge can be exposed.
When a combined population of children and adults was described in a paper, the results 
of the adult population must be separately presented to be included. The same applies to 
level of ID: when the study population also contained adults with an IQ of more than 70, 
the population with IQ ≤70 must be separately presented to be included. In some papers, 
combined interventions (pharmacological and non-pharmacological) are described. Papers 
are only included when the results of both of these interventions are studied separately. 
(Systematic) reviews of nonpharmacological interventions, as well as narrative papers 
without results and congress abstracts, were not included in the current review. 
2.2.2. Process of the study selection
After identifying papers through the electronic search, duplicates have been removed. 
Then, title and abstract of the papers have been scanned by two reviewers (PH and 
HH) independently, according to the predefined inclusion criteria mentioned above. 
After the selection of all relevant records on title and abstract, the databases of the two 
reviewers were merged to see if there was any disagreement about included papers. 
Any disagreement was solved by discussion in a consensus meeting. Reference lists 
of recent systematic reviews were studied by both reviewers (PH and HH) for relevant 
studies. Hereafter, full texts of all remaining papers have been assessed for eligibility by 
two reviewers (PH and HH) independently. Hand searches in reference lists of included 
papers was done to search for relevant papers to include. The potential relevant papers of 
both hand searches were discussed by both reviewers (PH and HH) before including the 
papers in the final database. After this step, the final database was created. See Figure 1 
for the flow chart of the selection of studies. Data extraction of the included studies has 
been performed by one reviewer (PH) and checked by the second reviewer (HH).
2.3 Quality assessment of the included studies
To evaluate the quality of the included studies, the Cochrane Risk Of Bias Tool (Higgins 
and Green, 2011) has been used by two reviewers independently (PH and HH) and any 
disagreement has been discussed in a second consensus meeting. With this tool, six domains 
were assessed to evaluate the quality of the included studies: selection bias, performance 
bias, detection bias, attrition bias, reporting bias and possible other bias. Low risk of a specific 
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bias is rated with a ‘+’. For example, there is a low risk of performance bias when participants 
and researchers do not know which intervention the participant will receive (blinding). When 
there is a high risk of a specific bias, that bias is marked with a ‘-‘. For example, when there is 
a high risk of selection bias due to inadequate concealment of allocations. A question mark 
is used when not enough information is given in the paper to make a clear judgement. The 
included studies have also been screened for mentioning conflicts of interest. 
2.4 Quality assessment of the current systematic review
AMSTAR (which stands for: A MeaSurement Tool to Assess systematic Reviews) is used 
by an independent researcher to assess the methodological quality of the current 
review (Shea et al., 2007). The goals of the AMSTAR include creating valid, reliable and 
useable instruments to differentiate between systematic reviews. Besides, the AMSTAR 
facilitates the development of high-quality reviews. The AMSTAR checklist consists of 
eleven questions and seems to be a valid and reliable instrument (Shea et al., 2009). 
3. RESULTS
The electronic search identified 6023 papers. After removing duplications, 4267 papers have 
been included in the initial database. These 4267 papers have been screened on title and 
abstract by two reviewers independently (PH and HH). The reference lists of recent systematic 
reviews (Chen, 2013, Flynn, 2012, Sturmey, 2012, Matson, 2013, Hwang and Kearney, 2013, 
Vereenooghe and Langdon, 2013, Jennings and Hewitt, 2015, Koslowski et al., 2016, Maber-
Aleksandrowicz et al., 2016, Osugo and Cooper, 2016, Unwin et al., 2016) were studied for 
relevant papers by these two reviewers as well. One relevant new paper was found. Both 
reviewers read 113 full text articles and screened these papers on the inclusion criteria. The 
main exclusion reason was the absence of study results (for example: narrative articles or 
study results on depressive symptoms were not published), see Figure 1. A total of 15 papers 
have been included after full text screening. Hand searches in reference lists of these included 
papers (also done by reviewers PH and HH) did not reveal other relevant papers to include 
in the final database. Therefore, the final database contained 15 papers. 
3.1 Description of the included studies
Five different types of non-pharmacological interventions are identified in the included 
studies of this review: Cognitive Behavioral Therapy, behavioral therapy, exercise 
4
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intervention, Social Problem-Solving Skills Program and Bright Light Therapy. Some of 
these interventions are developed for the ID population, others are adjusted versions of 
interventions of the general population. The interventions will be discussed in sections 
3.3.1 - 3.3.5 and the characteristics of the studies are presented in Table 1a and Table 1b. 
3.2 Quality assessment of the included studies
According to the Cochrane Risk of Bias Tool, none of the included papers had a low risk 
of bias on all domains and much is unclear due to a lack of reporting. Two studies scored 
a low risk of bias on five out of seven criteria (Hassiotis et al., 2013, Carraro and Gobbi, 
2014). Only one study mentioned no conflicts of interest (Hassiotis et al., 2013). In the 
other papers nothing was mentioned about any conflicts on this matter. In Table 2, the 
details of the quality assessment are shown. 
3.3.1. Cognitive behavioral therapy
Cognitive Behavioral Therapy (CBT) is the most common studied intervention to decrease 
depressive symptoms. CBT is a psychotherapy in which thoughts, beliefs and attitudes 
are discussed. In CBT, thoughts are modified in order to change mood and behavior. Eight 
studies focused on CBT (Lindsay et al., 1993, McCabe et al., 2006, McGillivray et al., 2008, 
Ghafoori et al., 2010, Hassiotis et al., 2013, McGillivray and Kershaw, 2013, McGillivray and 
Kershaw, 2015, Lindsay et al., 2015). Three studies were RCT’s with follow-up (McCabe 
et al., 2006, McGillivray et al., 2008, Hassiotis et al., 2013). Three studies were controlled 
trials with pre-, post- and follow-up (Lindsay et al., 2015, McGillivray and Kershaw, 2015, 
McGillivray and Kershaw, 2013). The study of Ghafoori et al. (2010) was a pilot study with 
one group with pre, post and follow-up measurements (Ghafoori et al., 2010). Two cases 
were described in the study of Lindsay and colleagues (Lindsay et al., 1993).
Seven of these studies reported significantly decreased depression symptoms after CBT, one 
high quality study (Hassiotis et al., 2013) did not find significant treatment effects. In the study 
of Lindsay et al. (2015) no significant effect was found in the BSI (Brief Symptom Inventory) 
depression scale, but they did found significant reductions in self-reported depression 
(Glasgow Depression Scale, GDS) and carer-reported depression (GDS). In six of the seven 
studies with positive results, the improvement maintained at follow-up. Based on the results 
and quality of the included studies, CBT seems to be an effective intervention to decrease 
depressive symptoms in adults with ID, although there are some conflicting results. 
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Figure 1. Flow chart of study selection 
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Table 1a. Characteristics of included studies.
Author (year) Study design Sample size Participants (age, 
gender and level of ID)
Intervention Measured 
depression 
outcome
Results on depressive symptoms
McCabe et al. 
(2006)
RCT n= 34: 19 EG, 15 CG. (The CG 
group later also took part of 
the EG). Total EG: 34
Mean age: 34.1 (EG), 
39.8 (CG)
 22M (16 EG + 6 CG)/27F 
(18 EG+9 CG)
Mild-moderate ID
Group CBT, 5 weeks, 
2h sessions. Control 
group: waiting list
BDI-II, ATQ-R Intervention significantly decreased depressive 
symptoms and negative automatic thoughts.
Follow-up (3 months, n=18): impact of the 
intervention on depressive symptoms sustained 
over time, no further improvement found.
McGillivray et 
al. (2008)
RCT n= 47: 20 TG, 27 CG. (Control 
group received treatment as 
well after follow-up (TG 2).
Mean age: 38.4 (TG) and 
31.2 (CG)
32 M (TG 13, CG19)/ 15 F 
(TG7, CG 8)
Mild ID
Staff administered 
group CBT program, 
12 weeks, 2h sessions.
BDI-II, ATQ-R Significant decrease in depressive symptoms and 
negative automatic thoughts in the CBT group.
Follow-up (3 months): positive effects maintained.
Ghafoori et al. 
(2010)
Pilot study, one 
group (pre, post 
and follow-up)
n= 8 Mean age: 20.0
2M/6F
Mild-moderate ID
Cognitive Behavioral 
Group Therapy 
Program, 9 weeks, 
1.5h sessions
SCL-90-R Significant improvements in six primary 
dimensions of the SCL-90-R, including ‘Depression’.
Follow-up (4 months): no significant treatment 
effects maintained at follow-up.
Hassiotis et al. 
(2013)
RCT n= 32: 16 TG, 16 CG. Mean age: 33.7 (M-iCBT) 
38.3 (TAU)
12M/20F,
Mild-moderate ID
M-iCBT, 16 weeks, 
1h sessions. Control: 
Treatment as usual
BDI-Y No significant treatment effect.
Follow-up (6 months): no significant effects on 
depression.
McGillivray & 
Kershaw (2013)
Controlled trial 
(pre, post and 
follow-up)
n= 82: 32 G1, 24 G2,
26 G3.
Mean age overall = 37*
47M/35F *
Mild ID
Staff administered 
group CBT program + 
with a staff-initiated 
referral to a GP (1), 
Staff administered 
group CBT program 
only (2), referral to GP 
only (3)
BDI-II, ATQ-R CB-only group and CB with GP referral group: 
greatest reduction in depression symptoms 
directly after the program. Significant reduction 
in frequency of negative automatic only in the CB-
only group.
Follow-up (8 months): CB strategies (particularly CB 
with referral to GP) appeared effective in reducing 
depressive symptoms and negative automatic 
thoughts.
McGillivray & 
Kershaw (2015)
Controlled trial 
(pre, post and 
follow-up)
n= 70: 23 G1, 23 G2,
24 G3
Mean age overall: 36.0* 
42M/28F*
Mild ID
Cognitive and 
behavioral strategies 
(group 1), cognitive 
focused strategies 
(group 2), behavioral 
focused strategies 
(group 3).
BDI-II, ATQ-R. The mean depression scores decreased in all three 
interventions groups after the intervention. No 
significant difference between groups.
Follow-up (6 months): group 1: all individuals 
indicated improvement, group 2: 67% maintained 
improvement, group 3: 47% maintained 
improvement.
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Table 1a. Characteristics of included studies.
Author (year) Study design Sample size Participants (age, 
gender and level of ID)
Intervention Measured 
depression 
outcome
Results on depressive symptoms
McCabe et al. 
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RCT n= 34: 19 EG, 15 CG. (The CG 
group later also took part of 
the EG). Total EG: 34
Mean age: 34.1 (EG), 
39.8 (CG)
 22M (16 EG + 6 CG)/27F 
(18 EG+9 CG)
Mild-moderate ID
Group CBT, 5 weeks, 
2h sessions. Control 
group: waiting list
BDI-II, ATQ-R Intervention significantly decreased depressive 
symptoms and negative automatic thoughts.
Follow-up (3 months, n=18): impact of the 
intervention on depressive symptoms sustained 
over time, no further improvement found.
McGillivray et 
al. (2008)
RCT n= 47: 20 TG, 27 CG. (Control 
group received treatment as 
well after follow-up (TG 2).
Mean age: 38.4 (TG) and 
31.2 (CG)
32 M (TG 13, CG19)/ 15 F 
(TG7, CG 8)
Mild ID
Staff administered 
group CBT program, 
12 weeks, 2h sessions.
BDI-II, ATQ-R Significant decrease in depressive symptoms and 
negative automatic thoughts in the CBT group.
Follow-up (3 months): positive effects maintained.
Ghafoori et al. 
(2010)
Pilot study, one 
group (pre, post 
and follow-up)
n= 8 Mean age: 20.0
2M/6F
Mild-moderate ID
Cognitive Behavioral 
Group Therapy 
Program, 9 weeks, 
1.5h sessions
SCL-90-R Significant improvements in six primary 
dimensions of the SCL-90-R, including ‘Depression’.
Follow-up (4 months): no significant treatment 
effects maintained at follow-up.
Hassiotis et al. 
(2013)
RCT n= 32: 16 TG, 16 CG. Mean age: 33.7 (M-iCBT) 
38.3 (TAU)
12M/20F,
Mild-moderate ID
M-iCBT, 16 weeks, 
1h sessions. Control: 
Treatment as usual
BDI-Y No significant treatment effect.
Follow-up (6 months): no significant effects on 
depression.
McGillivray & 
Kershaw (2013)
Controlled trial 
(pre, post and 
follow-up)
n= 82: 32 G1, 24 G2,
26 G3.
Mean age overall = 37*
47M/35F *
Mild ID
Staff administered 
group CBT program + 
with a staff-initiated 
referral to a GP (1), 
Staff administered 
group CBT program 
only (2), referral to GP 
only (3)
BDI-II, ATQ-R CB-only group and CB with GP referral group: 
greatest reduction in depression symptoms 
directly after the program. Significant reduction 
in frequency of negative automatic only in the CB-
only group.
Follow-up (8 months): CB strategies (particularly CB 
with referral to GP) appeared effective in reducing 
depressive symptoms and negative automatic 
thoughts.
McGillivray & 
Kershaw (2015)
Controlled trial 
(pre, post and 
follow-up)
n= 70: 23 G1, 23 G2,
24 G3
Mean age overall: 36.0* 
42M/28F*
Mild ID
Cognitive and 
behavioral strategies 
(group 1), cognitive 
focused strategies 
(group 2), behavioral 
focused strategies 
(group 3).
BDI-II, ATQ-R. The mean depression scores decreased in all three 
interventions groups after the intervention. No 
significant difference between groups.
Follow-up (6 months): group 1: all individuals 
indicated improvement, group 2: 67% maintained 
improvement, group 3: 47% maintained 
improvement.
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Table 1a. Continued
Author (year) Study design Sample size Participants (age, 
gender and level of ID)
Intervention Measured 
depression 
outcome
Results on depressive symptoms
Lindsay et al. 
(2015)
Controlled trial 
(pre, post and 
follow-up)
n= 24: 12 TG, 12 CG Mean age: 28.9 (TG), 33.1 
(CG)
12 M (6 TG + 6 CG)/ 12 F (6 
TG + 6 CG)
Mild ID
Experimental group: 
Individual CBT
Control group: waitlist 
(TAU)
BSI, GDS No significant effect on BSI depression score. 
Statistically significant reductions in self-reported 
depression (GDS) and carer-reported depression 
(GDS).
Follow-up: 3 to 6 months follow-up (treatment 
group only): Significant decrease on the GDS 
maintained.
Jahoda et al. 
(2015)
Feasibility study 
(one group: 
pre, post and 
follow-up)
n= 21 Mean age= 42.2
12M/ 9F
Mild-moderate-severe ID
Behavioral activation, 
10-12 sessions.
GDS-LD #
IDDS #
Significant reduction in self-report depressive 
symptoms. Positive change for informant reports 
on depressive symptoms.
Follow-up (3 months): reduction depressive 
symptoms maintained.
Heller et al. 
(2004)
RCT n= 53: 32 TG, 21 CG Mean age: 39.41 (TG), 
40.22 (CG)
24M/29F
Mild - moderate ID.
TG: 12 weeks, 3 days 
per week health 
promotion program, 
2 hrs a day (1h 
exercise + 1h health 
education). CG: no 
training.
CDI Participants in the intervention group were 
less depressed than those in the control group 
(marginally significant).
No follow-up.
Carraro & 
Gobbi (2014)
RCT n= 27: 14 EG, 13 CG Mean age overall: 40.1*
16M/11 F*
Mild-moderate ID
Short-term group-
base exercise 
program, 12 weeks, 
two times a week, 1h 
sessions.
Control group: 
painting activities
Zung 
Self-Rating 
Depression 
Scale
Significant reduction of depressive symptoms in 
the exercise group compared with the control 
group.
No follow-up.
Note. *: not specified per group. #: measurements especially developed for people with ID. Ab-
breviations: ATQ-R, Automatic Thoughts Questionnaire-Revised; BDI, Beck Depression Inventory; 
BDI-Y, Beck Depression Inventory Youth; BSI, Brief Symptom Inventory; CBT, Cognitive Behavior 
Therapy; CDI, Children’s Depression Inventory; F, female; GDS-LD, Glasgow Depression Scale for 
people with Learning Disabilities; ID, intellectual disabilities; IDDS, the Intellectual Disabilities 
Depression Scale; M, male; M-iCBT, Manualized Individual Cognitive Behavioral Therapy; SCL-
90-R, Symptom Checklist-90-Revised; TAU: treatment as usual. 
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Table 1a. Continued
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Intervention Measured 
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outcome
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No follow-up.
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BDI-Y, Beck Depression Inventory Youth; BSI, Brief Symptom Inventory; CBT, Cognitive Behavior 
Therapy; CDI, Children’s Depression Inventory; F, female; GDS-LD, Glasgow Depression Scale for 
people with Learning Disabilities; ID, intellectual disabilities; IDDS, the Intellectual Disabilities 
Depression Scale; M, male; M-iCBT, Manualized Individual Cognitive Behavioral Therapy; SCL-
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Table 2. Quality assessment of the included studies
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Matson (1982) - - - - + ? -
Lindsay et al. (1993) - - - - + ? -
Altabet et al. (2002) - - - - + ? -
Heller et al. (2004) ? ? + + + ? +
McCabe et al. (2006) ? ? + + + ? -
Anderson & Kazantzis (2008) - - - + + ? ?
McGillivray et al. (2008) ? ? + + + ? -
Ghafoori et al. (2010) ? ? - + + ? -
Hassiotis et al. (2013) ? + + + + ? +
McGillivray & Kershaw (2013) ? ? ? + ? ? ?
Carraro & Gobbi (2014) + - + + + ? +
Stuart et al. (2014) - - - + + ? -
Jahoda et al. (2015) - - + - + ? -
McGillivray & Kershaw (2015) - - - + + ? +
Lindsay et al. (2015) - - + + + ? +
 Note. + = low risk, - = high risk, ? = unclear.
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3.3.2 Behavioral therapy
In three studies the effect of behavioral therapy on depressive symptoms has 
been investigated (Matson, 1982, Stuart et al., 2014, Jahoda et al., 2015). Behavioral 
therapy is based on the theory that a large part of human behavior is learnt from 
the environment. In all three studies participants with mild ID have been included, 
Matson (1982) and Jahoda et al. (2015) also included participants with moderate or 
severe ID. None of these three studies on behavioral therapy used control groups next 
to the experimental groups. In the feasibility study of Jahoda et al., 21 participants 
were included in a one group study with pre, post and follow-up measurements. 
Matson (1982) and Stuart et al. (2014) reported case studies (respectively n=4 and 
n=1). Depressive symptoms were (significantly) decreased after behavioral therapy in 
all three studies. The patient in the study of Stuart et al. (2014) still had a depression 
score above the cut-off point after the intervention. In the studies of Matson (1982) and 
Jahoda et al. (2015) the reduction of depressive symptoms maintained at follow-up. 
Because of the small sample sizes and no use of control groups in the above studies, 
the results on behavioral therapy on decreasing depressive symptoms in adults with 
ID must be interpreted with caution. 
3.3.3 Exercise intervention
In two RCTs, the effect of exercise on depressive symptoms has been investigated 
(Heller et al., 2004, Carraro and Gobbi, 2014). Participants in the study of Heller et 
al. (2004) participated in a 12 weeks (3 day per week, 2hrs a day), health promotion 
program which consisted of 1h exercise and 1h health education per day. The 
participants in the study of Carraro et al. (2014) participated in a short-term group-
base exercise program (12 weeks, 2 times a week, 1h sessions). Both studies contained 
an intervention group and a control group and reported significant reductions on 
depressive symptoms in the intervention group. Unfortunately, both studies did not 
mention any follow-up measurements. Based on these two studies, we can conclude 
that exercise interventions to decrease depressive symptoms are promising. 
3.3.4 Social Problem-Solving Skills Program
The only study which focused on social problem-solving skills was a multiple single-
case study with three participants (Anderson and Kazantzis, 2008). Participants in 
this study had mild ID and got 15 individual sessions of Social Problem-Solving Skills 
PaulineHamers_BNW.indd   84 12/03/2020   16:39:05
85
Systematic review non‐pharmacological interventions
training where they were trained to solve the problems that they encountered in daily 
life. No control group has been used in this study. Reduction of depressive symptoms 
was seen in two out of three participants, in whom improvement maintained at the 
4 weeks follow-up. This study should be seen as a first exploration of the potential of 
problem-solving skills programs, because of the poor design of this study. 
3.3.5 Bright Light Therapy
Altabet et al. (2002) published three case studies investigating the effect of Bright Light 
Therapy (BLT) on depressive symptoms (Altabet et al., 2002). The participants had a 
profound ID and participated in a 12 weeks, five days a week, BLT program (no control 
group). Participants got BLT in the morning with a 10.000 lux light box. Positive effects 
on mood were found, but beneficial treatment effects were not uniform. At 3-week 
follow-up, treatment gains maintained. The 8-week follow-up showed increased 
depressive symptoms. As this study only contains case reports, it should be seen as a 
first consideration of the use of BLT to decrease depressive symptoms in adults with ID. 
3.4 Quality assessment of the current systematic review
The current study was evaluated by an independent researcher and scored 8 out of 11 
points. According to AMSTAR, the strengths of this review are the use of an ‘a priori’ 
design, the duplicate study selection and data extraction, and tables 1a-1b providing 
characteristics of the included studies. 
4. DISCUSSION
The current systematic review contains 15 studies evaluating the effect of a total of 
five different non-pharmacological interventions to decrease depressive symptoms 
in adults with ID. These five different types of non-pharmacological interventions 
are similar to those found by Holvast and colleagues in the elderly population with 
depression in primary care (Holvast et al., 2017). Based on our study, we can conclude 
that CBT is an effective non-pharmacological intervention to decrease depressive 
symptoms in adults with mild or moderate ID (Lindsay et al., 2015, McCabe et al., 
2006, McGillivray and Kershaw, 2015, McGillivray and Kershaw, 2013, McGillivray et 
al., 2008). However, these results must be interpreted with caution because of the 
methodological problems of some studies as seen in the quality assessment. In the 
4
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general population, CBT is a widely used effective treatment for depression (Butler et 
al., 2006). CBT can be used in the mild to moderate ID population to decrease depressive 
symptoms as well, although more RCTs are needed to establish its usefulness in clinical 
practice. The main part of the included studies in this paper include interventions for 
people with mild or moderate ID. In only two studies people with severe or profound 
ID have been included, even though it is known that they can suffer from depression 
as well (Hermans et al., 2013, Cooper et al., 2007). In general, conducting intervention 
studies in the ID population is challenging. For instance, ethical dilemmas, specific 
living conditions of people with ID, dependence on professional staff, a difficult 
informed consent procedure, the burden of the measurements and challenging 
behavior are issues researchers are confronted with when conducting intervention 
studies in this population (Oliver et al., 2002, Hamers et al., 2017). This might be an 
explanation why intervention studies with adults with severe ID are even more scarce. 
In the 1980s, Matson already published about behavioral therapy for adults with ID 
and depression. Unfortunately, none of the studies on behavioral therapy included in 
this review used control groups (Matson, 1982, Stuart et al., 2014, Jahoda et al., 2015). 
Therefore, we cannot conclude with certainty that behavioral therapy is responsible 
for the decrease in depressive symptoms. However, as positive results are published 
in these papers, it seems promising.
In the two studies (RCTs) investigating exercise as a non-pharmacological treatment to 
decrease depressive symptoms, intervention groups as well as control groups have been 
used (Carraro and Gobbi, 2014, Heller et al., 2004). Both studies reported positive results 
in decreasing depressive symptoms. In the study of Heller et al. (2004) participants got 
health education and exercise and in the study of Carraro & Gobbi (2004) participants 
got exercise only, which makes it hard to compare these two exercise studies. Despite 
this fact, exercise interventions seem promising interventions to decrease depression 
in adults with ID without psychical limitations and should be further studied.
The study of Anderson & Kazantzis (2008) was the only study in this review focusing 
on Social Problem-Solving Skills Program. Unfortunately, this was a multiple single-
case study with only three participants which makes it hard to draw any conclusions 
about the effect of this intervention on decreasing depressive symptoms (Anderson 
and Kazantzis, 2008). Bright Light Therapy (BLT) in adults with profound ID is studied by 
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Altabet and colleagues in 2002. Positive effects were seen on mood, but no conclusions 
can be drawn because of the small sample size and no control group (Altabet et al., 
2002), so more research is needed. The recent published pilot study with promising 
results of Hermans and colleagues (Hermans et al., 2017) is the first step towards more 
insight into the effect of BLT as a treatment for depression in adults with ID. 
A large part of the 15 included studies of this review are case reports or studies with a 
small sample size. Some of the reviewed studies also have methodological problems, 
for example: no control group or no follow-up. Despite the fact that a large number of 
adults with ID suffer from depressive symptoms, limited well conducted studies are 
carried out to evaluate the effect of non-pharmacological interventions to decrease 
depressive symptoms.
The strength of the current systematic review is that the whole study selection 
(from title/abstract to full text) and the quality assessment is done by two reviewers 
independently. Another strength of this study is that there was no restriction on 
publication year, so all relevant studies published before the start of this study are 
screened. Besides, the study protocol of this systematic review was registered at 
the start of the study, which makes the current systematic review transparent. The 
methodological quality of the current study was assessed with the AMSTAR checklist 
(Shea et al., 2007) by an independent researcher and received an AMSTAR score of 8 
(out of 11).
A limitation of the current systematic review is the small number of papers which could 
be included due to the inclusion criteria. Many studies were excluded because of lack of 
data on study methods and outcome measures. For example, in several papers the IQ 
level of participants was not mentioned. Further, depressive outcome measures were 
not reported in quite a few papers, for example in the case series of Tsiouris (Tsiouris, 
2007). Because of the small number of papers included in our review which are spread 
over five different kind of interventions, a meta-analyses on the effect of the non-
pharmacological treatments was unfortunately not possible. We did not use the ‘grey 
literature’ in this systematic review. So, papers could have been missed. Third, this review 
is limited by only including papers published in English. Fourth, the included studies 
are very different in study design which makes them hard to compare with each other.
4
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The used tool to evaluate the quality of the studies (the Cochrane Risk Of Bias Tool) is 
actually designed for (randomized) controlled trials. As for a more pragmatic approach, 
we used it to evaluate all the study designs of the included papers. Eventually, the 
use of this specific tool emphasized the poor quality of most of the studies. It is well 
known that there is a possibility of publication bias of papers with positive outcomes 
(Easterbrook et al., 1991, Dickersin et al., 1987, Turner et al., 2008, Luijendijk and 
Koolman, 2012) and therefore, papers with negative outcomes can be missed which 
may have influenced the results of the current review. 
In conclusion, currently CBT is the most well studied non-pharmacological intervention 
for depression in people with ID, which seems to be effective as well in the mild and 
moderate ID population. Other promising interventions are exercise and possibly 
behavioral therapy and bright light therapy. Although it is known that performing 
a RCT in adults with ID (and depression) can be challenging, we emphasize that 
further research, preferably RCTs, are needed to grow the evidence-base for non-
pharmacological interventions for people with ID and depression. In this way, the 
non-pharmacological treatment options in this population can be expanded, which 
is especially important for those with severe or profound ID who can often only rely 
on pharmacological treatments. 
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APPENDIX 1
Search strategies 
Embase.com
(‘depression’/exp OR ‘mental health’/exp OR ‘mental disease’/de OR ‘mental patient’/de 
OR ‘mood disorder’/de OR ‘major affective disorder’/de OR ‘minor affective disorder’/
de OR (depressi* OR bipolar* OR (season* NEAR/3 affecti*) OR dysphori* OR dysthymi* 
OR melancholi* OR pseudodementi* OR psychopatholog* OR ((mental* OR psychiatr*) 
NEAR/3 (health* OR disorder* OR disease* OR difficult* OR comorbid* OR co-morbid*)) 
OR ((mood OR affect*) NEAR/3 disorder*)):ab,ti) AND (‘psychiatric treatment’/de OR 
‘electroconvulsive therapy’/exp OR ‘psychotherapy’/exp OR ‘physical medicine’/exp OR 
‘exercise’/exp OR ‘chronotherapy’/exp OR ((non NEXT/1 pharmac*) OR nonpharmac* OR 
psychotherap* OR physiotherap* OR phototherap* OR kinesiotherap* OR kinesitherap* 
OR exercis* OR dramatherap* OR storytell* OR mindfulness* OR ((psychiatr* OR behav* 
OR cognit* OR psycho* OR dance OR activit* OR activat* OR running OR movement* 
OR physical* OR light OR group OR electroconvuls* OR drama OR socioemotion* OR 
emotion* OR mental*) NEAR/3 (treat* OR therap* OR interven*)) OR psychoeducat* 
OR ‘therapeutic work’ OR chronotherap* OR CBT):ab,ti) AND (‘intellectual impairment’/
de OR ‘mental deficiency’/exp OR ‘developmental disorder’/de OR (((intellectual* 
OR mental* OR learning) NEXT/1 (impair* OR disab* OR deficien* OR handicap* OR 
retard*)) OR (developmental* NEXT/1 (disorder* OR disab*)) OR (Down* NEAR/3 
syndrome*)):ab,ti) AND [english]/lim NOT (‘juvenile’/exp NOT adult/exp) 
Medline Ovid
(exp “Depression”/ OR exp “Mood Disorders”/ OR “mental health”/ OR “Mental 
Disorders”/ OR “Mentally Ill Persons”/ OR “Bipolar Disorder”/ OR (depressi* OR 
bipolar* OR (season* ADJ3 affecti*) OR dysphori* OR dysthymi* OR melancholi* OR 
pseudodementi* OR psychopatholog* OR ((mental* OR psychiatr*) ADJ3 (health* 
OR disorder* OR disease* OR difficult* OR comorbid* OR co-morbid*)) OR ((mood 
OR affect*) ADJ3 disorder*)).ab,ti.) AND (“Psychiatric Somatic Therapies”/ OR exp 
“Convulsive Therapy”/ OR exp “Psychotherapy”/ OR “Physical and Rehabilitation 
Medicine”/ OR “Psychiatric Rehabilitation”/ OR exp “Physical Therapy Modalities”/ OR 
exp “exercise”/ OR “chronotherapy”/ OR ((non ADJ pharmac*) OR nonpharmac* OR 
psychotherap* OR physiotherap* OR phototherap* OR kinesiotherap* OR kinesitherap* 
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OR exercis* OR dramatherap* OR storytell* OR mindfulness* OR ((psychiatr* OR behav* 
OR cognit* OR psycho* OR dance OR activit* OR activat* OR running OR movement* 
OR physical* OR light OR group OR electroconvuls* OR drama OR socioemotion* OR 
emotion* OR mental*) ADJ3 (treat* OR therap* OR interven*)) OR psychoeducat* OR 
“therapeutic work” OR chronotherap* OR CBT).ab,ti.) AND (exp “Intellectual Disability”/ 
OR “Developmental Disabilities”/ OR (((intellectual* OR mental* OR learning) ADJ 
(impair* OR disab* OR deficien* OR handicap* OR retard*)) OR (developmental* ADJ 
(disorder* OR disab*)) OR (Down* ADJ3 syndrome*)).ab,ti.) AND english.la. NOT ((exp 
child/ OR exp infant/ OR Adolescent/) NOT exp adult/) 
PsycINFO Ovid
(exp “Depression (emotion)”/ OR exp “Affective Disorders”/ OR “mental health”/ OR 
“Mental Disorders”/ OR “Bipolar Disorder”/ OR (depressi* OR bipolar* OR (season* 
ADJ3 affecti*) OR dysphori* OR dysthymi* OR melancholi* OR pseudodementi* 
OR psychopatholog* OR ((mental* OR psychiatr*) ADJ3 (health* OR disorder* OR 
disease* OR difficult* OR comorbid* OR co-morbid*)) OR ((mood OR affect*) ADJ3 
disorder*)).ab,ti.) AND (“Physical Treatment Methods”/ OR exp “Phototherapy”/ OR 
exp “Electroconvulsive Shock Therapy”/ OR exp “Psychotherapy”/ OR exp “Physical 
Therapy”/ OR exp “exercise”/ OR ((non ADJ pharmac*) OR nonpharmac* OR 
psychotherap* OR physiotherap* OR phototherap* OR kinesiotherap* OR kinesitherap* 
OR exercis* OR dramatherap* OR storytell* OR mindfulness* OR ((psychiatr* OR behav* 
OR cognit* OR psycho* OR dance OR activit* OR activat* OR running OR movement* 
OR physical* OR light OR group OR electroconvuls* OR drama OR socioemotion* 
OR emotion* OR mental*) ADJ3 (treat* OR therap* OR interven*)) OR psychoeducat* 
OR “therapeutic work” OR chronotherap* OR CBT).ab,ti.) AND (exp “Intellectual 
Development Disorder”/ OR “Developmental Disabilities”/ OR (((intellectual* OR 
mental* OR learning) ADJ (impair* OR disab* OR deficien* OR handicap* OR retard*)) 
OR (developmental* ADJ (disorder* OR disab*)) OR (Down* ADJ3 syndrome*)).ab,ti.) 
AND english.la. NOT ((100.ag. OR 200.ag.) NOT 300.ag.) 
Cochrane
((depressi* OR bipolar* OR (season* NEAR/3 affecti*) OR dysphori* OR dysthymi* 
OR melancholi* OR pseudodementi* OR psychopatholog* OR ((mental* OR 
psychiatr*) NEAR/3 (health* OR disorder* OR disease* OR difficult* OR comorbid* 
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OR co-morbid*)) OR ((mood OR affect*) NEAR/3 disorder*)):ab,ti) AND (((non NEXT/1 
pharmac*) OR nonpharmac* OR psychotherap* OR physiotherap* OR phototherap* 
OR kinesiotherap* OR kinesitherap* OR exercis* OR dramatherap* OR storytell* 
OR mindfulness* OR ((psychiatr* OR behav* OR cognit* OR psycho* OR dance OR 
activit* OR activat* OR running OR movement* OR physical* OR light OR group OR 
electroconvuls* OR drama OR socioemotion* OR emotion* OR mental*) NEAR/3 (treat* 
OR therap* OR interven*)) OR psychoeducat* OR ‘therapeutic work’ OR chronotherap* 
OR CBT):ab,ti) AND ((((intellectual* OR mental* OR learning) NEXT/1 (impair* OR disab* 
OR deficien* OR handicap* OR retard*)) OR (developmental* NEXT/1 (disorder* OR 
disab*)) OR (Down* NEAR/3 syndrome*)):ab,ti) NOT ((child* OR infan* OR adolescen*) 
NOT adult*) 
Web of Science
TS=(((depressi* OR bipolar* OR (season* NEAR/2 affecti*) OR dysphori* OR dysthymi* 
OR melancholi* OR pseudodementi* OR psychopatholog* OR ((mental* OR 
psychiatr*) NEAR/2 (health* OR disorder* OR disease* OR difficult* OR comorbid* 
OR co-morbid*)) OR ((mood OR affect*) NEAR/2 disorder*))) AND (((non NEAR/1 
pharmac*) OR nonpharmac* OR psychotherap* OR physiotherap* OR phototherap* 
OR kinesiotherap* OR kinesitherap* OR exercis* OR dramatherap* OR storytell* 
OR mindfulness* OR ((psychiatr* OR behav* OR cognit* OR psycho* OR dance OR 
activit* OR activat* OR running OR movement* OR physical* OR light OR group OR 
electroconvuls* OR drama OR socioemotion* OR emotion* OR mental*) NEAR/2 (treat* 
OR therap* OR interven*)) OR psychoeducat* OR “therapeutic work” OR chronotherap* 
OR CBT)) AND ((((intellectual* OR mental* OR learning) NEAR/1 (impair* OR disab* 
OR deficien* OR handicap* OR retard*)) OR (developmental* NEAR/1 (disorder* OR 
disab*)) OR (Down* NEAR/2 syndrome*))) NOT ((child* OR infan* OR adolescen*) NOT 
adult*)) AND LA=(english) 
Google scholar
Depression|depressive 
“nonpharmaceutical”|psychotherapy|phototherapy|”psychiatric|behavior|
cognitive|light therapy” “intellectual|intellectually|mental|mentally
 impairment|disabled|disability|deficiency|handicap|retarded|retardation”
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ABSTRACT
Due to the limited cognitive and communicative abilities of adults with intellectual 
disabilities (ID), current treatment options for depression are often limited to lifestyle 
changes and pharmacological treatment. Bright light therapy (BLT) is an effective 
intervention for both seasonal and non-seasonal depression in the general population. 
BLT is an inexpensive, easy to carry out intervention with minimal side effects. 
However, knowledge on its anti-depressant effect in adults with ID is lacking. Obstacles 
in realizing a controlled intervention study in this particular study population may have 
contributed to this lack. To study the effect of BLT on depression in this population, it 
is necessary to successfully execute a multicenter randomized controlled trial (RCT). 
Therefore, the study protocol and the management of anticipated obstacles regarding 
this trial are presented. 
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1. INTRODUCTION
Depression can be difficult to recognize and diagnose in people with intellectual 
disabilities (ID) because of their cognitive and verbal limitations and different 
manifestations of depression in this group compared to the general population 
(Hurley, 2008; Marston, Perry, & Roy, 1997). For example: crying, expressions of 
irritability, withdrawal and challenging behavior are common characteristics in 
adults with ID and depression (Charlot L., 2007; Hurley, 2008; S. Moss et al., 2000), 
but not part of standard diagnostic criteria (American Psychiatric Association, 2013). 
As a result, depression is poorly recognized in adults with ID (Hermans, Beekman, & 
Evenhuis, 2013). Nevertheless, depression is a common psychiatric disorder among 
adults with ID (Cooper, Smiley, Morrison, Williamson, & Allan, 2007; Hermans et al., 
2013), which can lead to social, cognitive and physical problems and has a negative 
impact on their quality of life (Alonso et al., 2004; Beekman et al., 2002; Bijl & Ravelli, 
2000; Coryell et al., 1993; Hays, Wells, Sherbourne, Rogers, & Spritzer, 1995; Judd et 
al., 2008; Murray & Lopez, 1997; Sprangers et al., 2000). However, there are barely any 
treatment options besides pharmacological treatment, especially for adults with severe 
or profound ID. In the Netherlands, cognitive behavioral therapy is one of the most 
regular therapies for depression, besides medication. Cognitive behavioral therapy 
can only be used in a small proportion of adults with ID due to their intellectual and 
verbal impairments. As a result, the current treatment options for adults with ID and 
depression are often limited to lifestyle changes (such as increasing activities) and 
pharmacological treatment. Because there is a high prevalence of polypharmacy in 
adults with ID (Haider, Ansari, Vaughan, Matters, & Emerson, 2014), the use of (an extra) 
medication is not preferred. Besides, the known side effects of anti-depressants are 
also inconvenient and, unfortunately, it can take some time for the anti-depressants 
work sufficiently. 
Several studies indicate that depression is associated with disturbances in the circadian 
rhythms (Boyce & Barriball, 2010; Bunney & Potkin, 2008; Germain & Kupfer, 2008; 
McClung, 2007; Monteleone, Martiadis, & Maj, 2011; Wirz-Justice, 2006). Circadian 
rhythms (for example: sleep-wake cycle, hormone levels and body temperature) 
are primarily controlled and regulated endogenously by several biological clocks 
which are located at different places in the body (Hastings, Maywood, & Reddy, 
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2008). The main biological clock is located in the hypothalamus brain region in the 
suprachiasmatic nucleus (SCN). Light is the major Zeitgeber of this main biological 
clock and influences the circadian rhythms via retinal light input (Wirz-Justice, 2006) if 
there is no eye disease (Reme, Rol, Grothmann, Kaase, & Terman, 1996). Other external 
factors, such as (social) activities, mealtimes, work schedules and rules and habits of 
a care institution, can influence these circadian rhythms as well (Boivin & Boudreau, 
2014; Kazemi et al., 2016; Naylor et al., 2000).
It is known that light exposure influences the level of the hormone melatonin in a 
healthy brain (Griefahn, Kuenemund, & Robens, 2006). When the amount of light 
decreases, the production of the hormone melatonin, which is created by the pineal 
gland and which influences feelings of sleepiness, increases by input of the SCN. 
Melatonin itself has also influence on the melatonin receptors in the SCN (Arendt, 
2006; Stehle, von Gall, & Korf, 2003; Wirz-Justice, 2013). Thus, the release of melatonin 
follows a circadian rhythm and changes in this release may occur due to a disrupted 
circadian sleep-wake rhythm. It is known, that many adults with depression experience 
tiredness and sleeping difficulties like insomnia (Almeida & Pfaff, 2005; Kaneita et 
al., 2006; Murphy & Peterson, 2015) and older people with ID have a significantly 
less stable and more fragmented sleep-wake rhythm than the general population 
(Maaskant, van de Wouw, van Wijck, Evenhuis, & Echteld, 2013).
The hormone cortisol is released during stress and the level of cortisol is associated 
with depression (Dettenborn et al., 2012; Hardeveld et al., 2014; Vreeburg et al., 2009). 
A chronically elevated cortisol secretion is associated with psychological and physical 
health problems such as high blood pressure, diabetes mellitus and depression 
(Schoorlemmer, Peeters, van Schoor, & Lips, 2009; Vreeburg et al., 2009). Treatment 
of depression may lead to a decrease in stress, which can lead to a decrease of the 
level of cortisol.
In the general population, Bright Light Therapy (BLT) is an effective intervention for 
both seasonal and non-seasonal depression and has been studied widely since the 
1980s (Even, Schroder, Friedman, & Rouillon, 2008; Golden et al., 2005; Kripke, 1998; 
Lieverse et al., 2011; Morgan & Jorm, 2008; Pail et al., 2011; Rosenthal et al., 1984; Schwartz 
& Olds, 2015; Thaler et al., 2011; Tuunainen, Kripke, & Endo, 2004; Wirz-Justice, 2013). 
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Golden and colleagues showed in their review and meta-analyses that the effects of 
BLT are comparable to those of anti-depressants (Golden et al., 2005). However, in a 
recent systematic review, Mårtensson and colleagues argued that the evidence of the 
effectiveness of BLT is inconclusive, partially because of methodological shortcomings 
of several studies (Martensson, Pettersson, Berglund, & Ekselius, 2015). Nevertheless, 
the overall experience with BLT for treatment of depression is positive. Another 
advantage of BLT is that it hardly causes side-effects as opposed to pharmacological 
treatment of depression. Besides, it will also reduce the costs of depression-treatment 
because BLT is relatively inexpensive and seems easy to deploy.
Although BLT has been studied since a couple of decades in the general population, 
only a few case reports have been published on its effect in adults with ID (Altabet, 
Neumann, & Watson-Johnston, 2002; Cooke & Thompson, 1998; Tsiouris, 2007). 
The results of these case reports seem promising, as BLT decreased the number of 
depressive symptoms. A pilot study into feasibility of BLT and using actigraphy in 
adults with ID was recently conducted (Hermans et al, 2015, submitted). Fourteen 
participants (eight men, average age 52) with moderate to profound ID were included. 
Hermans and colleagues concluded that caregivers indicated that BLT and the use of 
actigraphy was feasible for all participants. Also the severity of depressive symptoms 
had been decreased, but the results should be interpreted with caution because of 
the small sample size and the lack of a control group.
As BLT seems to influence the biological clock in the brain, it may have a different 
effect on depression in adults with ID, due to impaired brain development or brain 
damage. Consequently, research outcomes of BLT studies in the general population 
cannot be generalized to adults with ID. Furthermore, also environmental variables, 
for example time spent outside in daylight, may differ from the general population 
and can interfere with the effect of BLT in adults with ID. As a consequence, it is unclear 
whether BLT has the same anti-depressant effect in adults with ID as in the general 
population.
Although it is of great importance to investigate non-pharmacological treatment 
for depression in adults with ID it is quite understandable that so far, no high-
quality effect studies have been performed. Indeed, apart from meeting general 
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requirements for randomized controlled trials (RCT) (sample size with adequate 
power, representativeness, randomization, blinding, adequate statistics, budget), 
research in populations with ID generally has to meet specific challenges. Each study 
requires its own scenario with a detailed identification of potential obstacles, solutions, 
responsibilities and time slots. In this paper, we will describe the study protocol and 
how we have managed the anticipated obstacles. 
2. METHODS 
2.1 Objectives
The primary objective of this study is to investigate the effect of BLT on depressive 
symptoms in both intervention groups compared to regular care (control group). Our 
secondary objectives are: investigating if there is a significant difference in effect of 
BLT with lightbox I compared to lightbox II and if the effect of BLT is still visible four 
weeks after the end of the BLT (follow-up). Besides, we will investigate the effect of 
BLT on circadian rhythms (DLMO and actigraphy) and stress (level of cortisol) in the 
intervention groups. 
2.2 Study protocol
The current study is a multicenter randomized controlled trial (RCT) with 
measurements taken at three different time points: baseline (T0), directly after BLT 
(T1) and four weeks after BLT (T2). Participants will be randomized into three groups. 
Group I: this group will receive two weeks of BLT in the morning before noon with 
a 10.000 lux bright white lightbox, additional to their care as usual. Group II: this 
group will receive two weeks of BLT in the morning before noon with a bright white 
lightbox of < 499 lux (placebo group), additional to their care as usual. Group III: this 
group continues getting regular care with no additional intervention (control group). 
Randomization takes place through a computerized program which has been created 
by an independent data manager. Block stratification will be used to ensure that the 
participants are properly distributed over the study groups within each participating 
center. Blinding will be applied to the researchers, participants and caregivers. The 
researchers do not know which type of lightbox is distributed to the participant. This 
study is introduced by the participants and caregivers as a study where we compare 
two lightboxes with a different amount of lux. The participants and the care providers 
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do not know if lightbox type I or type II is distributed for the BLT. Besides, we make sure 
that participants of the same living area do not get BLT simultaneously. Participants 
and their caregivers are instructed not to mention details of the amount of light of 
the lightbox with the investigators. 
2.2.1 Study population, recruitment and inclusion
The study will be conducted in three care provider services in collaboration with the 
research group of Intellectual disability Medicine of the Erasmus University Medical 
Center Rotterdam in the Netherlands. The three care provider services (Amarant Group, 
Abrona and Ipse de Bruggen) are located in three different regions in the Netherlands 
and provide support or care to a large group of clients (approximately 12,000 clients) 
with borderline to profound ID. Recruitment will mainly be focused on clients who get 
long-term specialized care. Long-term specialized care refers to the living facilities of 
the health care provider services where people with ID live who depend on specialized 
care their whole life. To be included, participants must be 18 years or older, have an 
intellectual disability (IQ ≤ 70) and have severe enough depressive symptoms (score of 
≥ 14 on the depressive mood subscale of the Dutch version of the Anxiety, Depression 
And Mood Scale (ADAMS) (Hermans & Evenhuis, 2013; Hermans, Jelluma, van der Pas, 
& Evenhuis, 2012). Exclusion criteria are a diagnosis of bipolar disorder, prepartum 
and/or postpartum depression, dementia, current delirium, hypomanic, manic or 
psychotic episode, current suicidal behavior or suicidal expressions and if the lens of 
the eye is missing (aphakia). If a client has been treated with BLT, the last treatment 
must have ended more than four weeks ago. Because BLT may cause side effects if 
a participant uses certain photosensitizing medications or has certain diseases (for 
example porphyria, urticaria solaris or recent eye surgery), the participants’ physician 
will decide if it is safe to include the client in the study.
The sample size of this study has been calculated with the SAS/ETS 9.3 user’s guide 
(“SAS/ETS 9.3 user’s guide,” 2011) and is based on a clinically relevant difference of 
four points (decrease) on the depressive mood subscale of the ADAMS (Hermans & 
Evenhuis, 2013) after the intervention, based on the results of the pilot study (Hermans 
et al, 2015, submitted). Depressive symptoms in both intervention groups (group I 
and group II) are compared with depressive symptoms of participants who receive 
care as usual (group III), resulting in multiple comparisons. Therefore, a Bonferroni 
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correction will be applied and we will compare the groups at a significance level 
of 2.5% (α = 0.025) and power of 80% (β= 0.80). Taking this in consideration, each 
group should contain at least 45 participants. Anticipating on early loss to follow-
up of 20% of the participants, our aim is to include 57 participants in each study 
group, leading to including minimally 135 and maximally 171 participants. For our 
primary objectives, attrition in this study can be caused by absence of depression 
subscale scores (caregiver did not fill in the questionnaire(s)). Attrition in our secondary 
measurements can be caused by no approval of the secondary measurements by the 
legal guardian (or participants), failure of the material, problems with storage of the 
melatonin and cortisol samples, no DLMO or cortisol data because of too low values 
(DLMO) or too short hair (< 3 cm) (cortisol).
2.3 Informed consent procedure
Physicians and behavioral scientists of the three care provider services select potential 
participants who meet the inclusion criteria. The informed consent procedure in this 
study differs from the procedure in the general population: not all clients are able 
to give informed consent themselves. The client’s behavioral therapist or physician 
decides whether a client is able to understand the information and to make the 
decision to give consent for participation. If a client is considered able to understand 
the adapted information of the current study and to decide whether he wants to 
participate, the information and consent form are sent to the client. Otherwise, the 
information and consent form are sent to the legal representative. The professional 
caregivers of the client will be informed by an information letter sent by mail and 
e-mail.
2.4 Study intervention
Both BLT groups will receive BLT for the duration of 30 minutes per day at 20 centimeters 
distance for a period of 14 consecutive days, in the morning before 12 a.m. We intend 
to give BLT as early as possible after wake-up. A tape-measure is distributed together 
with the lightbox to measure the distance between the participant and the lightbox. 
Only when a distance of 20 centimeters is not possible, for example due to the use 
of a wheelchair, the 30 cm distance is allowed. In case of 30 centimeters distance, the 
duration of each session is extended from 30 to 60 minutes, according to the manual 
of the lightbox. To ease the burden, the participant may choose an activity he/she 
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feels comfortable with during the BLT. The participants in group I receive BLT (10.000 
lux) with the Philips energy light type HF3319 (UV-filtered lightbox). The participants 
in group II also receive BLT with the Philips energy light type HF3319, but a LEE filter 
is installed to significantly reduce the amount of lux to <499. This LEE filter (no. 299) 
is heat resistant and does not change the color of the light. In order to guarantee 
the safety of the participants, all lightboxes are checked by the Medical Technology 
Department of the Erasmus University Medical Center Rotterdam in the Netherlands. 
This department also measured the number of lux using a lux meter (Konica Minolta 
T-10A) at 20 centimeters distance and 30 centimeters distance. The average amount 
of lux produced by lightbox type I at a distance of 20 centimeters appeared 11214 
lux (range 10860 - 11640) and the average amount of lux of lightbox type II with the 
LEE filter appeared 317 lux (range 297 -329). The average amount of lux produced by 
lightbox type 1 at a distance of 30 centimeters appeared 7122 lux (range 6930-7380) 
and the average amount of lux of lightbox type II with the LEE filter appeared 198 lux 
(range 188-209).
All lightboxes are coded (A or B) by an independent researcher who is not involved 
in this study. The researchers who will distribute the lightboxes do not know which 
code belongs to which type of lightbox, and neither do participants and professional 
caregivers. After completion of the total study, the encryption will be broken. We are 
aware that the placebo (<499 lux) in this study may reduce the depressive symptoms 
as well as the original lightbox (10.000 lux) due to a placebo effect. For example, 
because the participant improved due to the extra attention which is given by the 
professional caregivers due to the BLT. To overcome this issue, we added a care as 
usual group (Group III). In this way, we can compare both intervention groups with a 
group of participants who do not get an added intervention and investigate if possible 
differences can be attributed to the amount of lux.
2.5 Diagnostic measures
2.5.1 Participant characteristics
Participants characteristics (gender, age, ethology of ID, level of ID, residential setting, 
psychiatric disorders, physical medical conditions, use of medication, BLT in the 
past, treatment for depression during study intervention) will be collected through 
participants’ medical and psychological files. The professional caregiver is asked how 
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much time a participant spends outdoors per day, at what time the participant gets 
up and goes to bed (weekdays and weekends) and whether the participant smokes 
or drinks alcohol (including the amount).
2.5.2 Depression
Depressive symptoms will be studied with the depressive mood subscale of the ADESS 
(the Dutch version of the Anxiety, Depression And Mood Scale (ADAMS) (Hermans & 
Evenhuis, 2013; Hermans et al., 2012) which is completed by a professional caregiver. The 
internal consistency, test-retest reliability and inter-rater reliability of the Dutch version 
of this subscale are good (α = 0.85, ICC = 0.78 and ICC = 0.78) (Hermans & Evenhuis, 
2013; Hermans et al., 2012). Its sensitivity and specificity against the gold standard (the 
PAS-ADD interview (S. Moss, 2011)) are 83% and 64%, respectively (Hermans & Evenhuis, 
2013; Hermans et al., 2012). Depressive symptoms are further investigated with the Dutch 
Signalizing Depression List for people with Intellectual Disabilities (SDL-ID) (Roeden, 
1989) and the subscale “Irritability” of the Aberrant Behavior Scale (ABC) (Aman, Singh, 
Stewart, & Field, 1985), to be completed by a professional caregiver. The SDL-ID has good 
internal consistency and inter-rater reliability (α = 0.77 and r = 0.87) (Roeden, 1989) and 
shows a high correlation with the ADAMS depressive mood subscale (r = 0.71) (Hermans 
et al., 2012). The ABC consists of five subscales, but only the subscale “Irritability” will 
be used in this study, because irritability is a characteristic symptom of depression in 
people with ID. The internal consistency of this subscale is good (α = 0.89) (Rojahn, Rowe, 
Kasdan, Moore, & van Ingen, 2011). Presence of a major depressive disorder according to 
DSM criteria will be investigated with the Dutch translation of the PAS-ADD (Psychiatric 
Assessment Schedule for Adults with Developmental Disability) Clinical Interview (S. 
Moss, 2011) before the start of BLT. The PAS-ADD will be conducted by the researchers 
with the professional caregiver and, if possible, also with the participant. In participants 
with a diagnosis of major depression at T0, the PAS-ADD is completed again at T1. 
2.5.3 Sleep-wake rhythm
The circadian sleep-wake rhythm will be studied by examining the sleep-wake pattern 
using actigraphy (AW2 Philips Respironics) four days before the start of BLT (T0), during 
the last four days of BLT (T1), and for four days four weeks after the end of BLT (T2) in 
group I and II. Dim Light Melatonin Onset (DLMO) is also a marker to assess the circadian 
sleep-wake rhythm (Klerman, Gershengorn, Duffy, & Kronauer, 2002; Lewy, 2007; Lewy, 
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Cutler, & Sack, 1999). DLMO in saliva will be studied at T0 and T1 in group I and II. In both 
intervention groups, the saliva samples will be collected by the professional caregivers 3 
hours before bedtime, 2 hours before bedtime, 1 hour before bedtime and at bedtime. 
The melatonin samples are analysed using the RIA method. The DLMO will be calculated 
by the hockey-stick method (Danilenko, Verevkin, Antyufeev, Wirz-Justice, & Cajochen, 
2014). 
2.5.4 Stress
We will longitudinally study stress in both intervention groups by investigating the 
cortisol level in scalp hair samples (Dettenborn et al., 2012; Manenschijn, Koper, Lamberts, 
& van Rossum, 2011; Russell, Koren, Rieder, & Van Uum, 2012). A scalp hair sample of at 
least three centimetres is required to analyse the cortisol level before and after BLT. The 
scalp hair sample will be collected six weeks after the end of BLT by trained professionals. 
Because life events are related to depression and stress in adults with ID (Hermans & 
Evenhuis, 2012), participant’s life events in the year prior to this study will be examined 
using the Checklist Life Events developed by our research group (Hermans & Evenhuis, 
2012) and this questionnaire will be completed by the professional caregiver. 
The circadian sleep-wake rhythm measurements (Actiwatch and DLMO) and stress 
(cortisol level) are not primary outcome measures. The researchers have chosen not to 
burden the ‘care-as-usual group’ (group III) with measurements whose results are not 
necessary to answer the primary research question. The following outcome measures are 
also measured in just the two intervention groups: the expectations of the participant 
and/or their professional caregiver concerning the effect of BLT will be collected prior 
to the BLT using a questionnaire, and compliance is registered during the intervention 
period (two weeks of BLT) by the professional caregivers. As we use the AW2, which has 
an integrated light sensor, the amount of light to which a participant is exposed could 
be measured. However, Burkhalter and colleagues found that the data of the light sensor 
was not reliable due to the fact that the light sensors were covered by the sleeves of 
the participants (Burkhalter et al., 2015). Therefore, the light data of the AW2 will not be 
used to evaluate compliance to the intervention. Adherence to the BLT therapy (start 
time, duration and distance) will be measured using a daily log. The study procedure 
is presented in Figure 1. 
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Recruitment 
Informed consent procedure
Physician checks for possible    
medical contraindications
Group I (10,000 lux)
n = 57
Group II (< 499 lux)
n = 57
Group III (care as usual)
n = 57
Retrieving personal and 
environmental characteristics 
from participants’ medical and 
psychological files.
PAS-ADD interview
Expectation questionnaire
(T2)      Questionnaires
             Actiwatch measurement
Randomisation
Bright light Therapy
Collection of scalp hair sample
Exclusion: refusal to 
participate
Exclusion: establishment of 
an absolute contraindication
Baseline questionnaires (T0) Exclusion: ADESS depressive mood subscale score < 14 
Retrieving personal and 
environmental characteristics 
from participants’ medical and 
psychological files.
Retrieving personal and 
environmental characteristics 
from participants’ medical and 
psychological files.
Saliva sample for DLMO
Actiwatch measurement
Bright light Therapy
PAS-ADD interview
Expectation questionnaire
 PAS-ADD interview
Saliva sample for DLMO
Actiwatch measurement
Compliance is 
registered 
using a log.
  (T1)  Questionnaires 
      Saliva sample for DLMO
       Actiwatch measurement
  (T1)  Questionnaires 
      Saliva sample for DLMO
       Actiwatch measurement
  (T1)  Questionnaires 
Compliance is 
registered 
using a log.
PAS-ADD interview 
(in case of depression at T0)
PAS-ADD interview 
(in case of depression at T0)
PAS-ADD interview 
(in case of depression at T0)
(T2)      Questionnaires
             Actiwatch measurement
Collection of scalp hair sample
(T2)      Questionnaires
             
Figure 1. Flow chart study procedure 
 
2.6 Statistical analyses
Data will be analyzed using IBM SPSS statistics. The intention to treat basis will be 
used in all analyses: participants are analyzed in the group in which they have been 
randomized. If the ADESS depressive mood subscale score of T1 is missing, the 
participant is called a drop-out (loss to follow up). Also a minimum of ten days of 
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BLT is necessary for the analyses. If a participant has had less than ten days of BLT, 
the ADESS depressive mood subscale scores of these participant are not included 
in the analyses. Missing data will not be imputed, but will be reported. Multivariate 
regression analysis will be used to investigate the effect of BLT on depression. The 
ADESS depressive mood subscale scores of the three research groups of T1 will be 
used. The ADESS depressive mood subscale scores of participants in group I and group 
II will be compared separately with the ADESS depressive mood subscale scores of 
participants in the care as usual care group. Group differences at T0 will be statistically 
corrected. For the two primary analyses, a significance level of p= 0.025 will be used, 
to correct for the increased risk of a type 1 error due to multiple comparisons. BLT will 
be considered effective if depressive symptoms decrease significantly (lower ADESS 
depressive mood subscale score) after intervention with BLT. Multivariate analysis of 
variance (MANOVA) will be used to investigate if the effect of BLT with lightbox type 
I (10.000 lux) is larger than BLT with lightbox type II (<499 lux). MANOVA’s will also be 
used to investigate the changes in circadian rhythms, DLMO and stress. To examine 
if the possible effect of BLT still exists four weeks after the end of the BLT (follow-up), 
ANOVA repeated measures will be used. Expectations prior to the BLT, compliance of 
the BLT and patients characteristics will be taken into account as possible confounders. 
2.7 Ethical considerations
The Dutch law (the Medical Research Involving Human Subjects Act) applies to the ‘no, 
unless principle’ and therefore, scientific research with adults with ID (if they are not 
able to understand the information of the study and to decide about participation) is 
in principle forbidden. There is an exception for therapeutic research which may be 
of direct benefit to the participants and cannot be done in another study population 
and for non-therapeutic research which is conducted with a selected population 
(group restricted) and for whom the risks and burden are negligible and with 
minimal objections. Our intervention study meets the criteria for therapeutic research 
because BLT may be an antidepressant, as it is in the general population, and can be 
of great direct benefit for the participants. Further, to participate in our study, a legal 
representative must provide consent for the participants which are not able to decide 
for themselves. Participants will maintain their own regular care and treatment and the 
current study will not interfere with the standard care and treatment. The medication 
of the participants will not be adjusted. This study is part of the Healthy Ageing and 
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Intellectual Disability study. Ethical approval for the current study was obtained for 
all three care provider services by the Ethics Committee of the Erasmus University 
Medical Center Rotterdam in the Netherlands (MEC-2014-632). This study follows the 
guidelines of the Declaration of Helsinki (64ste WMA General Assembly, October 2013). 
This trial is registered (NTR number: NTR5162). Inclusion of the participants started in 
May 2015 and is still ongoing. 
3. OBSTACLE MANAGEMENT
Several obstacles were observed prior to the start of this study. First, there are 
obstacles specific for research in adults with ID. An obstacle results from the specific 
living conditions of adults with ID because inclusion of participants with ID often takes 
place through care provider services. Therefore, apart from management consent 
to perform the study, optimal collaboration and commitment of managers and staff 
of these care provider services are necessary to successfully complete research in 
this population. Therefore, managers and staff were informed and motivated by 
educational sessions and written information prior to the start of the study. In the 
past, this approach led to good results (Hilgenkamp et al., 2011). Furthermore, clients 
are not able to sign up themselves because of cognitive and verbal impairments. As 
a result, an obstacle was how to motivate physicians and behavioral scientists to sign 
up their clients. In a period of four months prior to the start of the recruitment, all 
involved professionals and their managers were informed by educational sessions and 
written information about depression in adults with ID and the study protocol. At the 
start of the recruitment period, the professionals were informed again by email and 
an information letter and during the study through quarterly newsletters.
Participants may not be able to give permission to be included themselves. 
Consequently, the participants may not be motivated to participate, which can be 
an obstacle during this study. Therefore, the participants will be informed by the 
professional caregivers by making use of a simplified version of the patient information 
letter with pictograms. In the current study, participants are dependent on the care 
of professional caregivers. These professional caregivers are key figures in this study, 
because they are involved in several diagnostic measurements as well as in arranging 
BLT in the morning. To inform the professional caregivers, flyers were distributed and 
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written information letters were sent. In this way, professional caregivers were also 
motivated to discuss possible participants with the involved physician or behavioral 
scientist.
Next, the burden of intervention and measurements for both participants and 
professional caregivers can be an obstacle in this study; this is specifically addressed 
in Dutch legislation on research in incompetent study groups. To ease the burden, the 
distribution and information about the lightbox and secondary outcome measures 
(actigraphy, DLMO and cortisol) by the researcher are combined with the PAS-ADD 
interview. Some diagnostic measurements required adaption, too. Van Dijk et al. (2012) 
found that 32% of participants with borderline to profound ID were not able to wear 
an Actiwatch for measuring sleep-wake rhythm, due to anticipated loss or breakage 
of the actiwatch, or to fear, resistance or refusal by participants (or as anticipated by 
professional caregivers) (van Dijk, Hilgenkamp, Evenhuis, & Echteld, 2012). In the study 
of Hylkema & Vlaskamp it was mentioned that insufficient arm movements were an 
obstacle in using actigraphy in adults with ID (Hylkema & Vlaskamp, 2009). To succeed 
in using actigraphy in our study, we have written a detailed information letter with 
pictograms to explain the measurement with the AW2 for both the participant and 
the professional caregivers. Also oral information is given when the AW2 is distributed.
The measurement of DLMO in adults with ID was another obstacle in this study, 
because taking multiple saliva samples can be difficult in our study population. We 
have added special information for optimising the saliva collection in adults with ID 
into the regular DLMO instruction letter for the professional caregivers. Furthermore, 
we diminished the number of saliva samples from the usual five samples to four, 
because DLMO can also be calculated with four samples. With one sample less, the 
participants will be hampered less in their daily activities and it also eases the burden 
on the professional caregivers.
Another obstacle was how to measure the cortisol level over a period of time without 
subjecting participants to invasive measurements like repeatedly taking blood 
samples. Measuring cortisol in scalp hair is a relatively new, non-invasive method to 
determine long-term cortisol levels in humans (Dettenborn et al., 2012; Manenschijn 
et al., 2011; Russell et al., 2012). Hair cortisol concentrations are not subject to variations 
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due to acute stress and can reflect cortisol exposure over months to years (Manenschijn 
et al., 2011; Wester & van Rossum, 2015). Second, there are obstacles specifically for 
BLT studies. Different contraindications and exclusion criteria for BLT were used in 
previous BLT studies in the general population (Benedetti et al., 2005; Dallaspezia 
et al., 2012; Dauphinais et al., 2012; Lam et al., 2006; Lieverse et al., 2008; Oren et 
al., 2002; Terman, Terman, & Ross, 1998). Therefore, we have made  an overview of 
the photosensitizing medications and relevant diseases and clearly stated if a given 
medication or disease is an absolute contraindication or a relative contraindication 
(inclusion is possible), based on relevant literature (Meesters & Letsch, 1998; Terman 
& Terman, 2005; Wirz-Justice, 2013), the advice of consulted ophthalmologists, and 
the ‘Pharmacotherapeutic Compass’ (www.farmacotherapeutischkompas.nl) which 
contains all medicines available in the Netherlands.
From the beginning, there is a debate about which placebo intervention can be used 
in BLT studies. Furthermore, each intervention can have a certain degree of effect, 
regardless whether the intervention contains the appropriate dosage or administration 
(Andrews, 2001; Khan, Khan, & Brown, 2002). In some BLT studies, a (deactivated) ion 
generator is used as a placebo treatment (Dauphinais et al., 2012; Eastman, Young, 
Fogg, Liu, & Meaden, 1998; Flory, Ametepe, & Bowers, 2010). Other BLT studies use 
dim red light, which is considered to be not anti-depressant (Lieverse et al., 2008; 
Loving, Kripke, Elliott, Knickerbocker, & Grandner, 2005; Wirz-Justice et al., 2011). We 
chose to reduce the amount of lux to a point where it is widely considered not to be 
anti-depressant (<499 lux). The two lightboxes used in this study are identical from 
the outside and have the same color of light. Professionals involved in this study do 
not have influence on or knowledge of the randomization sequence; neither do the 
researchers. As a result, low inclusion or selective loss to follow-up is possible due to 
the fact that professionals and/or legal representatives may not want clients to get 
a placebo treatment and still have to undergo effect measurements (Group II) or no 
intervention at all (Group III). Therefore, the study protocol and the necessity of the 
three study groups were discussed in the educational sessions prior to the study, in the 
patient information letters and also further explained if this was requested. Third, there 
is an obstacle which is specific for depression intervention studies in adults with ID. As 
mentioned before, depression can be difficult to recognize and diagnose in people 
with ID because of the cognitive and verbal difficulties and different manifestations of 
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depression in this group compared to the general population (Hurley, 2008; Marston 
et al., 1997). Consequently, an obstacle in this study is including enough participants 
who meet the inclusion criteria of enough depressive symptoms. To optimize inclusion, 
the different manifestations of depression in adults with ID were discussed in the 
educational sessions and newsletters mentioned before. As a result of the discussed 
obstacles, a minimum of six to nine months are required for preparation of the study. 
An overview of the obstacles and consequences for the organization of the study, as 
well as obstacle management are presented in Table 1. 
Table 1. Obstacles, consequences and obstacle management for research in adults with ID, in 
BLT studies and in depression intervention studies in adults with ID. 
Obstacles specific in research in adults with ID
Obstacles Consequences for the 
organization of the study
Obstacle management in the 
current study
Specific living conditions 
of participants: inclusion 
often through care 
provider services.
Collaboration, consent and 
commitment of managers 
and staff.
Managers and staff are informed 
and motivated by educational 
sessions and written information.
Clients are not able to sign 
up themselves because of 
the cognitive and verbal 
impairments: Professional 
staff needs to sign up 
clients.
Motivate physicians and 
behavioral scientists to sign 
up their clients.
Educational sessions and written 
information about depression 
in adults with ID and the study 
protocol prior to the study.
Information by email and an 
information letter at the start of 
the study. Quarterly newsletters 
during the study.
Study population is 
partially or completely 
incompetent to decide to 
participate.
Motivation of participants 
who cannot give consent 
themselves. 
(Legal) ethical 
requirements.
Using a simplified version of 
the patient information letter 
with pictograms, pointing out 
the potential direct benefit for 
participants.
Clients are dependent 
on care of professional 
caregivers.
Inform and motivate 
professional caregivers for 
the study.
Flyers were distributed and 
written information letters are 
sent to inform the professional 
caregivers.
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Table 1. Continued 
Acceptation of intervention 
and measurements.
Decrease the burden 
of intervention and 
outcome measurements 
for participants and 
professional caregivers. 
Some measurements 
require adaptation for our 
study population.
Distribution of the light box, 
explanation of the intervention 
and measurements as well as the 
PAS-ADD interview are combined 
at the same moment.
Actigraphy: detailed information 
letter with pictograms and oral 
information.
DLMO: special instructions into 
the regular DLMO instruction 
letter and adjustment of the 
number of saliva samples
Cortisol: hair cortisol is used 
instead of blood or urine samples.
Obstacles specific in Bright Light Therapy studies
Obstacles Consequences for the 
organization of the study
Obstacle management
Various contraindications 
and exclusion criteria 
were used in previous 
BLT studies in the general 
population.
Figuring out which 
contraindications and 
exclusion criteria apply to 
our study population.
Developing a list of relative and 
absolute contra-indications for 
BLT in adults with ID.
Placebo bright light 
therapy differs across BLT 
studies.
Choosing the right placebo 
condition for this study.
Two (at the outside) identical light 
boxes are used. Adjustment of 
the amount of lux (<499) in the 
placebo condition.
Low motivation to sign up 
or give consent because 
of the randomization 
procedure (RCTs).
(Risk of being selected for a 
non-intervention group).
Low or selective inclusion / 
selective loss to follow-up.
Information about the study 
protocol is given in the 
educational sessions and patient 
information letters and further 
explained if requested.
Obstacle specific in depression intervention studies in adults with ID
Obstacle Consequence for the 
organization of the study
Obstacle management
Depression is not 
recognized in a large part 
of the ID population.
(Risk of) low inclusion. Specific manifestations of 
depression in adults with ID are 
discussed in the educational 
sessions and newsletters.
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4. DISCUSSION
This first multicenter Bright Light Therapy (BLT) randomized controlled trial (RCT) in 
adults with intellectual disabilities (ID) and depression may provide an opportunity to 
improve our knowledge of BLT in this population. The information of the preparation 
period of this study can be of great interest for other researches for designing and 
performing their study. In this paper, we discussed that it is difficult to carry out a high 
quality multicenter RCT on the effects of BLT in adults with ID and depression because 
of the obstacles in research in adults with ID, obstacles specifically for BLT studies 
and an obstacle specifically for depression intervention studies in adults with ID. It is 
necessary to measure the hormones melatonin and cortisol objectively to investigate 
the effect of BLT on the circadian rhythms and stress. Unfortunately, investigating the 
effect of BLT in a study population of adults with ID is challenging due to obstacles in 
measuring depressive symptoms, circadian rhythm (DLMO and actigraphy) and stress 
(cortisol). In addition, other obstacles may arise during the study. For instance, in a 
BLT study a low baseline melatonin secretion was found which may have influenced 
the limited intervention effects (Burkhalter et al., 2015). Besides, Martensson and 
colleagues suggest that the effect of BLT could not be confirmed in several studies due 
to methodological problems like a small study population (Martensson et al., 2015). 
After the inclusion period, it will come clear whether we have successfully managed 
all anticipated obstacles prior to the start of the study and if new obstacles did appear 
during the study. When BLT is effective in our study population it may enlarge the 
treatment options for depression in this population. BLT can then become a non-
pharmacological treatment for decreasing depressive symptoms in adults with ID. 
Especially, for those who not benefit from pharmacological treatment, those with 
polypharmacy and adults with ID who cannot tolerate or refuse medication.
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ABSTRACT 
Background: Although a large number of adults with intellectual disabilities (ID) have 
depressive symptoms, non-pharmacological treatments are scarce. We investigated 
whether bright light therapy (BLT) is effective in decreasing depressive symptoms 
compared to care as usual.
Methods: This multicenter randomized controlled trial consisted of three study groups 
(10.000 lux BLT, dim light BLT and a no-BLT group). Participants received BLT for 30 
minutes in the morning (14 consecutive days), additional to their regular care. Primary 
outcome: depressive symptoms measured with the ADAMS Depressive Mood subscale 
one week after the end of BLT (same time period in the no-BLT group).
Results: 41 participants were included in our trial. In both BLT groups a significant 
decrease in depressive symptoms was seen. No significant differences were found 
between 10.000 lux BLT and no-BLT (p = 0.199), and no significant differences between 
dim light BLT and no-BLT (p = 0.451). A minimum amount of side effects and no adverse 
events were reported.
Conclusions: In both BLT interventions a decrease in depressive symptoms was seen. 
With 10.000 lux BLT, depressive symptoms decreased even below the clinical cut-off 
point, which makes BLT a promising intervention for clinical practice. 
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INTRODUCTION 
Depression is common in the general population and has a large impact on functioning 
in daily life (Wittchen et al., 2011). Compared to the general population, even higher 
numbers of depression and depressive symptoms are found in the population of adults 
with intellectual disabilities (ID) (Cooper, Smiley, Morrison, Williamson, & Allan, 2007; 
Hermans, Beekman, & Evenhuis, 2013). Despite the large number of adults with ID 
and depressive symptoms, treatment options, especially for those with severe ID, are 
scarce (Hamers, Festen, & Hermans, 2018). Some adults with mild or moderate ID and 
without major verbal limitations, may benefit from psychological interventions, for 
example Cognitive Behavioral Therapy (CBT) (Vereenooghe & Langdon, 2013), but a 
large part of adults with ID and depressive symptoms get pharmacological treatment 
or no treatment at all. Pharmacological side effects, high numbers of polypharmacy, 
the lack of non-pharmacological interventions for those with severe ID, together with 
the high prevalence of depressive symptoms in adults with ID, makes investigating 
other non-pharmacological interventions extremely important. 
Bright light therapy
In the general population, Bright Light Therapy (BLT) is broadly studied and used 
in clinical practice to treat seasonal affective disorder and non-seasonal depression 
(Even, Schroder, Friedman, & Rouillon, 2008; Golden et al., 2005; Lieverse et al., 2011; 
Martiny, 2004; Nussbaumer et al., 2015; Tuunainen, Kripke, & Endo, 2004). The working 
mechanism is not fully understood, but it is suggested that disturbances in the circadian 
rhythms are involved (Germain & Kupfer, 2008; Monteleone, Martiadis, & Maj, 2011; 
Wirz-Justice, 2006). Our main biological clock, which controls our circadian rhythms, is 
situated in the hypothalamus in the suprachiasmatic nucleus (SCN). Retinal light input 
is the main influencer of the biological clock (Wirz-Justice, 2006). Neural pathways 
from the SCN lead to the pineal gland where melatonin is produced. In this way, light 
can influence the secretion of melatonin: when the amount of light increases, the 
production of the hormone melatonin is decreased (Griefahn, Kuenemund, & Robens, 
2006). The effect of BLT is comparable to those of pharmacological interventions 
to decrease depressive symptoms (Golden et al., 2005) and BLT can even be more 
effective when combined with antidepressants (Lam et al., 2016). Besides, BLT seems 
6
PaulineHamers_BNW.indd   129 12/03/2020   16:39:08
130
Chapter 6
to be a safe intervention without major side effects (Brouwer et al., 2017; Kogan & 
Guilford, 1998; Meesters & Letsch, 1998). 
Unfortunately, the results of BLT studies in the general population cannot be 
generalized to the population of adults with ID, because many adults with ID have 
some kind of brain damage that might interfere with the abovementioned neural 
pathways; for example, congenital brain damage, progressive brain damage or damage 
caused by traumatic injury. Furthermore, a large amount of adults with ID are care 
dependent and have physical and/or mobility problems. Therefore, it is possible that 
they benefit less from direct daylight because they do not spend the same amount 
of time outside compared to the general adult population. 
In the ID population, BLT did not get much attention yet. Since 1998, some case reports 
were published (Altabet, Neumann, & Watson-Johnston, 2002; Cooke & Thompson, 
1998; Tsiouris, 2007). These first explorations of BLT in the ID population showed 
promising results. However, systematic report of the results and control groups were 
lacking. A feasibility study in the Netherlands showed that BLT is a feasible intervention 
for adults with ID. Besides, they found a decrease in depressive symptoms after BLT in 
almost all patients and in nearly half of the sample a clinical relevant improvement was 
found (Hermans, Soerokromo, & Evenhuis, 2017). As larger studies with control groups 
are needed to expand the knowledge of the effect of BLT in the ID population, the 
primary objective of our study was to investigate whether BLT is effective in decreasing 
depressive symptoms in two BLT intervention groups compared to no-BLT (control 
group). Our secondary objective was to examine if there is a significant difference in 
the effect of BLT between the two BLT intervention groups. Besides, we examined if 
the effect of BLT is still visible four weeks after the end of BLT. 
METHOD
Participants
Potential participants were recruited in three large care provider centers in the 
Netherlands that are part of the Healthy Ageing and Intellectual Disabilities Consort 
(HA-ID Consort). Physicians, psychologists and behavioral scientists of the care provider 
centers selected potential participants and decided whether a potential participant 
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was able to understand the information of the study and to make the decision to give 
informed consent for participation. If the participant was not able to decide, the legal 
guardian was informed and gave written consent. Recruitment and inclusion of the 
participants started in May 2015 and ended in September 2017. The data collection 
ended in November 2017. 
Inclusion and exclusion criteria
Adults with ID (IQ ≤ 70) and with depressive symptoms were included in this study. 
To be included, a minimum score of 14 (clinical cut-off point) was needed on the 
Depressive Mood subscale of the Dutch version of the Anxiety, Depression And 
Mood Scale (ADAMS; range 0 - 39) (Hamers, van Ool, et al., 2018; Hermans & Evenhuis, 
2013). Exclusion criteria were checked by a physician and behavioral scientist who 
were involved with the care of the participant. Exclusion criteria were: a diagnosis 
of bipolar disorder, prepartum and/or postpartum depression, dementia, current 
delirium, hypomanic, current manic or psychotic episode, current suicidal behavior 
or suicidal expressions and aphakia (the lens of the eye is missing). In addition, because 
of possible side effects in combination with BLT, the physician excluded participants 
who used specific photosensitizing medications, had recent eye surgery or certain 
diseases, for example porphyria, urticaria solaris. Previous BLT sessions must have 
ended more than four weeks prior to the inclusion. 
Ethical regulation and trial registration
Written informed consent was retrieved from each participant or from their legal 
guardian if the participant was not able to decide for himself due to the ID. The study 
did not interfere with the usual care and treatment of the participants. Ethical approval 
for all three care provider centers was given by the Ethics Committee of the Erasmus 
University Medical Center Rotterdam in the Netherlands. Guidelines of the Declaration 
of Helsinki (64th WMA General Assembly, October 2013) were followed. Besides, 
this study is registered prior to the start of the study (NTR number: NTR5162) and 
CONSORT guidelines regarding Randomized Trials of Nonpharmacologic Treatments 
were followed (Boutron, Altman, Moher, Schulz, & Ravaud, 2017). 
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Study design 
Randomization and masking
We conducted a multicenter randomized controlled trial (RCT) with three study 
groups to investigate the effect of BLT in adults with depressive symptoms. Block 
stratification was used to ensure that participants were properly distributed over the 
three study groups within each of the three participating centers. Block stratification 
was performed by a computerized program developed by an independent data-
manager. One researcher (PH) enrolled the participants and used the outcomes of 
the digital randomization to assign the participants to the right group. To ensure 
blinding of the researchers, lightboxes were coded before the start of the study by 
an independent researcher. Furthermore, the researchers and the professional staff 
were not informed about which type of lightbox was distributed to the participants. 
The participants and their professional caregivers were not blinded and were told that 
two lightboxes with different amount of lux were tested in the current study. They 
were instructed not to share details of the lightboxes and the amount of lux with the 
researchers. Participants living together at the same residence did not get BLT at the 
same time. When data-collection was finished, the blinding was broken. No changes 
to methods were made after trial commencement. 
Sample size
Prior to this study, the ideal sample size was calculated based on a clinically relevant 
decrease of four points on the Depressive Mood subscale of the ADAMS (Hermans & 
Evenhuis, 2013; Hermans, Jelluma, van der Pas, & Evenhuis, 2012). Details of the sample 
size calculation are previously published (Hamers, Evenhuis, & Hermans, 2017). Our 
aim was to include at least 57 participants in each group. Hence, a maximum of 171 
participants would be included in our study. Unfortunately, after an inclusion period 
of almost two and a half years (May 2015- September 2017), the intended sample size 
was not reached. A large screening with the inclusion criteria of this study among 
adults with ID (>1000 participants) in the three participating care provider centers 
from October 2016 to March 2017 revealed some potential participants, but did not 
give enough perspective to extent the inclusion period longer than September 2017. 
Detailed information of our study protocol and the different obstacles we faced in this 
study are published previously (Hamers et al., 2017). 
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Intervention
In group I, participants received BLT with a 10.000 lux bright white UV-filtered lightbox 
(Philips Energy lightbox, type HF3319), additional to their care as usual. Participants in 
group II received BLT with a bright white lightbox with on average 317 lux, additional to 
their care as usual. In group II we used the same lightbox as in group I, but a LEE filter 
(no. 299) was installed. This heat resistant filter did not change the colour of the light. 
On the outside, the two lightboxes looked the same when they were turned off. The 
participants in group III got no BLT only care as usual (control group). Participants in the 
two intervention groups received 30 minutes BLT in the morning as early as possible 
after wake-up (at least before 12 a.m.), for a period of 14 consecutive days. Usually, 
BLT was given during breakfast. Besides oral information, a detailed BLT manual with 
pictograms was given to the participant and the professional caregiver before the 
start of the intervention. The professional caregivers were asked to report adherence 
in a daily log. The distance between the participant and the lightbox was 20 cm (tape-
measures were distributed). A distance of 30 cm was only allowed when the 20 cm 
distance was not possible, for example because of wheelchair use. When a 30 cm 
distance was used, BLT was extended with 30 minutes per day according to the manual 
of the lightbox. The treatment distances in group I and group II were the same. The 
amount of lux of all lightboxes was measured by the Medical Technology Department 
of the Erasmus University Medical Center Rotterdam in the Netherlands with use of a 
lux meter (Konica Minolta T-10A). The average amount of lux at 20 cm of the lightboxes 
used in group I was 11214 lux (range 10860 - 11640) and 317 lux (range 297 -329) in 
group II. At a distance of 30 cm, the average amount of lux of lightboxes type I was 
7122 lux (range 6930-7380) and the average amount of lux of lightboxes type II was 
198 lux (range 188-209). The Medical Technology Department checked all lightboxes 
used in this trial on safety. Physicians, psychologists and behavioral scientists were 
asked, but not obligated, not to make changes in (medication) treatment four weeks 
prior to enrollment and up to six weeks after the end of the intervention if this was not 
considered necessary. Caregivers were asked to report changes in treatment during 
the study. 
Objectives and outcomes
The primary objective of this study was to examine if BLT is effective in decreasing 
depressive symptoms in two BLT intervention groups compared to no BLT, one 
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week after the end of BLT. The Depressive Mood subscale (13 items) of the Anxiety, 
Depression And Mood Scale (ADAMS) was used to study these depressive symptoms 
prior to BLT (Baseline, T0) and one week after BLT (T1) (Hamers, van Ool, et al., 2018; 
Hermans & Evenhuis, 2013; Hermans et al., 2012). The measurements in the control 
group (no BLT) had the same frequency.
Our secondary objectives were to examine if there is a significant difference in effect 
of BLT between both intervention groups. The ADAMS Depressive Mood subscale 
scores on T0 and T1 of group I and group II were used to investigate this objective. 
Further, we examined if the effect of BLT is still visible four weeks after the end of the 
BLT intervention with use of the Dutch ADAMS Depression subscale scores of group I 
and II at T0 and T2. Additionally, subgroup analyses were used to examine depressive 
symptoms in the three different groups on T1 and T2.
In addition to the ADAMS Depressive Mood subscale, the Dutch Signalizing Depression 
List for people with Intellectual Disabilities (SDL-ID) (Roeden, 1989) was used to 
evaluate the effectiveness of BLT as well, because this measurement contains items 
that are complementary to the Dutch ADAMS Depressive Mood subscale. Besides, 
a subscale of the Aberrant Behavior Checklist (ABC) (Aman, Singh, Stewart, & Field, 
1985) was used to measure “Irritability”, because it is known that a large part of adults 
with ID and depressive symptoms have symptoms of irritability. In the Netherlands, 
these measurements are often used in clinical practice to evaluate the effectiveness 
of interventions. The questionnaires were completed by a professional caregiver at 
T0, T1 and T2. ABC scores were only available on baseline.
The presence of a major depression disorder according to the criteria of DSM-IV 
was investigated with the PAS-ADD Clinical Interview, which is a semi-structured 
psychiatric interview developed for adults with ID (Moss, 2011). Prior to the start of 
the study, the participants (if possible) and the professional caregivers of those in 
both BLT groups were asked to complete a questionnaire about the expectations 
of the BLT intervention. Besides, the professional caregivers were asked to report 
compliance, adverse events and side effects in a daily log during the intervention. 
In case of a serious adverse event (SAE), such as hospitalizations, serious illness or 
death, professional caregivers were asked to report to the researchers immediately. 
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We retrieved information on sex, age, level of ID, use of medication, residential setting, 
treatment during study intervention and BLT in the past by participants’ medical and 
psychological files. 
Statistical analyses
Data were analyzed using IBM SPSS Statistics 24. Prior to the start of the study, we 
stated in our study protocol that the intention to treat basis shall be used. None of the 
participants assigned to one of the three study groups switched to another study arm. 
Missing data on T1 and T2 were not imputed but reported. Baseline characteristics 
of the participants, baseline depression scores, baseline ABC Irritability scores were 
checked for any significant differences between the three groups. Expectations prior 
to the BLT, total amount of BLT days, compliance with the intervention and date of 
the intervention/control group period (quarter) were analyzed with One-way ANOVA 
(2-sided) for continuous data and Chi-squared tests for categorical data to check for 
confounders. Baseline differences between the groups were taken as a confounder 
into the analyses.
To investigate the effect of BLT on depressive symptoms, multivariate regression 
analyses were used. The ADAMS depressive mood subscale of group I and group II 
were compared separately with those of group III (control group). Independent t-tests 
were used to investigate if there was a significant difference in effect of BLT between 
both intervention groups. ANOVA repeated measures were used to investigate the 
effect of BLT at follow-up (four weeks after the end of BLT). For the subgroup analyses, 
paired samples T-tests were used to investigate the ADAMS depression subscale scores 
on T1 and T2 in the three different study groups. A Bonferroni correction resulted in 
a significant level of p =0.017 (.05/3). A Bonferroni correction corrects for increased 
risk of a type 1 error due to multiple comparisons. Effect sizes were measured using 
Cohen’s d. All statistical analyses mentioned above were also conducted with the 
SDL-ID total scores. 
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RESULTS 
Patient characteristics 
Between May 2015 and September 2017, 41 participants were included in our trial. 
Twelve participants were randomly assigned to group I, 15 participants to group II 
and 14 participants to group III. Figure 1 shows the flow diagram of our study. One 
participant of group II was excluded after the intervention, because there was no 
compliance to the study protocol (14 days of BLT were given in a six week period, 
instead of in a two week period). The characteristics of the participants of the three 
groups are presented in Table 1. The participants were aged between 24 and 81 years 
and all levels of ID were covered in this study. According to norms of Zeilinger et 
al. (2011), 60.0% of our total sample had an ABC Irritability percentile ranking score 
above 80% (Zeilinger, Weber, & Haveman, 2011), which means these participants had 
a considerable amount of challenging behavior.
On baseline, there were significant differences in ‘sex’ between the three groups 
(p =0.024) and we corrected for this baseline difference as appropriate. Expectations 
prior to the BLT (p =0.056), total amount of BLT days (p = 0.060), compliance with the 
intervention (p = 0.420), and date of the intervention/control group period (quarter of 
the year) (p = 0.058), were checked for the possibility of influencing the T1 depression 
scores. None of these variables were confounders. At baseline, none of the participants 
was classified with a Major Depressive Disorder. There were no significant differences 
between the three groups on baseline ADAMS depressive symptoms (p=0.390) and 
SDL-ID total score (p =0.709). 
Primary outcomes
Table 2 shows the clinical outcomes on depressive symptoms measured on 
baseline (T0), one week after the intervention (T1) and four weeks after the end of 
the intervention (T2). The multivariate regression analyses showed no significant 
differences between groups I and III on depressive symptoms measured with the 
ADAMS depression subscale on T1 (p = 0.199), and no significant differences between 
group II and group III on T1 (p = 0.451). 
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Secondary outcomes
Independent Samples t-test revealed no significant differences between group I T1 
and group II T1 ADAMS depression subscale scores (p = 0.394). Likewise, there were 
no significant differences between group I T1 and group II T1 SDL-ID scores (p = 0.101). 
ANOVA repeated measures were used to examine if the effect of BLT was still visible 
four weeks after the end of BLT. We used the ADAMS depression subscale scores at 
Time 1 (baseline, T0), Time 2 (one week after BLT, T1) and Time 3 (four week follow-up, 
T2). In group I, Mauchly’s test, 𝒳2(2) = 4.70, p = 0.095 did not indicate any violation of 
sphericity. There was a significant effect for time in this group (p= 0.008). Post hoc 
tests using the Bonferroni correction for multiple comparisons revealed significant 
differences on ADAMS depression subscale scores between Time 1 and Time 3 in 
group I (p = 0.004). In group II, Mauchly’s test, 𝒳2(2) = 1.72, p =0 .423 did not indicate 
any violation of sphericity and there was a significant effect for time as well (p= 0.013). 
Post hoc tests using the Bonferroni correction showed significant differences between 
Time 1 and Time 3 (p =0.008) in this group. 
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Figure 1. Flow diagram participants. *Professional caregiver did not complete the questionnaires at this time point. 
**No compliance to the study protocol. 
Assessed for eligibility (n=120) 
Excluded  (n=79) 
• Not enough depressive symptoms (n=35)
• Declined to participate (legal guardian) (n=19)
• Declined to participate (participant) (n=5)
• Medical contra-indication (n=13)
• Other reasons (n=7)
Excluded from analysis (n=0)  
Analysed  T0-T1 (n=11) 
Analysed  T0-T2 (n=12) 
Lost to follow-up T1 (n=1)* 
Lost to follow-up T2 (n=0) 
Discontinued intervention (n=0)  
Allocated to Group I (n=12) 
Received allocated intervention (n=12) 
Allocation
Analysis
Follow-Up 
Randomized (n=41) 
Enrollment 
Allocated to Group II (n=15) 
Received allocated intervention (n=15) 
Allocated to Group III (n=14) 
Received allocated intervention (n=14) 
Lost to follow-up T1 (n=1)* 
Lost to follow-up T2 (n=1)* 
Discontinued intervention (n=0)  
Lost to follow-up T1 (n=0) 
Lost to follow-up T2 (n=0) 
Discontinued intervention (n=0)  
Excluded from analysis (n=1)** 
Analysed  T0-T1 (n=13) 
Analysed  T0-T2 (n=13) 
Excluded from analysis (n=0)  
Analysed  T0-T1 (n=14) 
Analysed  T0-T2 (n=14) 
Figure 1. Flow i ram participants. *Professional caregiver did not complete the qu stionnaires at this time 
point. **No compliance to the study protocol. 
PaulineHamers_BNW.indd   138 12/03/2020   16:39:08
139
Results RCT bright light therapy
Table 1. Participants characteristics
Group I
BLT 10.000 lux 
n=12
Group II
BLT dim light 
n=14
Group III
Control group 
n=14
p- valuea
Sex
 Male (%)
 Female (%)
5 (41.7)
7 (58.3)
4 (28.6)
10 (71.4)
11 (78.6)
3 (21.4)
.024
Age, years
 Mean (SD) 56.17 (11.33) 57.14 (11.41) 52.07 (14.29)
.531
Level of ID (%)
 Mild
 Moderate
 Severe
 Profound
5 (41.7)
2 (16.7)
3 (25.0)
2 (16.7)
2 (14.3)
2 (14.3)
7 (50.0)
3 (16.7)
2 (14.3)
8 (57.1)
2 (14.3)
2 (14.3)
.076
Medication use (%)b
 Antidepressants
 Antipsychotics
 Benzodiazepines
 Anti-epileptics
 Contraception
 Beta blockers
 Anxiolytics
 Melatonin
 No medication used 
 Missing data
6 (50.0)
9 (75.0)
4 (33.3)
5 (41.7)
2 (16.7)
1 (8.3)
0 (0.0)
0 (0.0)
1 (8.3) 
0 (0.0)
6 (42.9)
9 (64.3)
5 (35.7)
4 (28.6)
2 (14.3)
0 (0.0)
0 (0.0)
1 (7.1)
3 (21.4) 
0 (0.0)
6 (42.9)
8 (57.1)
3 (21.4)
2 (14.3)
1 (7.1)
1 (7.1)
0 (0.0)
0 (0.0)
2 (14.3) 
1 (7.1)
.728
.650
.653
.404
.665
.540
.386
.440
 .596
ABC Irritability subscale
 Mean (SD) 9.17 (4.49) 10.36 (7.62) 12.00 (6.45)
.530
Total BLT days
 Mean (SD) 13.00 (1.54) 12.14 (2.07) n.a.
.249
Date of BLT intervention/ 
control group period, n (%) 
 1st Quarter of the year
 2nd Quarter of the year
 3rd Quarter of the year
 4th Quarter of the year
6 (50.0)
4 (33.3)
1 (8.3)
1 (8.3)
2 (14.3)
4 (28.6)
2 (14.3)
6 (42.9)
6 (42.9)
4 (28.6)
3 (21.4)
1 (7.1)
.164
Abbreviations: BLT: Bright Light Therapy; SD: standard deviation; ID: Intellectual Disability; ABC: the Aberrant 
Behavior Checklist; n.a.: not applicable. a Calculated as comparisons of the three groups, using ANOVA for 
continuous variables or Chi-square tests for discrete variables. The comparison of total BLT days was only 
calculated for the two intervention groups. b Some participants used more than 1 medication. Significant test 
values are in bold type. 
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Table 2. Outcomes ADAMS Depression subscale and SDL-ID Totalscore
Group I
10.000 lux
Group II
BLT dim light
Group III
Control group
ADAMS Depression subscale T0
 Mean (SD) 21.83 (5.49) 19.86 (3.70) 19.43 (4.70)
ADAMS Depression subscale T1
 Mean (SD) 13.73 (5.68)a 16.00 (6.92) 18.86 (7.38)
ADAMS Depression subscale
Change T0-T1
 Mean (95%CI) 8.36 (3.50-13.23) b 3.54 (0.82-6.26)b 0.57 (-3.91-5.05)
Cohen’s d Effect size T0-T1 
(95%CI)
1.52
(-0.66-3.70)
0.73
(-1.26-2.72)
0.10
(-2.11-2.30)
ADAMS Depression subscale T2
Mean (SD) 11.25 (7.03)a 14.85 (7.70) 16.29 (8.42)
ADAMS Depression subscale
Change T0-T2
Mean (95%CI) 10.58 (5.61-15.55)b 5.39 (2.13-8.64)b 3.14 (-1.62-7.91)
Cohen’s d Effect size T0-T2 
(95%CI)
1.75
(-0.67-4.17)
0.87
(-1.29-3.04)
0.48
(-1.96-2.91)
SDL-ID Total scores T0
 Mean (SD) 38.17 (6.63) 39.29 (3.41) 37.57 (6.16)
SDL-ID Total scores T1
 Mean (SD) 30.82 (6.23)a 35.15 (6.14) 38.07 (7.98)
SDL-ID Total scores
Change T0-T1
 Mean (95%CI) 8.00 (3.43-12.57) b 4.00 (.060-7.94) -0.50 (-4.24-3.24)
Cohen’s d Effect size T0-T1
 (95%CI)
1.19
(-1.32-3.71)
0.88
(-0.91-2.66)
-0.07
(-2.62-2.47)
SDL-ID Total scores T2
 Mean (SD) 29.33 (5.94)a 32.69 (6.03)a 35.50 (7.62)
SDL-ID Total scores
Change T0-T2
 Mean (95%CI) 8.83 (3.35-14.32)b 6.85 (3.37-10.33)b 2.07 (-1.91-6.06)
Cohen’s d Effect size T0-T2
 (95%CI)
1.47
(-0.95-3.88)
1.42
(-0.35-3.17)
0.31
(-2.16-2.78)
T0: baseline, T1: one week after intervention, T2: follow-up 4 weeks. Clinical cut-off point ADAMS Depression 
subscale = 14. Clinical cut-off point SDL-ID Total score = 35. a Mean score below clinical cut-off point. b 
Significant difference (a significant level of p=0.017 (.05/3) was used to correct for increased risk of a type 1 
error due to multiple comparisons). 
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The results of the subgroup analyses (paired samples t-tests) including the eff ect sizes 
measured with Cohen’s d can be found in Table 2. In group I, we found a signifi cant 
diff erence with a very large eff ect size (d = 1.52) between T0 and T1 ADAMS depression 
subscale scores (p =0.003). We also found a signifi cant diff erence with a very large 
eff ect size (d = 1.75) between T0 and T2 ADAMS depression subscale scores in group I 
(p = 0.001). In group II, a signifi cant diff erence with a medium eff ect size (d = 0.73) was 
found between T0 and T1 ADAMS depression subscale scores (p =0.015). Furthermore, 
we found a signifi cant diff erence with a large eff ect size (d= 0.87) between T0 and T2 
ADAMS depression subscale scores (p= 0.004). In group III, no signifi cant diff erences 
were found between T0 and T1 ADAMS depression subscale scores (p = 0.787). Likewise, 
we found no signifi cant diff erences between T0 and T2 ADAMS depression subscale 
scores (p = 0.178). Table 2 also shows the subgroup analysis with paired samples t-tests 
of the SDL-ID scores and the eff ect sizes measured with Cohen’s d. 
Figure 2 shows the mean change in ADAMS Depression subscale scores over time 
in the three groups. In group I, the mean ADAMS depression subscale score and the 
mean SDL-ID score on T1 and T2 decreased below the clinical cut-off  points. In group 
II, only the mean SDL-ID score on T2 was below the clinical cut-off  point. In group III, 
no mean scores on T1 and T2 decreased below the clinical cut-off  points. 
Figure 2. Mean change in ADAMS Depression subscale score (13 items) in patients randomly 
assigned to one of the three study groups. 
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In group I, 75.0% of the participants had a decreased ADAMS depression subscale 
score on T1. In group II and group III this was 71.4% and 57.1% respectively. When 
further examined, the depression scores of 45.5% of the participants in group I and 
7.7% of the participants in group II, were decreased 40% or more after BLT. In group 
III, 14.3% of the participants had 40% or more decreased depression scores after their 
control group period. 
The multivariate regression analyses with the SDL-ID scores on T1 showed significant 
differences between group I and group III (p  =  0.046). It was found that ‘group’ 
significantly predicted the T1 SDL-ID scores (p= 0.014). There were no significant 
differences on T1 SDL-ID scores between group II and group III (p = 0.401).
After the analyses for the whole sample (n=40), we checked if BLT with less than 10 
days (in a period of 14 days) influenced the outcomes. Therefore, we repeated all 
analyses in a sample excluding the participants who had less than 10 BLT days in the 
14 day period. In total, one participants of group I and three participants of group 
II were excluded for this sample analyses (n=36). The patient characteristics of this 
sample can be found in Table 3 and depression outcomes of this sample can be found 
in Table 4, both placed in the supplement. In this sample, we did not find significant 
differences between the BLT groups and control group or between both BLT groups 
on our primary outcome measure. 
Adverse events and side effects
No serious adverse events or adverse events were reported during this trial. A 
minimum amount of side effects were registered in the daily logs. Headache was 
reported twice in group II and fatigue or drowsiness was mentioned three times in 
group I and once in group II. In the daily logs other striking behavior regarding the 
BLT was reported as well: some participants turned away their face or body from the 
lightbox. In group I, this was reported four times, and in group II six times. 
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DISCUSSION
Non-pharmacological treatment options for adults with ID and depressive symptoms 
are limited. As far as we know, this is the first multicenter randomized controlled trial 
investigating the effect of BLT on depressive symptoms in adults with ID. We found no 
significant effect between the three trial groups on our primary outcome. However, 
the results of our secondary analyses suggest that BLT with 10.000 lux decreases 
depressive symptoms directly after the intervention period and at follow-up, showing 
very large effect sizes. In the dim light group, there are also significant decreases in 
depressive symptoms directly after the intervention and at follow-up with medium 
to large effect sizes. We did not find significant decrease of depressive symptoms in 
our control group.
Prior to the current study, only a couple of case reports (Altabet et al., 2002; Cooke 
& Thompson, 1998; Tsiouris, 2007) and one feasibility study (Hermans et al., 2017) 
were published on BLT for adults with ID and depressive symptoms. Positive results 
were found in these first explorations of BLT to decrease depressive symptoms in 
adults with ID, but these must be interpreted with caution because of the lack of 
a randomization procedure and control groups. Therefore, the strengths of the 
current study, for example, the block randomization and blinding procedures, and 
the strictly protocolled intervention, makes this study adding important information 
to the existing literature (Hamers, Festen, et al., 2018). As most studies, our study has 
a couple of limitations which must be mentioned. The first limitation is the small 
sample sizes of the three groups. During our study, we faced a number of obstacles 
(Hamers et al., 2017). From the 120 potential participants who were signed up for the 
study, only 41 could be included in our trial. The strict inclusion criteria of our trial, for 
example, the exclusion of people with bipolar disorder and people who use specific 
photosensitizing medications, contributed to the safety of our trial, but also lowered 
the number of participants enrolled in our study. With our small sample size, significant 
differences between the intervention groups and the control group, and between 
both intervention groups may be hard to find, due to a lack of power. The confidence 
intervals of the mean change between baseline and T1 and between baseline and T2 
in group I, suggest that in a larger sample it is likely that significant differences could 
be found. The second limitation of our study is the high prevalence of psychotropic 
6
PaulineHamers_BNW.indd   143 12/03/2020   16:39:09
144
Chapter 6
medication used in all three groups. Consequently, the BLT intervention in this study 
cannot completely be seen as a monotherapy, but more as an add-on treatment. Since 
it is known that in the population of adults with ID (and depressive symptoms), high 
numbers of psychotropic medication are used, our sample seems quite representative.
It is interesting to note that in our study, antipsychotics are used more frequently 
than antidepressants, which was quite unexpected because exclusion criteria of our 
study prevented including participants with psychotic symptoms or bipolar disorder. 
Furthermore, in our sample, antipsychotics are used more often than in samples of 
adults with ID without depressive symptoms. From existing literature, we know that 
a large part of adults with ID use antipsychotics off-label for challenging behavior 
(de Kuijper et al., 2010). It is possible that in our study, a large part of the participants 
who use antipsychotics have depressive symptoms which are being expressed with 
challenging behavior (also regarding the high scores on the ABC Irritability subscale 
at baseline), and therefore treated with off-label antipsychotics.
Except for a significant difference in depressive symptoms between group I and group 
III after the intervention measured with one questionnaire in our secondary outcomes, 
we did not find any significant differences in depressive symptoms between the 10.000 
lux condition, dim light condition and care as usual. However, we did find that half 
of the participants recovered for at least 40% from their depressive symptoms after 
10.000 lux BLT and less than 15% recovered for at least 40% after dim light BLT or 
no BLT (control group). Overall, we do see a positive trend in decreasing depressive 
symptoms in our 10.000 lux BLT group, with the number of depressive symptoms even 
beneath the clinical cut-off points after the intervention. This makes BLT a promising 
intervention to decrease depressive symptoms in clinical practice. Therefore, RCTs 
with lager sample sizes (also with and without used psychotropic medication), are 
needed to further investigate the (direct) effect of BLT on depressive symptoms of 
adults with ID.
In summary, to the best of our knowledge, this is the first multicenter RCT investigating 
the effect of BLT on depressive symptoms in adults with ID. Our results show significant 
decreases of depressive symptoms in both intervention groups, but not in the control 
group. Overall, significant differences between both intervention groups, and between 
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the intervention groups and control group were not found, which is possibly due to 
a sample size problem. Trial replications with larger samples are needed. Compared 
to psychotropic medication, BLT has limited side effects, is not expensive and 
can have immediate effect after a short period. This makes BLT a promising non-
pharmacological treatment option to decrease depressive symptoms in adults with ID. 
DATA SHARING
Requests for sharing the anonymous database of this trial should be addressed to the 
corresponding author. 
6
PaulineHamers_BNW.indd   145 12/03/2020   16:39:09
146
Chapter 6
REFERENCES 
Altabet, S., Neumann, J. K., & Watson-Johnston, S. (2002). Light therapy as a treatment of sleep 
cycle problems and depression. Ment Health Asp Dev Disabil, 5(1), 1-6.
Aman, M. G., Singh, N. N., Stewart, A. W., & Field, C. J. (1985). The aberrant behavior checklist: A 
behavior rating scale for the assessment of treatment effects. American Journal of Mental 
Deficiency, 89(5), 485-491.
Boutron, I., Altman, D. G., Moher, D., Schulz, K. F., & Ravaud, P. (2017). CONSORT Statement 
for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT 
Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med, 167(1), 40-47. doi:10.7326/
m17-0046
Brouwer, A., Nguyen, H. T., Snoek, F. J., van Raalte, D. H., Beekman, A. T. F., Moll, A. C., & Bremmer, 
M. A. (2017). Light therapy: is it safe for the eyes? Acta Psychiatr Scand, 136(6), 534-548. 
doi:10.1111/acps.12785
Cooke, L. B., & Thompson, C. (1998). Seasonal Affective Disorder and response to light in two 
patients with learning disability. J Affect Disord, 48(2-3), 145-148.
Cooper, S. A., Smiley, E., Morrison, J., Williamson, A., & Allan, L. (2007). Mental ill-health in adults 
with intellectual disabilities: prevalence and associated factors. Br J Psychiatry, 190, 27-35.
de Kuijper, G., Hoekstra, P., Visser, F., Scholte, F. A., Penning, C., & Evenhuis, H. (2010). Use of 
antipsychotic drugs in individuals with intellectual disability (ID) in the Netherlands: 
prevalence and reasons for prescription. J Intellect Disabil Res, 54(7), 659-667. doi:10.1111/
j.1365-2788.2010.01275.x
Even, C., Schroder, C. M., Friedman, S., & Rouillon, F. (2008). Efficacy of light therapy in 
nonseasonal depression: a systematic review. J Affect Disord, 108(1-2), 11-23.
Germain, A., & Kupfer, D. J. (2008). Circadian rhythm disturbances in depression. Hum 
Psychopharmacol, 23(7), 571-585.
Golden, R. N., Gaynes, B. N., Ekstrom, R. D., Hamer, R. M., Jacobsen, F. M., Suppes, T., . . . Nemeroff, 
C. B. (2005). The efficacy of light therapy in the treatment of mood disorders: A review and 
meta-analysis of the evidence. American Journal of Psychiatry, 162(4), 656-662.
Griefahn, B., Kuenemund, C., & Robens, S. (2006). Shifts of the hormonal rhythms of melatonin 
and cortisol after a 4 h bright-light pulse in different diurnal types. Chronobiol Int, 23(3), 
659-673. doi:10.1080/07420520600650679
Hamers, P. C. M., Evenhuis, H. M., & Hermans, H. (2017). A multicenter randomized controlled 
trial for bright light therapy in adults with intellectual disabilities and depression: Study 
protocol and obstacle management. Res Dev Disabil, 60, 96-106.
Hamers, P. C. M., Festen, D. A. M., & Hermans, H. (2018). Non-pharmacological interventions for 
adults with intellectual disabilities and depression: a systematic review. J Intellect Disabil 
Res, 62(8), 684-700. doi:10.1111/jir.12502
Hamers, P. C. M., van Ool, J. S., Festen, D. A. M., Hendriksen, J. G. M., Bindels, P. J. E., & Hermans, 
H. (2018). Reliability and validity of the Dutch Anxiety, Depression And Mood Scale in adults 
aged <50 years with intellectual disabilities. J Appl Res Intellect Disabil.
PaulineHamers_BNW.indd   146 12/03/2020   16:39:09
147
Results RCT bright light therapy
Hermans, H., Beekman, A. T., & Evenhuis, H. M. (2013). Prevalence of depression and anxiety in 
older users of formal Dutch intellectual disability services. J Affect Disord, 144(1-2), 94-100.
Hermans, H., & Evenhuis, H. (2013). Handleiding Angst, Depressie En Stemming Schaal voor 
mensen met een verstandelijke beperking.
Hermans, H., Jelluma, N., van der Pas, F. H., & Evenhuis, H. M. (2012). Feasibility, reliability and 
validity of the Dutch translation of the Anxiety, Depression And Mood Scale in older adults 
with intellectual disabilities. Res Dev Disabil, 33(2), 315-323.
Hermans, H., Soerokromo, N., & Evenhuis, H. (2017). The applicability of bright light therapy in 
adults with moderate, severe or profound intellectual disabilities: a brief report. J Intellect 
Disabil Res, 61(6), 618-623.
Kogan, A. O., & Guilford, P. M. (1998). Side effects of short-term 10,000-lux light therapy. Am J 
Psychiatry, 155(2), 293-294.
Lam, R. W., Levitt, A. J., Levitan, R. D., Michalak, E. E., Cheung, A. H., Morehouse, R., . . . Tam, E. 
M. (2016). Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients 
With Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 
73(1), 56-63. doi:10.1001/jamapsychiatry.2015.2235
Lieverse, R., Van Someren, E. J. W., Nielen, M. M. A., Uitdehaag, B. M. J., Smit, J. H., & Hoogendijk, 
W. J. G. (2011). Bright light treatment in elderly patients with nonseasonal major depressive 
disorder: A randomized placebo-controlled trial. Archives of General Psychiatry, 68(1), 61-70.
Martiny, K. (2004). Adjunctive bright light in non-seasonal major depression. Acta Psychiatr 
Scand Suppl(425), 7-28.
Meesters, Y., & Letsch, M. C. (1998). The dark side of light treatment for seasonal affective 
disorder. International Journal of Risk and Safety in Medicine, 11(2), 115-120.
Monteleone, P., Martiadis, V., & Maj, M. (2011). Circadian rhythms and treatment implications in 
depression. Prog Neuropsychopharmacol Biol Psychiatry, 35(7), 1569-1574.
Moss, S. (2011). PAS-ADD : clinical interview: Pavilion.
Nussbaumer, B., Kaminski-Hartenthaler, A., Forneris, C. A., Morgan, L. C., Sonis, J. H., Gaynes, 
B. N., . . . Gartlehner, G. (2015). Light therapy for preventing seasonal affective disorder. 
Cochrane Database Syst Rev(11), CD011269. doi:10.1002/14651858.CD011269.pub2
Roeden, J. (1989). Signaallijst Depressie voor Zwakzinnigen.
Tsiouris, J. A. (2007). Light therapy for seasonal depression in persons with intellectual disability: 
Literature review and four case series. Ment Health Asp Dev Disabil, 10(4), 137-144.
Tuunainen, A., Kripke, D. F., & Endo, T. (2004). Light therapy for non-seasonal depression. 
Cochrane Database Syst Rev(2), CD004050.
Vereenooghe, L., & Langdon, P. E. (2013). Psychological therapies for people with intellectual 
disabilities: a systematic review and meta-analysis. Res Dev Disabil, 34(11), 4085-4102. 
doi:10.1016/j.ridd.2013.08.030
Wirz-Justice, A. (2006). Biological rhythm disturbances in mood disorders. Int Clin 
Psychopharmacol, 21 Suppl 1, S11-15.
6
PaulineHamers_BNW.indd   147 12/03/2020   16:39:09
148
Chapter 6
Wittchen, H. U., Jacobi, F., Rehm, J., Gustavsson, A., Svensson, M., Jonsson, B., . . . Steinhausen, 
H. C. (2011). The size and burden of mental disorders and other disorders of the brain in 
Europe 2010. Eur Neuropsychopharmacol, 21(9), 655-679.
Zeilinger, E. L., Weber, G., & Haveman, M. J. (2011). Psychometric properties and norms of the 
German ABC-Community and PAS-ADD Checklist. Res Dev Disabil, 32(6), 2431-2440. 
PaulineHamers_BNW.indd   148 12/03/2020   16:39:09
149
Results RCT bright light therapy
SUPPLEMENTARY MATERIAL 
Table 3. Participants characteristics (n=36)
Group I
BLT 10.000 lux 
n=11
Group II
BLT dim light 
n=11
Group III
Control group 
n=14
p- valuea
Sex
 Male (%)
 Female (%)
4 (36.4)
7 (63.6)
3 (27.3)
8 (72.7)
11 (78.6)
3 (21.4)
.022
Age, years
 Mean (SD) 57.64 (10.61) 58.82 (9.72) 52.07 (14.29)
.408
Level of ID (%)
 Mild
 Moderate
 Severe
 Profound
5 (45.5)
2 (18.2)
3 (27.3)
1 (9.1)
1 (9.1)
1 (9.1)
7 (63.6)
2 (18.2)
2 (14.3)
8 (57.1)
2 (14.3)
2 (14.3)
.026
Medication use (%)b
 Antidepressants
 Antipsychotics
 Benzodiazepines
 Anti-epileptics
 Contraception
 Beta blockers
 Anxiolytics
 Melatonin
 No medication used 
 Missing data
6 (54.5)
8 (72.7)
4 (36.4)
4 (36.4)
2 (18.2)
1 (9.1)
0 (0.0)
0 (0.0)
1 (9.1) 
0 (0.0)
 5 (45.5)
6 (54.5)
5 (45.5)
3 (27.3)
1 (9.1)
0 (0.0)
0 (0.0)
1 (9.1)
3 (27.3) 
0 (0.0)
 6 (42.9)
8 (57.1)
3 (21.4)
2 (14.3)
1 (7.1)
1 (7.1)
0 (0.0)
0 (0.0)
2 (14.3) 
1 (7.1)
.763
.657
.565
.558
.670
.621
.446
.420
.516
ABC Irritability subscale
 Mean (SD) 8.64 (4.30) 12.00 (7.64) 12.00 (6.45)
.473
Total BLT days
 Mean (SD) 13.36 (0.92) 13.09 (0.94) n.a.
.501
Date of BLT intervention/ 
control group period, n (%) 
 1st Quarter of the year
 2nd Quarter of the year
 3rd Quarter of the year
 4th Quarter of the year
6 (54.5)
4 (36.4)
0 (0.0)
1 (9.1)
2 (18.2)
3 (27.3)
0 (0.0)
6 (54.5)
6 (42.9)
4 (28.6)
3 (21.4)
1 (7.1)
.026
Abbreviations: BLT: Bright Light Therapy; SD: standard deviation; ID: Intellectual Disability; ABC: the Aberrant 
Behavior Checklist; n.a.: not applicable. a Calculated as comparisons of the three groups, using ANOVA for 
continuous variables or Chi-square tests for discrete variables. The comparison of total BLT days was only 
calculated for the two interventiongroups. b Some participants used more than 1 medication. Significant test 
values are in bold type. 
6
PaulineHamers_BNW.indd   149 12/03/2020   16:39:09
150
Chapter 6
Table 4. Outcomes ADAMS Depression subscale and SDL-ID (n=36)
Group I
10.000 lux
Group II
BLT dim light
Group III
Control group
ADAMS Depression subscale T0
 Mean (SD) 22.36 (5.43) 19.36 (3.64) 19.43 (4.70)
ADAMS Depression subscale T1
 Mean (SD) 13.60 (5.97) a 15.45 (7.44) 18.86 (7.38)
ADAMS Depression subscale
Change T0-T1
 Mean (95%CI) 9.10 (3.96 – 14.24) b 3.91 (0.84-6.98) 0.57 (-3.91-5.05)
Cohen’s d Effect size T0-T1 
(95%CI)
1.62
(-0.70-3.93)
0.70
(-1.63-3.03)
0.10
(-2.11-2.30)
ADAMS Depression subscale T2
Mean (SD) 11.91 (6.98) a 14.10 (8.08) 16.29 (8.42)
ADAMS Depression subscale
Change T0-T2
Mean (95%CI) 10.46 (4.95-15.96) b 5.70 (1.57-9.83) b 3.14 (-1.62-7.91)
Cohen’s d Effect size T0-T2
 (95%CI)
1.75
(-0.74-4.24)
0.88
(-1.62-3.38)
0.48
(-1.96-2.91)
SDL-ID Total scores T0
 Mean (SD) 38.55 (6.82) 39.36 (3.70) 37.57 (6.16)
SDL-ID Total scores T1
 Mean (SD) 30.90 (5.56) a 35.73 (6.53) 38.07 (7.98)
SDL-ID Total scores
Change T0-T1
 Mean (95%CI) 8.40 (3.37-13.43) b 3.64 (-1.11-8.38) -0.50 (-4.24-3.24)
Cohen’s d Effect size T0-T1
 (95%CI)
1.20
(-1.52-3.93)
0.72
(-1.40-2.83)
-0.07
(-2.62-2.47)
SDL-ID Total scores T2
 Mean (SD) 30.00 (5.75) a 33.10 (6.19) a 35.50 (7.62)
SDL-ID Total scores
Change T0-T2
 Mean (95%CI) 8.55 (2.50 -14.59) b 6.60 (2.07-11.13) b 2.07 (-1.91 -6.06)
Cohen’s d Effect size T0-T2
 (95%CI)
1.42
(-1.09-3.93)
1.31
(-0.74-3.36)
0.31
(-2.16-2.78)
T0: baseline, T1: one week after intervention, T2: follow-up 4 weeks. Clinical cut-off ADAMS Depression 
subscale = 14. Clinical cut-off point SDL-ID Total score = 35. a Mean score below clinical cut-off point. b 
Significant difference (a significant level of p= 0.017 (.05/3) was used to correct for increased risk of a type 1 
error due to multiple comparisons).
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GENERAL DISCUSSION
High point prevalence rates of depressive symptoms are found in adults with 
intellectual disabilities (ID), even though depressive symptoms can be hard 
to recognize in this population (1-5). The overall aim of this thesis was to add 
knowledge on diagnostics of depressive symptoms and long-term stress, and on non-
pharmacological treatment options to treat depressive symptoms in adults with ID. In 
this final chapter, the main findings of this thesis, opportunities and implications for 
future research, and implications for clinical practice are discussed. 
Main findings
The Dutch ADAMS is applicable in adults with intellectual disabilities of all ages
Symptoms of depression in adults with ID are often expressed differently compared to 
those in the general population, which may be a reason why these specific symptoms 
are not always recognized as being part of a Major Depressive Disorder (MDD) in 
adults with ID (5-8). Frequently expressed clinical representations of depression in 
adults with ID are crying, signs of irritability, challenging behavior and withdrawal 
from social interactions (6, 9). These specific characteristics are not included in the 
characteristics of MDD such as defined in the fifth Diagnostic and Statistical Manual 
of Mental Disorders (DSM-5) (10), but these specific characteristics can be found in the 
adapted criteria and accompanying notes of MDD described in the Diagnostic Manual-
Intellectual Disability 2 (DM-ID-2) (8). Because depressive symptoms can be hard to 
recognize in adults with ID, current prevalence numbers regarding MDD in adults 
with ID seem an underestimation, even though the numbers are already high (11). 
Further, when depressive symptoms are not recognized, patients might not getting 
proper treatment. In order to further improve the recognition of depressive symptoms 
in adults with ID, reliable and valid instruments are needed. Research regarding the 
reliability and validity of the Dutch Anxiety, Depression And Mood Scale (ADAMS) in 
adults aged 50 years or older was published by Hermans and colleagues in 2012 (12). 
Therefore, we investigated the reliability and validity of the Dutch ADAMS in adults 
with ID aged <50 years (13). Our study (Chapter 2), together with the results of the study 
in 2012, showed that the Dutch ADAMS is a reliable and valid instrument to screen for 
depressive and anxiety symptoms in adults with ID (12, 13). In the Netherlands, this 
instrument is now used in many different health care organizations for adults with ID. 
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Non-pharmacological interventions to treat depressive symptoms in adults with intellec-
tual disabilities
In the stepped-care model of the Dutch Multidisciplinary Guideline for Depression 
(2013), treatment of MDD usually starts with less invasive treatment options, depending 
on the duration and severity of the depression (14). Basic interventions to treat 
depressive symptoms included in this stepped care model are e.g. psychoeducation, 
structuring of daily life and active monitoring of the patient. These basic interventions 
can be combined with low-intensity interventions such as bibliotherapy, self-help 
and self-management, physical activity or psychosocial interventions (14). When 
these interventions do not have enough effect, higher intensity treatment options 
can be used, such as psychotherapy and/or pharmacological treatment (14). Non-
pharmacological interventions to treat depressive symptoms are widely studied and 
used in the general population (15-20). In clinical practice, depressive symptoms in 
adults with ID are usually treated with psychotropic medications, and there is some 
evidence that antidepressants in this population are effective (21-23). Most of the non-
pharmacological interventions recommended in the guideline for depression of the 
general population are not suitable for all adults with ID because of verbal, cognitive 
and physical limitations. Unfortunately, pharmacological treatment is not always 
the most desirable way to treat depressive symptoms in adults with ID. For example 
because of the short and long term negative side effects which are reported regularly 
in research and clinical practice in this population (24-29). In addition, negative side 
effects of psychotropic medications seem to occur more frequent in adults with ID 
compared to without ID (25, 29, 30). Therefore, other treatment options are needed 
for adults with ID.
In the stepped-care model of the Dutch Multidisciplinary Guideline for Depression 
(2013), non-pharmacological treatment for depressive symptoms with the use of Bright 
Light Therapy (BLT) is mentioned as a possible intervention for seasonal depression 
(14). This is one of the few potentially suitable non-pharmacological interventions 
for adults with ID because no level of communication or self-reflection is needed. 
Unfortunately, this section of the stepped-care guideline was published in 2005 and 
not revised in 2013, and therefore not adapted with recent study results of BLT for 
non-seasonal depression (31-33), including findings about comparable effect sizes 
between pharmacological treatment for depression and BLT (34).
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In clinical practice, more knowledge was needed into the effectiveness of non-
pharmacological treatments for depressive symptoms in adults with ID. Therefore, 
we conducted a systematic review, which is described in Chapter 4 (35). This review 
contained 15 studies (describing five different types of interventions) on non-
pharmacological interventions to decrease depressive symptoms in adults with ID. 
Cognitive Behavioral Therapy (CBT) was the most studied non-pharmacological 
intervention in adults with ID (36-43). CBT is effective in reducing depressive 
symptoms in adults with mild or moderate ID. Other types of non-pharmacological 
interventions presented in our systematic review, all with limited number of studies 
and participants, were: behavioral therapy (44-46), exercise interventions (47, 48), a 
social problem solving skills program (47), and Bright Light therapy (BLT) (49). Some of 
these interventions, for example the exercise interventions, showed positive results. An 
important finding of our review was that a large part of the included studies showed 
methodological problems (e.g. small sample sizes or the lack of a control group). 
Therefore, we concluded that not only more research is needed, but also more well 
designed studies are needed to draw reliable conclusions about the effectiveness of 
these non-pharmacological interventions.
In the studies of our systematic review, predominantly adults with mild or moderate 
ID were included (35). As a consequence, adults with severe or profound ID are 
underrepresented. In most of these interventions to decrease depressive symptoms, 
a relative high level of communication and self-reflection is needed, and therefore, 
these interventions cannot be used in adults with severe or profound ID (35). Bright 
Light Therapy could be a promising non-pharmacological intervention for people with 
ID (including for those with severe or profound ID), because no level of communication 
or self-reflection is needed (35). However, only three case studies (49-51) on BLT in 
adults with ID were published. Therefore, Hermans et al. (2017) conducted a small pilot 
study (n=14) on BLT in adults with ID, which gave more insight in the feasibility of BLT 
in adults with ID (52). They showed that BLT was applicable and decreased depressive 
symptoms in the majority of the adults with ID, even in those with severe or profound 
ID, and those with challenging behavior (52). Because of the small sample size of this 
pilot study, and because no control patients were included, a randomized controlled 
trial (RCT) with a larger sample size was needed to expand our knowledge on this type 
of non-pharmacological intervention in this specific population. 
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Bright light therapy to decrease depressive symptoms in adults with ID
As far as we know, we conducted the first multicenter randomized controlled trial 
to examine the effect of BLT on depressive symptoms in adults with ID (Chapter 6). 
BLT with 10.000 lux showed a significant decrease in depressive symptoms with a 
very large effect size one week after the end of the 14 day BLT period, and at four 
week follow-up. In 45.5% of the participants of this group, depressive symptoms were 
decreased with 40% or more. In our dim light group (300 lux), a significant decrease 
in depressive symptoms was found as well, although in this group a medium (T1) to 
large effect size (T2) was found, and only 7.7% of the participants recovered 40% or 
more. In the care as usual group, no significant decrease in depressive symptoms was 
found. We did not find significant differences in decrease of depressive symptoms 
between the three study groups after the intervention (or care as usual period). This 
may be due to our rather small sample size, resulting in a lack of power.
An interesting finding of our RCT is that antipsychotics were used more often by the 
participants than antidepressants. As a diagnosis of psychoses and bipolar disorder 
were exclusion criteria for our trial, our hypothesis is that these antipsychotics 
were prescribed off-label for challenging behavior. Behavior that can be caused by 
underlying depressive symptoms, and this was probably not recognized as such. In our 
RCT, we found high baseline numbers on the Aberrant Behavior Checklist Irritability 
scale (53). Irritability is a frequently expressed clinical representation of depression and 
listed as challenging behavior in adults with ID, supporting our hypothesis. 
Hair glucocorticoids in adults with ID and depressive symptoms
To gain more inside in long-term stress in adults with ID and depressive symptoms, we 
performed the first small explorative study on long-term hair glucocorticoids, which 
may be a potential non-invasive biomarker for long-term stress in this population 
(Chapter 7). Significant positive correlations were found between depressive symptoms 
and hair cortisol, and we found a trend towards a negative correlation between hair 
cortisone and anxiety symptoms. The increase in mean cortisone after BLT could point 
towards an increased conversion of the active cortisol into the inactive cortisone. We 
could only include 14 participants in our study, and for that reason, our results must 
be seen as a first exploration on this biomarker which, in the future, may be a potential 
tool to investigate long-term stress in adults with ID. This kind of objective markers 
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is especially needed in those adults with ID who cannot communicate about their 
health and health related factors. 
STUDY LIMITATIONS
In research in adults with ID, especially in clinical trials, several difficulties are faced (54-
56). In Chapter 5 of this thesis, we described the study protocol of our RCT on the effect 
of BLT in adults with ID, and we gave an overview of the obstacles we encountered 
during the preparation and execution of our study. Besides, we gave an overview of 
how we tried to manage these difficulties. The main obstacle we faced during our 
RCT was finding and recruiting enough participants with ID and elevated depressive 
symptoms who could participate in our study. After one year of recruitment, when 
the inclusion number remained low, we extended the inclusion period with another 
year, and actively screened adults with ID, living in the three participating health care 
organizations, for depressive symptoms. This screening identified adults with ID and 
elevated depressive symptoms that were not recognized prior to the screening. This 
added screening slightly elevated the inclusion number of our study. Unfortunately, 
after an inclusion period of almost 2.5 years, we could include 41 participants. Although 
this is the highest number of included patients in a BLT study in this population, we 
faced a lack of statistical power. This major inclusion obstacle might be the reason 
why large intervention studies in this population are lacking. 
OPPORTUNITIES AND IMPLICATIONS FOR FUTURE RESEARCH 
Biomarkers and other objective instruments to measure long-term stress in adults with ID
At this moment, the Academic Collaboration Center for people with ID ‘Healthy Ageing 
and Intellectual Disabilities’ (HA-ID, in Dutch ‘GOUD’) is preparing a 10-year follow-
up of the large cross-sectional epidemiological study on health and health related 
factors in elderly with ID which started in 2008 (57). One of the added measurements 
in this follow-up study will be the collection of hair samples in adults with ID (with and 
without depressive symptoms) to investigate hair glucocorticoids. When more research 
in larger sample sizes on this biological marker is completed, this method, together 
with relevant questionnaires, may give us more insight in the way hair glucocorticoids 
can be used as a biomarker to examine long-term stress in adults with ID. In the future, 
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this could help professionals in clinical practice to examine long-term stress in adults 
with ID with a more objective marker. This is especially helpful in those patients who 
cannot communicate about life events or other stress related factors such as sleep 
deprivation, diseases or pain. Together with the use of hair glucocorticoids, other 
innovative technologies to measure (mental) heath related factors such as (long-term) 
stress, emotions and pain (such as with heart rate and/or skin conductance) need to 
be investigated in adults with ID. In the future, it would be interesting to combine 
outcomes of objective biomarkers which retrospectively measure long-term stress 
with objective stress measurements that are used in the present. In this way, more will 
be known about (chronic) stress in adults with ID, and this knowledge can contribute 
to care for those (previously unknown) people suffering from (chronic) stress. 
Research in the population of adults with ID
In order to manage one of the main obstacles in research in adults with ID, including 
enough participants with ID in a study, especially in randomized controlled trials, 
international collaborations are needed. We invite international colleagues to replicate 
our BLT study to expand the knowledge on this non-pharmacological treatment option 
to treat depressive symptoms in adults with ID. We published the study protocol of our 
trial and the obstacles we faced, including corresponding obstacle management (58). 
Recently, a systematic review was published on the obstacles faced in conducting RCTs 
in adults with ID (55). Our study and this recent review, can be helpful in optimizing 
research in this population of adults with ID. If more results of high quality studies 
investigating non-pharmacological interventions for adults with ID and depressive 
symptoms are available, we can work towards more evidence-based care in this field. 
Funding for research
Obtaining funding for research in adults with ID can be difficult and challenging, which 
may also be part of the reason why large trials are not performed. Studies in the 
population of adults with ID, especially intervention studies, frequently take more 
time both in preparation and execution of the study compared to the same kind 
of studies in the general population. Therefore, funding agencies should take these 
challenges into account when funding intervention in adults with ID. Without high 
quality research (were obstacles are tackled), there will still be gaps in knowledge, for 
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example regarding the best way that depressive symptoms in adults with ID can be 
diagnosed and treated.
Three Dutch health care provider services for adults with ID (Amarant, Ipse de Bruggen 
and Abrona), in collaboration with Erasmus University Medical Center Rotterdam, form 
the Academic Collaboration Center for people with ID ‘Healthy Ageing and Intellectual 
Disabilities’(HA-ID, in Dutch ‘GOUD’), to make research in adults with ID possible. 
Their large financial and organizational support in times of government cutbacks, 
shows their recognition of the need for more knowledge on health-related factors, 
diagnostic instruments and evidence-based interventions in adults with ID. Important 
topics that all will contribute to optimizing care for this vulnerable population. The 
Dutch government recently acknowledged the need for more funding for further 
development of the infrastructure of the Academic Collaboration Centers for people 
with ID. In these Academic Collaboration Centers, many different disciplines (care 
organizations for people with ID and their staff, researchers, policy makers and 
educational settings), all involved in the care of people with ID, work together to gain 
more knowledge on how to optimize the care for people with ID. Six already existing 
and successful Academic Collaborations centers for people with ID in the Netherlands, 
including the Academic Collaboration center HA-ID, are currently funded on a 
structural basis by the Dutch Government. With this structural funding, in combination 
with the financial and organizational support of health care provider services for adults 
with ID, more resources are available to bring research in this population to a higher 
level. In this way, we can further develop inclusive research, optimize implementation 
of results in regular care, and further collaborate with educational settings, which all 
contributes to optimizing care for people with ID. 
IMPLICATIONS FOR CLINICAL PRACTICE
Screening for depressive symptoms
To prevent underdiagnoses of depression in adults with ID, regular screening, 
especially for those who are at risk for developing a depression, is recommended. 
For example, adults with ID who experienced negative life events, who have sleep 
problems or other (mental) health symptoms related to depression, should be 
screened for depressive symptoms twice a year. The results of this screening should 
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be discussed in a multidisciplinary team and, if elevated depressive symptoms are 
found, more diagnostic research is necessary. We recommend the use of (The Dutch 
version of) the Anxiety Depression and Mood Scale (ADAMS, in Dutch: ADESS), that 
can be used in all adults with ID, to screen for depressive symptoms. The Dutch ADAMS 
manual and questionnaire are available free of charge (downloads are available at 
www.goudonbeperktgezond.nl). The use of the DM-ID-2 depression section (Chapter 
12) (8), with adapted criteria of the DSM-5 and accompanying notes on the different 
expressions of depression in adults with ID, is recommended for diagnosing depression 
in clinical practice. Especially for adults with moderate to profound ID. 
Education of care professionals
As mentioned before, depressive symptoms in adults with ID are frequently missed. 
In order to recognize the specific symptoms of depression in adults with ID, and 
to identify those who are vulnerable for developing depressive symptoms, more 
education for (future) care professionals on this topic is needed. 
Bright light therapy in adults with ID
The results of the effect of BLT to treat depressive symptoms in adults with ID are still 
inconclusive, most probably due to our small sample size. Nevertheless, this non-
pharmacological treatment has been used increasingly in adults with ID in clinical 
practice in recent years. Therefore, an instruction will be made in the near future 
to share our knowledge of BLT in adults with ID. One should be aware that BLT, in 
combination with specific photosensitizing medications, can cause (severe) damage 
to the eye or skin. Further, BLT can worsen suicidal expressions and cause or severe 
mania. As a consequence, BLT should not be used in adults with ID without consulting 
a physician, preferably a physician for people with ID or a psychiatrist with relevant 
knowledge of this specific population. 
CONCLUSION OF THIS THESIS
Knowledge about health-related factors, such as depression and stress (and associated 
interventions), with regard to adults with ID, lags behind knowledge about these subjects 
in adults without ID. This thesis contributes to the knowledge on the psychometric 
properties of the Dutch Anxiety, Depression And Mood Scale (ADAMS), and a novel 
8
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potential biomarker to examine long-term stress in adults with ID. Further, we looked 
into the theoretical construct of the influence of light on mood and sleep. Non-
pharmacological interventions for adults with (all levels of) ID and depressive symptoms, 
especially bright light therapy, are evaluated. With the novel and innovative knowledge 
on various themes that emerged from this thesis, an attempt was made to further close 
the knowledge gap, and to contribute to optimizing care for adults with ID. 
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SUMMARY 
Chapter 1 General introduction
The point prevalence rates of depressive symptoms in adults with intellectual 
disabilities (ID) are high, even though depressive symptoms can be hard to recognize 
in this population. Diagnoses of major depressive disorder are often missed, leading 
to undertreatment of those in need. Further, there is a lack of non-pharmacological 
interventions to treat depressive symptoms in adults with ID. Therefore, we studied the 
literature on this topic, and investigated the effect of a potential non-pharmacological 
intervention to treat depressive symptoms in adults with ID: bright light therapy (BLT). 
The overall aim of this thesis was to add knowledge on diagnostics of depressive 
symptoms and long-term stress, and on non-pharmacological treatment options to 
treat depressive symptoms in adults with ID. 
Chapter 2  Reliability and validity of the Dutch Anxiety, Depression And Mood 
Scale in adults aged <50 years with intellectual disabilities
To prevent underdiagnoses of depression in adults with ID, instruments with good 
psychometric quality are needed to adequately detect depressive symptoms in adults 
with ID. In the past, the reliability and validity of the Dutch Anxiety, Depression And 
Mood Scale (ADAMS, in Dutch: ADESS) was investigated in elderly with ID (aged 50 
years and older). This instrument was found to be feasible, reliable and valid in that 
population. The Dutch ADAMS was not investigated in adult with ID below the age 
of 50 years. In chapter 2 of this thesis, the study on the reliability and validity of the 
Dutch ADAMS in adults with ID aged <50 years is described. This study showed that the 
Dutch ADAMS is a reliable instrument to measure depressive symptoms and anxiety 
symptoms in adults with ID (<50 years). The scale is consistent in measuring over time 
and between different raters. It is also a valid instrument because the scale investigates 
the concept of interest, namely depressive symptoms and anxiety symptoms in adults 
with ID. These results, together with previous research on elderly with ID, confirm that 
the Dutch ADAMS can now be used in the whole adult ID population. 
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Chapter 3  The influence of personal light exposure on mood and sleep in 
patients with (mental) health problems: a systematic review
This study gains more insight in the working mechanism of light on mood and sleep. 
This was necessary as chronotherapeutic interventions, such as bright light therapy, 
are used to treat depressive symptoms although little is known about the influence of 
personal light exposure prior to these interventions. In this study, we aimed to give an 
overview of the studies focusing on this topic. After a systematic literature search, 12 
papers focusing on light, mood and sleep could be included. Overall, the quality of the 
included studies was fair and many methodological problems, e.g. small sample sizes 
and inaccurate personal light exposure measurements, were found. In some studies, 
less exposure to light, was associated with more depressive symptoms and sleep 
problems. In some other studies, these associations were not found. Some groups of 
patients with (mental) health problems were exposed to less personal light compared 
to healthy control subjects. No strong conclusions could be drawn on the association 
between personal light exposure, sleep and mood in patients with (mental) health 
problems because of contrasting results. Some studies found associations between 
light, mood and sleep but others did not find these associations. Further, there is a 
lack of high quality papers with large sample sizes, and personal light exposure was 
measured in a unreliable way. 
Chapter 4  Non‐pharmacological interventions for adults with intellectual 
disabilities and depression: a systematic review
There was limited knowledge of non-pharmacological interventions for depressive 
symptoms in adults with ID, especially for those with severe or profound ID. Therefore, 
a systematic review has been performed to increase knowledge into the effectiveness 
of these interventions in adults with ID. After an electronic search in six databases, 
we have included 15 studies in our systematic review. These 15 studies described five 
types of non-pharmacological interventions. Cognitive Behavioral Therapy was the 
most studied intervention (eight studies), and is found to be effective in decreasing 
depressive symptoms in adults with mild or moderate ID. Other studies, generally 
with small sample sizes or other methodological problems, focused on behavioral 
therapy (three studies), exercise intervention (two studies), social problem-solving 
skills intervention (one study), and bright light therapy (one study). Because of the 
small number of studies on these types of interventions, we concluded that some of 
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these interventions show promising results, but more studies are needed to further 
expand our knowledge into the effectiveness of these interventions. Overall, we 
concluded that there is a lack of high quality studies investigating the effect of non-
pharmacological interventions to treat depressive symptoms in adults with ID. 
Chapter 5  A multicenter randomized controlled trial for bright light therapy 
in adults with intellectual disabilities and depression: study proto-
col and obstacle management
As seen in Chapter 4, there are limited non-pharmacological interventions to treat 
depressive symptoms in adults with ID. Therefore, more research regarding this topic 
was needed. In this chapter, we described the study protocol of our randomized 
controlled trial (RCT) into the effectiveness of bright light therapy (BLT) in adults with 
ID. Besides, the obstacles which we faced during our RCT, and the management of 
these obstacles are described. For example obstacles regarding recruitment and the 
informed consent procedure. In addition, we had to deal with low motivation to sign 
up to participate in the study because of the risk of being randomized into the control 
group, the medical contraindications for bright light therapy, and finding the optimal 
placebo treatment option. Information on the study protocol, the obstacles we faced 
and their management, can be helpful for researchers who, for example, want to 
replicate our study on the effect of BLT on depressive symptoms in adults with ID. 
Chapter 6  The effect of Bright Light Therapy on depressive symptoms in 
adults with intellectual disabilities: results of a multicenter ran-
domized controlled trial
To evaluate the effectiveness of bright light therapy (BLT) in adults with ID, we 
conducted a multicenter randomized controlled trial. Adults with ID were eligible 
for the study when they had a Depressive Mood subscale score of 14 or more on 
the ADAMS. A Depressive Mood subscale score of 14 or more is an indication of the 
presence of a major depressive disorder. Those who were eligible and gave consent, 
were randomized into one of the three study arms: BLT with 10.000 lux, BLT with 
300 lux (dim light: a filter was installed without changing the color of the light), or a 
control condition without BLT. In the general population, BLT with 10.000 lux is used 
to treat depressive symptoms, and 300 lux is considered to be not anti-depressant. 
For example, 300 lux to 500 lux light intensities are regularly found in offices. In both 
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BLT groups, participants received BLT additional to their care as usual. BLT was given 
for a period of two weeks, with a duration of 30 minutes in the morning as soon as 
possible after wake up.
In a period of 2.5 years, 41 participants were included in this study. Their age ranged 
from 24 to 81 years, and by chance an even amount of males and females were 
included. Minimal side effects and no (serious) adverse events were reported. We found 
no significant differences in effect between both BLT groups and the control condition. 
In both intervention groups, BLT decreased the amount of depressive symptoms, and 
no significant decrease of depressive symptoms was found in the control group. Only 
with 10.000 lux BLT, the amount of depressive symptoms decreased below the clinical 
cut-off point. Although we could only include 41 participants, this is, as far as we know, 
the largest study into the effectiveness of BLT in adults with ID. This study showed that 
BLT might be a promising intervention to treat depressive symptoms in adults with 
ID, but (larger) trial replications are needed. 
Chapter 7  Effect of bright light therapy on long-term stress levels in adults 
with intellectual disabilities and depressive symptoms
To the best of our knowledge, we were the first to use head hair samples to 
retrospectively examine hair cortisol and hair cortisone in adults with ID and depressive 
symptoms. We also examined whether BLT influenced hair cortisol and hair cortisone 
concentrations. To measure hair cortisol and hair cortisone, Liquid chromatography-
tandem mass spectrometry (LC-MS/MS) was used. A scalp hair sample was available 
in 17 out of 26 participants who received BLT. Scalp hair samples of 14 participants 
could be included in our analyses: seven were randomized in our 10.000 lux BLT group 
and seven were randomized in our dim light BLT group (300 lux). Moderate significant 
correlations were found between hair cortisol and baseline depression scores, and hair 
cortisone was significantly elevated after BLT, particularly after BLT with 300 lux (dim 
light). The use of scalp hair samples to retrospectively investigate long-term stress 
levels in adults with ID seems to be a promising method to objectify the stress level 
in the past. 
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Chapter 8 General discussion
In this final chapter, the main findings, opportunities and implications for future 
research, and implications for clinical practice are summarized. In general, more 
high quality randomized controlled trials on non-pharmacological interventions 
to treat depressive symptoms in adults with ID are needed. We must work towards 
more evidence-based interventions in this field to optimize care, and to contribute to 
increase the quality of life for adults of this population. In order to perform high quality 
studies, the main obstacle (including enough participants) must be tackled, and more 
funding is needed for research in this group of adults with ID. In clinical practice, 
we must be alert on adults with ID who are vulnerable for developing depressive 
symptoms. More training in this area is necessary for (future) healthcare professionals. 
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SAMENVATTING
Hoofdstuk 1 Algemene inleiding
Er zijn veel volwassenen met een verstandelijke beperking (VB) en depressieve 
klachten. Depressieve klachten zijn lastig te herkennen bij deze groep. De diagnose 
‘Depressieve stoornis’ wordt regelmatig niet gesteld terwijl ze wel aanwezig is en 
hierdoor wordt diegene er ook niet voor behandeld. Ook zijn er maar weinig niet-
farmacologische interventies om depressieve symptomen bij volwassenen met 
een VB te behandelen. Daarom hebben we de literatuur bekeken op dit gebied, 
en onderzochten we wat het effect is van lichttherapie op depressieve klachten bij 
volwassenen met een VB. Het algemene doel van dit proefschrift was om bij te dragen 
aan kennis omtrent het herkennen van depressieve klachten en lange termijn stress bij 
volwassenen met een VB, en om meer te weten te komen over niet-farmacologische 
behandelmogelijkheden voor depressieve klachten bij volwassenen met een VB. 
Hoofdstuk 2  De betrouwbaarheid en validiteit van de Nederlandse vertaling 
van de Angst, Depressie en Stemming Schaal voor volwassenen 
(<50 jaar oud) met een VB
Meetinstrumenten met goede psychometrische eigenschappen zijn noodzakelijk om 
depressieve symptomen bij volwassenen met een VB op een adequate manier te 
detecteren. In het verleden is de betrouwbaarheid en validiteit van de Nederlandse 
Angst, Depressie en Stemming Schaal (ADESS) onderzocht bij ouderen met een VB 
(50 jaar en ouder). Uit dat onderzoek bleek dat het gebruik van de ADESS haalbaar, 
betrouwbaar en valide is in die populatie. De ADESS was niet onderzocht bij 
volwassenen met een VB jonger dan 50 jaar. In hoofdstuk 2 van dit proefschrift, is 
het onderzoek naar de betrouwbaarheid en validiteit van de ADESS bij volwassenen 
met een VB jonger dan 50 jaar beschreven. Deze studie toonde aan dat de ADESS 
een betrouwbaar meetinstrument is om angst- en stemmingsklachten te meten bij 
volwassenen met een VB onder de 50 jaar. De schaal is betrouwbaar in herhaalde 
metingen over de tijd en ook wanneer verschillende beoordelaars de schaal invullen. 
Dit meetinstrument is ook een valide meetinstrument omdat de schaal het te meten 
concept (angst- en stemmingsklachten) ook daadwerkelijk meet. Deze resultaten, 
samen met het onderzoek bij ouderen met een VB, bevestigen dat de ADESS gebruikt 
kan worden in de gehele populatie van volwassenen met een VB. 
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Hoofdstuk 3  Een systematisch literatuur onderzoek naar de invloed van per-
soonlijke lichtblootstelling op stemming en slaap bij patiënten 
met (mentale) gezondheidsproblemen
Deze studie geeft ons meer inzicht in het werkingsmechanisme van licht op 
stemming en slaap. Dit was noodzakelijk omdat chronotherapeutische interventies, 
zoals lichttherapie, worden gebruikt om depressieve symptomen te verminderen, 
hoewel er weinig bekend is over de invloed van persoonlijke blootstelling aan licht 
voorafgaand aan deze interventies. In deze studie wilden we een overzicht geven van 
de studies die zich op dit onderwerp richten. Na een systematische literatuurstudie 
konden uiteindelijk 12 artikelen over licht, stemming en slaap worden geïncludeerd. 
Over het algemeen was de kwaliteit van deze studies redelijk, maar er werden ook 
veel methodologische problemen gevonden zoals een klein aantal geïncludeerde 
patiënten, en de onnauwkeurige manier van het meten van de persoonlijke 
lichtblootstelling. In sommige studies werd minder blootstelling aan licht geassocieerd 
met meer depressieve symptomen en slaapproblemen, maar in sommige andere 
studies werden deze associaties niet gevonden. Sommige groepen patiënten werden 
blootgesteld aan minder licht in vergelijking met gezonde controle patiënten. 
Vanwege de tegengestelde resultaten, konden er geen sterke conclusies getrokken 
worden over het verband tussen persoonlijke lichtblootstelling, slaap en stemming 
bij patiënten met diverse gezondheidsproblemen. Daarnaast is er op dit gebied een 
gebrek aan studies van hoge kwaliteit met grote steekproefgroottes, en wordt de 
persoonlijke lichtblootstelling in de meeste onderzoeken op een onnauwkeurige 
manier gemeten. 
Hoofdstuk 4  Een systematisch literatuur onderzoek naar niet-farmacolo-
gische interventies voor volwassenen met een verstandelijke 
beperking en depressieve klachten
Er was weinig bekend over niet-farmacologische interventies om depressieve 
klachten te behandelen bij volwassenen met een VB, vooral voor de groep met 
een (zeer) ernstige VB. Daarom hebben we een systematisch literatuuronderzoek 
uitgevoerd om meer kennis te vergaren over de effectiviteit van niet-farmacologische 
interventies om depressieve symptomen te behandelen bij volwassenen met een 
VB. Na een elektronische zoekopdracht in zes databases konden we uiteindelijk 15 
studies includeren. Deze 15 studies beschrijven vijf soorten niet-farmacologische 
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interventies. Cognitieve gedragstherapie (CGT) was de meest bestudeerde interventie 
(acht studies), en CGT is effectief gebleken bij het verminderen van depressieve 
symptomen bij volwassenen met een lichte of matige VB. Andere studies, over 
het algemeen met een laag aantal deelnemers en ook andere methodologische 
problemen, waren gericht op gedragstherapie (drie studies), fysieke interventies 
(twee studies), sociale probleemoplossende vaardigheden (één studie) en lichttherapie 
(één studie). Sommige van deze interventies behaalden veelbelovende resultaten. 
Het totaal aantal studies naar niet-farmacologische behandeling voor depressieve 
klachten bij volwassenen met een VB is gering en studies met een hoge mate van 
kwaliteit ontbreken. Daarom zijn er meer studies van hoge kwaliteit nodig zijn om 
onze kennis over de effectiviteit van niet-farmacologische behandeling voor depressie 
bij volwassenen met een VB verder uit te breiden. 
Hoofdstuk 5  Studieprotocol en obstakelmanagement van een multicenter 
gerandomiseerd onderzoek met controlegroep naar het effect 
van lichttherapie voor depressieve klachten bij volwassenen 
met een VB
In hoofdstuk 4 van dit proefschrift is beschreven dat er maar weinig niet-
farmacologische interventies zijn om depressieve klachten bij volwassenen met 
VB te behandelen. Daarom was meer onderzoek naar dit onderwerp nodig. In dit 
hoofdstuk beschrijven we het onderzoeksprotocol van de studie naar het effect van 
lichttherapie op depressieve klachten bij volwassenen met een VB, de obstakels die 
wij tegen kwamen, en de manier waarop wij daarmee zijn omgegaan. Obstakels 
die we tegenkwamen lagen op het gebied van: de werving en het includeren van 
volwassenen met een VB, de toestemmingsprocedure, de lage motivatie om deel 
te nemen aan het onderzoek vanwege het risico gerandomiseerd te worden in de 
controlegroep, het feit dat depressieve symptomen regelmatig gemist worden bij 
volwassenen met een VB, de medische contra-indicaties voor lichttherapie en het 
vinden van de optimale placebo-behandeloptie. Informatie over het studieprotocol, 
de obstakels die wij tegen kwamen en daarnaast de manier waarop wij die hebben 
aangepakt, kunnen nuttig zijn voor onderzoekers die ook onderzoek willen doen 
naar het effect van lichttherapie op depressieve klachten bij volwassenen met een VB. 
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Hoofdstuk 6  Het effect van lichttherapie op depressieve symptomen bij 
volwassenen met een VB: resultaten van een multicenter geran-
domiseerd onderzoek met controle groep
Met behulp van een multicenter gerandomiseerd onderzoek met controlegroep 
hebben we onderzocht wat het effect is van lichttherapie op depressieve klachten 
bij volwassenen met een VB. Volwassenen met VB kwamen in aanmerking voor 
de studie wanneer ze een score van 14 of hoger hadden op de Depressieve 
stemming subschaal van de ADESS. Een score van 14 of hoger op deze subschaal 
is een aanwijzing voor het hebben van een depressieve stoornis. Wanneer er naast 
genoeg depressieve symptomen toestemming was voor deelname aan de studie, 
werd de cliënt gerandomiseerd in een van de drie studiegroepen: lichttherapie 
met 10.000 lux (fel licht), lichttherapie met 300 lux (gedimd licht: er werd gebruik 
gemaakt van een ingebouwde filter die de kleur van het licht niet veranderde) of 
de controle groep zonder lichttherapie. Lichttherapie met 10.000 lux wordt bij de 
algemene bevolking gebruikt om depressieve klachten te verminderen en 300 lux 
wordt gezien als niet effectief om depressieve klachten te verminderen. 300 lux 
lichtintensiteit kan vergeleken worden met het aantal lux dat normaliter gevonden 
wordt in kantoren (300-500 lux). In beide lichttherapie groepen ontvingen de 
deelnemers lichttherapie naast hun reguliere zorg. Lichttherapie werd aangeboden 
voor een periode van twee aaneengesloten weken, 30 minuten per dag, in de ochtend 
zo snel mogelijk na ontwaken. In een periode van 2.5 jaar hebben uiteindelijk 41 
deelnemers deelgenomen aan dit onderzoek. Hun leeftijd varieerde van 24 tot 81 jaar 
en evenveel mannen als vrouwen deden mee. Tijdens het onderzoek werden er maar 
weinig bijwerkingen gezien, en deze waren niet ernstig van aard. We vonden geen 
significante verschillen in het effect van de lichttherapie tussen beide lichttherapie 
groepen en de controleconditie. In beide lichttherapie groepen verminderde de 
hoeveelheid depressieve symptomen. In de controle groep werd geen significante 
afname van depressieve symptomen gezien. Alleen met 10.000 lux lichttherapie 
daalde de hoeveelheid depressieve symptomen onder het klinische afkappunt. 
Hoewel we slechts 41 deelnemers konden includeren, is dit onderzoek, voor zover wij 
weten, het grootste onderzoek naar de effectiviteit van lichttherapie bij volwassenen 
met een VB. Deze studie toont aan dat lichttherapie een veelbelovende interventie 
kan zijn om depressieve symptomen te behandelen bij volwassenen met VB, maar 
herhaling van dit onderzoek (met grotere onderzoeksgroepen) is noodzakelijk. 
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Hoofdstuk 7  Het effect van lichttherapie op het langdurige stressniveau van 
volwassenen met een VB en depressieve symptomen
Voor zover wij weten, hebben wij de eerste studie verricht waarbij plukjes hoofdhaar 
gebruikt worden om het haarcortisol- en haarcortisongehalte te onderzoeken bij 
volwassenen met een VB en depressieve symptomen. We onderzochten ook of 
lichttherapie invloed had op het haarcortisol- en haarcortisongehalte. Hierbij werd 
gebruik gemaakt van vloeistofchromatografie met massaspectrometer (LC-MS / MS). 
Een pluk hoofdhaar was beschikbaar bij 17 van de 26 deelnemers die lichttherapie 
ontvingen tijdens de studie. De plukjes hoofdhaar van 14 deelnemers hebben we 
kunnen analyseren: zeven cliënten kregen lichttherapie met 10.000 lux en zeven 
cliënten kregen lichttherapie met gedimd licht (300 lux). We vonden een significante 
samenhang tussen haarcortisol en baseline depressiescores. Haarcortison was 
significant verhoogd na lichttherapie, vooral na lichttherapie met gedimd licht. Bij 
volwassenen met een VB lijkt het gebruik van plukjes hoofdhaar een veelbelovende 
objectieve methode om het stressniveau in het verleden te onderzoeken. 
Hoofdstuk 8 Algemene discussie
In dit laatste hoofdstuk, worden de belangrijkste bevindingen, kansen en implicaties 
voor toekomstig onderzoek en implicaties voor de klinische praktijk beschreven. Er zijn 
meer gerandomiseerde, gecontroleerde onderzoeken van hoge kwaliteit nodig naar 
niet-farmacologische interventies voor de behandeling van depressieve symptomen 
bij volwassenen met een VB. We moeten toewerken naar meer evidence-based 
interventies op dit gebied om de zorg voor deze kwetsbare groep te optimaliseren. 
Op die manier kunnen we bijdragen aan de verbetering van de kwaliteit van leven 
voor volwassenen in deze populatie. Om studies van hoge kwaliteit uit te voeren, moet 
het belangrijkste obstakel (voldoende deelnemers includeren) worden aangepakt en 
daarnaast is er meer financiering nodig. In de klinische praktijk moeten we alert zijn 
op volwassenen met een VB die kwetsbaar zijn voor het ontwikkelen van depressieve 
symptomen. Meer scholing op dit gebied is noodzakelijk voor (toekomstige) 
zorgprofessionals. 
PaulineHamers_BNW.indd   202 12/03/2020   16:39:12
203
Samenvatting
PaulineHamers_BNW.indd   203 12/03/2020   16:39:12
204
Chapter 9
DANKWOORD 
Dit proefschrift werd mede mogelijk gemaakt door….
Een promotietraject doorloop je niet alleen. Daar zijn veel verschillende mensen, ieder 
op hun eigen manier, bij betrokken. Op deze pagina’s wil ik hen graag bedanken.
Allereerst wil ik de cliënten en wettelijk vertegenwoordigers die betrokken waren bij 
mijn onderzoek bedanken. Zonder jullie had ik mijn onderzoek niet uit kunnen voeren. 
De (persoonlijk) begeleiders die betrokken waren bij mijn onderzoek wil hartelijk 
danken voor hun enthousiasme, inzet en flexibiliteit. Ook de zorgprofessionals van 
Amarant, Abrona en Ipse de Bruggen die betrokken waren bij het knippen van de 
haarplukjes voor het cortisolonderzoek wil ik graag bedanken. Wat fijn dat ik een 
beroep op jullie kon doen. Verder wil ik de gedragskundigen en artsen bedanken 
voor het aanmelden van de cliënten en het invullen van vragenlijsten. Ook wil ik 
de masterstudenten en medewerkers van de zorgorganisaties bedanken die 
hebben bijgedragen aan de dataverzameling voor het valideringsonderzoek van 
de ADESS en het screeningsonderzoek naar depressieve klachten binnen de GOUD-
zorgorganisaties.
De drie zorgorganisaties die samen met de vakgroep Geneeskunde voor Verstandelijk 
gehandicapten van het Erasmus MC de Academische Werkplaats GOUD vormen, 
investeren gezamenlijk in wetenschappelijk onderzoek. Ik ben hen dankbaar dat 
ik deel mag uitmaken van deze inspirerende academische werkplaats. Graag wil ik 
de (voormalig) bestuurders van deze zorgorganisaties ten tijde van mijn onderzoek 
bedanken: Ronald Helder (Amarant), Marc Bindels (Amarant), Jan van Hoek (Ipse de 
Bruggen), Jan Duenk (Abrona) en Toke Piket (Abrona). Daarnaast wil ik de leden van 
de GOUD-stuurgroep bedanken: Frank Brouwers (Amarant), Marcel Schellart (Ipse 
de Bruggen) en Ineke Bootsman (Abrona). Tijdens mijn onderzoek heb ik regelmatig 
praktische zaken rondom mijn onderzoek besproken met de interne coördinatoren 
van GOUD. Hartelijk dank Erwin van den Hout (Amarant), Ineke Bootsman (Abrona) 
en Joris van Erp (en later Cor van Rongen). Wat fijn om korte lijntjes te hebben met de 
praktijk! Natuurlijk vergeet ik de huidige interne GOUD-coördinator van Amarant niet: 
Patricia Smit-Brekelmans. Patricia, ik wil jou bedanken voor de fijne samenwerking 
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tijdens mijn onderzoek, de gezellige lunch overleggen, de vele autoritjes naar diverse 
vergaderingen in het land, en het feit dat jij je betrokkenheid en bezorgdheid toonde 
in zaken die speelden in mijn privé leven. Dit alles heb ik ontzettend gewaardeerd. 
Ook wil ik graag de implementatiecoaches van GOUD bedanken. Wat fijn dat wij 
een beroep op jullie kunnen doen en jullie ons helpen met het implementeren van 
kennis en producten in de praktijk. Daarnaast wil ik Yvonne Swaans bedanken voor 
het regelen van allerlei praktische zaken.
Beste em. prof. dr. Evenhuis, beste Heleen, in de eerste jaren van mijn promotietraject 
was jij mij promotor. Jouw passie voor onderzoek in de VB-sector is enorm inspirerend. 
Dank voor het pionieren, je bereidheid om mee te denken en kritische blik op mijn 
eerste manuscripten.
Beste prof. dr. Bindels, beste Patrick, wat fijn dat jij in de laatste helft van mijn 
promotietraject mijn promotor was. Het was prettig om met jou te sparren over mijn 
onderzoek en de artikelen die ik schreef, en om feedback te krijgen vanuit een andere 
invalshoek.
Heidi, mijn copromotor en dagelijkse begeleider. Wat fijn dat ik altijd bij jou terecht 
kan met vragen of om te brainstormen. Dank voor het feit dat jij mij liet werken op 
de manier die ik het prettigst vind, voor jouw kritische blik op mijn manuscripten en 
het vertrouwen. Ik waardeer het zeer dat jij mij veel vrijheid gaf, maar er wel voor mij 
was wanneer dat nodig was. Ik kijk terug op een prettig verlopen promotietraject, en 
dat heb ik mede aan jou te danken. Daarnaast heb ik ook fijne herinneringen aan het 
EAMHID congres in Luxemburg dat wij samen bezochten.
Dederieke, manager van de vakgroep en mijn copromotor vanaf de 2e helft van mijn 
promotieonderzoek. Ik wil jou bedanken voor het feit dat ik altijd bij terecht kan met 
vragen of om even te sparren. Niet alleen over werk, maar ook over zaken daarbuiten. 
Ik waardeer het zeer dat jouw deur altijd open staat en dat we altijd een beroep op je 
kunnen doen wanneer nodig.
Thessa, samen met Dederieke vorm jij het management van de vakgroep. 
Sinds een aantal jaar ben jij werkzaam in het buitenland en hierdoor heb jij mijn 
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promotieonderzoek vanaf een afstand meegemaakt. Hartelijk dank voor jouw input 
tijdens de beginperiode van mijn promotietraject.
Geachte leden van de beoordelingscommissie – prof. dr. Jan van Busschbach, prof. dr. 
Petri Embregts en prof. dr. Anita Hokken-Koelega, graag wil ik jullie bedanken voor 
het lezen en beoordelen van mijn proefschrift.
In 2014 begonnen Renske G. en ik ieder aan ons promotietraject binnen het GOUD2 
onderzoek. Graag wil Renske bedanken voor het jaar dat wij samen zijn opgetrokken 
als de nieuwe lichting promovendi binnen GOUD. In 2016 startte Sylvie Beumer binnen 
GOUD2. Sylvie, ik wil je graag bedanken voor de fijne overlegmomenten over zowel 
onderzoek als de klinische praktijk. Ook heb ik mooie herinneringen aan de tijd in 
Barcelona tijdens het EAMHID Congres. Ook andere (oud) GOUD-collega’s wil ik 
bedanken: Heidi, Thessa, Alyt, Stijn, Luc, Marieke, Josje, Channa en Ellen. De uitkomsten 
van jullie onderzoeken vormen de basis voor de latere GOUD onderzoeken. Alyt, wat 
fijn dat ik altijd een beroep op jou kan doen om mee te denken met de statistische 
analyses van mijn onderzoek.
Inmiddels is GOUD 3 gestart, en zijn er veel nieuwe collega’s bijgekomen. Bedankt 
M&M&M (Marleen, Mireille, Marie-Louise), Theodore, Roy, Anne-Marie, Cor, Annemieke, 
Kim en Laura. Binnen de vakgroep Geneeskunde voor Verstandelijk Gehandicapten wil 
ik Mylène, Sandra, Renske, Marlies en Marieke bedanken. Dank allen voor de prettige 
tijd op de afdeling, de gezellige borrels, etentjes en fijne lunchwandelingen. Ook wil 
ik Miriam bedanken voor de secretariële ondersteuning. Mylène, wat goed dat we 
samen hebben gewerkt aan het systematic review over licht en gezondheid, en wat 
fijn dat ik een beroep kan doen op jouw kennis omtrent de actiwatch data. Bedankt 
ook voor de gezellige tijd tijdens de SLTBR congressen die we bezocht hebben. Over 
de SLTBR congressen gesproken: dank ook aan Erasmus MC collega Babette Bais voor 
de gezellige tijd in Berlijn en Groningen!
Binnen Amarant maak ik deel uit van de Commissie Wetenschappelijk onderzoek. In 
eerste instantie met Heidi Hermans en later Moniek Voermans als voorzitter. Wat leuk 
om samen met jullie en de andere leden van de commissie de lopende onderzoeken 
binnen Amarant te bespreken, en deel te mogen nemen aan de onderzoeksymposia 
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van Amarant. Graag zou ik een aantal gedragskundigen binnen Amarant willen 
bedanken voor het feit dat ik deel uit mocht maken van de intervisiegroep tijdens mijn 
promotietraject: Petra, Michelle, Heidi, Mirjam en collega’s die tijdelijk aangesloten zijn. 
En wat leuk Mirjam, dat ook jij inmiddels onderzoek doet binnen een academische 
werkplaats voor mensen met een verstandelijke beperking!
Oud-collega’s van het dr. Leo Kannerhuis Brabant (LKHB, destijds onderdeel van 
Amarant) wil ik bedanken voor de gezellige etentjes en belangstellende berichtjes. 
En in het bijzonder Claudia, die mij in 2014 de vacature voor de promotieplek binnen 
GOUD stuurde, omdat ze vond dat die baan echt bij mij zou passen. Goed gezien 
Claudia! Verder wil ik mijn voormalig manager van het LKHB bedanken. Sussiel, wat fijn 
dat jij, ondanks dat ik tijdens de sollicitatieprocedure voor de baan als gedragskundige 
bij het LKHB een heftige periode doormaakte, mij toch hebt aangenomen. Beste 
Katinka, mijn werkbegeleider destijds, dank voor de fijne gesprekken en wandelingen. 
Ik denk nog regelmatig terug aan de jaren bij het LKHB, waar we met een fijn en 
bevlogen team goed werk hebben verzet.
Tijdens mijn promotietraject heb ik ook samen mogen werken met mensen van 
buiten onze academische werkplaats. Voor het artikel over de betrouwbaarheid en 
validiteit van de ADESS werkte ik samen met dr. Jans van Ool en dr. Jos Hendriksen 
van Kempenhaeghe. Ik wil jullie beiden hartelijk danken voor de fijne en efficiënte 
samenwerking. Daarnaast kwam ik Jans regelmatig tegen bij verschillende congressen 
op diverse werelddelen, en daar heb ik fijne herinneringen aan!
Voor het artikel over cortisol in hoofdhaar heb ik binnen het Erasmus MC samengewerkt 
met prof. dr. Liesbeth van Rossum, prof. dr. Yolanda de Rijke en Drs. Mesut Savas. 
Hartelijk dank voor de fijne samenwerking en het feit dat wij van jullie expertise 
gebruik mogen maken. Hopelijk zetten we de samenwerking in de toekomst voort, 
er is immers nog een hoop te ontdekken op het gebied van cortisol in hoofdhaar bij 
mensen met een verstandelijke beperking.
Mijn lieve vriendinnen Debby, Judith, Debbie C. en Anika wil ik bedanken! We go 
long way back, soms wel >30 jaar! En ook alle andere vrienden en kennissen wil ik 
graag bedanken voor alle gezellige theetjes, borrels, etentjes, (NS)wandelingen, dagjes 
PaulineHamers_BNW.indd   207 12/03/2020   16:39:13
208
Chapter 9
en weekendjes weg, theatervoorstellingen, film- en docu avonden, en bezoeken 
aan concerten en festivals. Wat fijn dat jullie er waren, ook in moeilijkere tijden. De 
afgelopen jaren stak ik veel tijd en energie in mijn promotieonderzoek, en moest ik 
daarnaast dealen met heftige zaken in mijn privéleven. Hierdoor zag ik sommigen van 
jullie minder dan dat ik zou willen, en moest ik soms ook afspraken afzeggen. Ik vind 
het fijn dat jullie desondanks nog steeds deel uit maken van mijn leven!
Graag wil ik mijn schoonouders Harrie en Marly bedanken voor het feit dat we altijd 
een beroep op jullie kunnen doen wanneer we oppas nodig hebben voor onze 
dochter.
Wanneer een kind opgevoed wordt door een jurist en een verpleegkundige, wat voor 
effect heeft die opvoeding dan op het latere leven van het kind? De ‘cure’ en de ‘care’ 
als het ware in een mooie mix. Bij mij kwam het tot uiting in grondig en gestructureerd 
werken volgens (strenge zelf opgelegde) structuren, planningen en deadlines, met 
daarnaast een groot verantwoordelijkheidsgevoel en de drang om daadwerkelijk iets 
bij te dragen aan de maatschappij. Dankjewel pap en mam, dat jullie mij mijn eigen 
keuzes lieten maken, mij vrijheid gaven en mijn nieuwsgierig, eigenwijs en zelfstandig 
de wereld lieten ontdekken, en dat jullie op onze dochter konden passen wanneer 
dat nodig was.
Mam, in de jaren voor mijn geboorte werkte jij als Z-verpleegkundige en groepshoofd 
in de zorg voor mensen met een verstandelijke beperking op het ‘t Hooge Veer in 
Tilburg. Hoe bijzonder is het dat ik, nu bijna 40 jaar later, meer dan 10 jaar in dienst 
ben bij diezelfde zorgorganisatie. Tijdens mijn jeugd raakte ik door jouw werk bekend 
met mensen met een verstandelijke beperking, en ben ik opgegroeid met jouw passie 
voor dit vakgebied. Wat ben trots op jou, dat jij tot aan jouw pensioen hebt gewerkt 
binnen de zorg, waar je steeds zocht naar manieren om het leven van de cliënten te 
veraangenamen. En mijn naamgenoot waarbij je nu vrijwilligerswerk doet: die boft 
zeker met zo’n betrokken en bevlogen maatje!
Pap, van jou heb ik de pragmatische manier van werken, perfectionisme, 
doorzettingsvermogen en het plannen en organiseren meegekregen. Deze 
eigenschappen kwamen tijdens mijn klinische werk en promotieonderzoek ontzettend 
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goed van pas. Wat fijn dat je regelmatig vroeg hoe de stand van zaken was m.b.t. mijn 
promotieonderzoek. Ik hoop dat je geniet van je welverdiende pensioen.
Mijn zusje Nicolle, dank dat jij in de afgelopen jaren, samen met jouw man Oscar, in 
kon springen als oppas voor Frédérique wanneer dat nodig was. Ook dank voor het 
feit dat ik jou meerdere keren als taxi kon inzetten wanneer de NS mij weer eens op 
station ergens in het land liet stranden.
Mijn lieve dochter Frédérique, toen ik in 2014 aan dit promotietraject begon was je 
net 6 jaar geworden en zat je in groep 3. Nu, wanneer ik dit dankwoord schrijf, ben jij 
een mooie spontane en sociale tiener die geniet van het leven, altijd vrolijk is en die 
na de zomervakantie naar het voortgezet onderwijs gaat. Wat ben ik toch ontzettend 
trots op jou! Je tovert altijd weer een lach op mijn gezicht en je laat mij zien waar het 
in het leven echt om gaat. Dikke knuffel van mij voor jou! Gaan we binnenkort weer 
samen een weekendje weg?
Lieve Bart, al 20 jaar ben jij mijn maatje, mijn tegenpool, de rust in mijn leven en mijn 
plek om thuis te komen. Een promotietraject vraagt niet alleen van de promovendus 
veel tijd en energie, ook van een partner. Wat ben ik blij dat jij taken van mij over kon 
nemen wanneer dat nodig was, vakanties wilde verzetten wanneer ik weer eens de 
wereld over wilde vliegen om een presentatie te geven op een interessant congres, 
mij in alle stilte liet werken wanneer dat nodig was, en niks wat ik vraag te veel voor 
jou is. Ik waardeer je enorme geduld, rust en het feit dat je zo’n lieve vader bent voor 
onze dochter. De afgelopen jaren waren, door omstandigheden waarop wij geen 
invloed hebben gehad, verre van makkelijk, en daarbij vergeleken is promoveren ‘a 
piece of cake’. Ik ben zo blij dat ik samen met jou belangrijke en moeilijke beslissingen 
in ons leven heb kunnen maken. Ik hoop dan ook dat we, samen met onze dochter 
Frédérique, nog lang en vooral ook in goede gezondheid van het leven mogen 
genieten. Ik houd heel veel van jou! X
Pauline 
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CURRICULUM VITAE
Pauline Hamers werd geboren op 20 mei 1980 in Tilburg. In 1992 
startte zij in de brugklas HAVO/VWO van het Cobbenhagen 
College. Na haar HAVO eindexamen ging zij naar het VWO. In 
1998 ging Pauline Sociaal Pedagogische Hulpverlening (SPH) 
studeren aan de Fontys Hogeschool in Eindhoven. Tijdens het 
4e jaar liep zij haar jaarstage bij de medisch-orthopedagogische 
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PHD PORTFOLIO 
Erasmus MC Department:  General Practice, Intellectual Disability Medicine 
PhD period:   01-09-2014 - 30-06-2019 (wtf: 0.89) 
Promotor:   Prof. Dr. P.J.E. Bindels 
Copromotoren:   Dr. H. Hermans  
 Dr. D.A.M. Maes-Festen 
1. PhD training 
Year Workload  
(ECTS) 
General courses 
- Medical library courses (searching and EndNote)
- BROK (Good Clinical Practice)
- Research Integrity
- Biomedical English Writing and Communication
2014 
2015, 2019 
2015 
2018 
1.0 
2.0 
0.3 
4.0 
Specific courses 
- Anxiety and depression in adults with ID, GITP
- NIHES Biostatistical Methods I: Basic Principles, part A (CC02A)
2016 
2017 
1.0 
2.0 
Seminars and workshops 
- PAOK Section EAA Behavior and sleep disturbances Training,
Rotterdam, the Netherlands
- NVO congress, Amsterdam, the Netherlands
- NVO congress, Ede, the Netherlands
2017 
2018 
2019 
0.3 
0.3 
0.3 
Presentations 
- Department oral presentations
- Study oral presentations (managers, physicians, caregivers,
psychologists, and behavioral scientists) 
- Oral and poster presentations Amarant Research symposium,
Rijsbergen and Tilburg, the Netherlands 
- Research symposia Ipse de Bruggen, Zwammerdam, the
Netherlands 
2014-2019 
2014-2016 
2016-2019 
2017 + 
2019 
2.0 
4.0 
1.0 
0.6 
National and international conferences 
- Symposium Colors of the Future (Developments in ID-medicine),
Rotterdam, the Netherlands (attendance)
- Symposium NPG “Focus op kennis en onderzoek”, Utrecht,
the Netherlands (oral presentation)
- 15th IASSIDD World Congress, Melbourne, Australia
(oral presentation)
- 4th Tranzo AWVB Symposium, Tilburg, the Netherlands
(attendance)
2014 
2015 
2016 
2017 
0.3 
1.0 
2.0 
0.3 
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- 4th Chronotherapy Network the Netherlands (CNN), symposium, 
Leiden, the Netherlands (attendance) 
- 29th Society of Light Treatment and Biological Rhythms Congress 
(SLTBR), Berlin, Germany (poster presentation) 
- 11th European Congress Mental Health in Intellectual Disability, 
Luxembourg, Luxembourg (EAMHID) (2 oral presentations) 
        -      30th Society of Light Treatment and Biological Rhythms   
               Congress  (SLTBR), Groningen, the Netherlands  
               (poster presentation) 
        -      18th IASSIDD European Congress, Athens, Greece   
               (oral presentation + chair mental health symposium) 
        -     Vilans Congress  'Zoek het uit’, Nieuwegein,  the Netherlands    
              (poster presentation) 
        -     3rd Implementation Science Conference, Utrecht,  
              the Netherlands (attendance) 
        -     5th Tranzo AWVB Symposium,  Tilburg, the Netherlands    
              (attendance) 
        -     12th European Congress Mental Health in   
              Intellectual Disability (EAMHID), Barcelona, Spain 
              (oral presentation) 
 
2017 
 
2017 
 
2017 
 
2018 
 
 
2018 
 
2019 
 
2019 
 
2019 
 
2019 
0.3 
 
2.0 
 
2.0 
 
2.0 
 
 
2.0 
 
1.0 
 
0.3 
 
0.3 
 
2.0 
 
2. Teaching 
 
Year Workload 
(Hours/ECTS) 
 
Lecturing 
 
- Guest lectures: “Depression in adults with ID and light therapy”, 
Intellectual Disability physicians alumni network 
 
 
 
2015 + 
2016 
 
 
 
1.0 
 
Supervising Masters theses 
 
- 1 Medical Science master student  
- 2 Pedagogical Science master students  
- Supervising student session ‘How to judge a paper’ 
 
 
 
2015 
2015-2016 
2018 
 
 
4.0 
8.0 
0.3 
3. Other Year 
 
 
 
- Member of the Scientific Research Committee Amarant 
- Best Poster Award (30th Society of Light Treatment and Biological 
Rhythms Congress  (SLTBR), Groningen, the Netherlands) 
 
 
2015 -  
2018 
 
1.0 
- 
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